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ABSTRACT 
The matrix (MA) domain of HIV-1 mediates proper Gag localization and 
membrane binding by interacting with phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2], 
a phospholipid that is found predominantly at the plasma membrane (PM). HIV-1 MA 
also interacts with RNA, which prevents Gag from binding to membranes containing 
phosphatidylserine (PS), a prevalent negatively charged phospholipid. These results 
suggest that the MA-bound RNA promotes PM-specific localization of HIV-1 Gag by 
blocking non-specific interactions with cellular membranes that do not contain PI(4,5)P2. 
In this thesis, I examined whether PI(4,5)P2 dependence and RNA-mediated 
inhibition collectively determine MA phenotypes across a broad range of retroviruses. By 
comparing a panel of Gag-leucine-zipper constructs (GagLZ) containing MA of different 
retroviruses, I found that membrane binding mediated by retroviral MA can be broadly 
divided into two categories: those that are PI(4,5)P2-dependent and RNase responsive, 
and those that are neither. I also found that the PM-localization and virus-like particles 
(VLP) release of the former group is sensitive to the overexpression of a PI(4,5)P2-
depleting enzyme, polyphosphoinositide 5-phosphatase IV (5ptaseIV), while the latter 
group is much less sensitive to 5ptaseIV overexpression. Structural analyses further 
suggest that the basic patch size of the retroviral MA confer susceptibility to RNA-
mediated membrane binding inhibition. 
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In my thesis, I also provided in vitro and cell-based evidence supporting that 
RNA-mediated suppression occurs in cells and that RNA can inhibit membrane binding 
of HIV-1 Gag at a concentration that is much lower than the estimated RNA 
concentration in the cell. Hence, RNA-mediated suppression is a physiologically relevant 
mechanism that prevents Gag from binding promiscuously to prevalent PS-containing 
membranes. 
Finally, I examined the roles of PI(4,5)P2 and RNA in regulating the targeting of 
HIV-1 Gag to the site of assembly, the virus-containing compartments (VCC), in primary 
macrophages. I found that the VCC localization and virus release of HIV-1 are severely 
impaired upon 5ptaseIV overexpression. However, HIV-1 MA only contributes to 
membrane binding but not in Gag targeting to the VCC. I also determined that HIV-1 
nucleocapsid (NC) is important for VCC-specific localization of HIV-1 Gag. This 
suggests that targeting of HIV-1 Gag to the VCC adopts a different mechanism than Gag 
targeting to the PM in HeLa and T cells. 
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CHAPTER I 
Introduction 
Retroviruses are enveloped RNA viruses that can replicate in a host cell using a 
unique process known as reverse transcription (see Life cycle of retroviruses) (1). A 
number of retroviruses have been linked to diseases in humans and animals. These 
infections have killed millions of lives and resulted in severe financial losses. Human 
immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency 
syndrome (AIDS), was discovered in 1983. Since the beginning of the pandemic, there 
has been 39 million AIDS-related deaths with 35 million people presently living with 
HIV/AIDS worldwide (2). Retroviruses that infect livestock, such as Bovine leukemia 
virus (BLV) and Jaagsiekte sheep retrovirus (JSRV), have serious impact on the 
agricultural economy due to the death of cattle, increased veterinary costs, reduced 
reproductive efficiency and milk production (3, 4). To date, there is no cure or vaccine 
for these diseases. Thus, continued research efforts are needed for the development of 
effective treatments for and prevention against these viral infections. 
Types of retroviruses 
All retroviral genomes contain a highly conserved gene that encodes for an enzyme 
known as reverse transcriptase (RT) (1, 5). RT is essential for the virus to carry out 
reverse transcription, converting the viral RNA genome into complementary DNA 
(cDNA). Alignment of the RT sequence has unraveled the phylogeny relationship among 
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the different retroviruses (6). Based on this, the family of retroviridae can be subdivided 
into six different genera, namely alpharetrovirus, betaretrovirus, gammaretrovirus, 
deltaretrovirus, epsilonretrovirus, lentivirus and spumavirus [for retrovirus phylogeny 
tree, see Weiss et al 2006 (6)].  Aligning conserved amino acid residues within RT and 
other RT-like sequences have led to the discovery of retroelements including endogenous 
retroviruses (ERV) (6, 7). These elements serve as footprints of ancient retroviral 
infections and can be used as molecular markers to study evolution. In human, ERV 
makes up a surprisingly large portion (8%) of the genome (8, 9). While most human ERV 
(henceforth referred to as HERV) do not contain functional open reading frames (ORFs) 
and therefore are not able to replicate, some HERVs, such as HERV-K, contains ORFs 
for all retroviral genes. HERV-K belongs to the genus betaretrovirus. Upregulated 
HERV-K protein expression and/or RNA transcripts have been associated with various 
autoimmune diseases, cancer and HIV-1 infection (10, 11). However, the direct role of 
HERV-K in disease pathogenesis remains controversial. Despite the intact retroviral 
genome, the expression level of HERV-K in general is very low, making it difficult to 
study in vitro (12-14). Thus, to improve the protein expression of HERV-K, using 
bioinformatics approach, two groups reconstructed the infectious sequence of HERV-K 
(14, 15). In one of the studies, the consensus sequence of HERV-K 113 and another 
closely related HERV-K was utilized to construct HERV-KCON. These codon optimized 
HERV-K sequences are powerful tools for studying the biology of these ancient 
retroviruses and their relationships with diseases.   
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Retroviral genome 
Retroviruses can also be broadly divided into simple and complex viruses based 
on their genomic organization (Fig. 1.1). All retroviruses contain four essential genes – 
gag, env, pol and pro. The gene product of gag directs the synthesis of virus core during 
assembly; env contains the information for the viral envelope protein, which is essential 
for the entry step of virus replication (see Life cycle of retroviruses); pol encodes the 
reverse transcriptase and integrase enzymes; and pro is necessary for virus maturation. 
Simple retroviruses, such as murine leukemia virus (MLV) and mouse mammary tumor 
virus (MMTV), only encode these four genes, while complex retroviruses, such as HIV 
and human T-lymphotropic virus (HTLV), contain additional non-structural genes (Fig. 
1.1). HIV-1 encodes six other genes: tat, rev, nef, vif, vpr and vpu, each playing different 
roles during replication (Table 1.1). In addition to these genes, HIV-2 and some simian 
immunodeficiency viruses (SIV) also contain vpx, which is important in counteracting a 
restriction factor known as SAM domain and HD domain-containing protein 1 
(SAMHD1) for successful infection in cells with myeloid lineage (see Chapter IV). 
Oncogenic retroviruses such as HTLV and Rous sarcoma virus (RSV) contain tax and src 
oncogene, respectively, which stimulate uncontrolled proliferation of host cells (1). 
Insertion of retroviral genome near the promoter region of a proto-oncogene in the host 
genome may also result in the onset of cancer. 
Life cycle of retroviruses 
A Retrovirus initiates infection by interacting its envelope proteins with host 
cell’s surface-exposed receptor (Fig. 1.2) (16). Binding to the receptor leads to the 
internalization of the virus core into the cell. While most retroviruses enter the cell by 
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direct fusion with the plasma membrane, some retroviruses such as ecotropic (narrow 
host range) and amphotropic (wide host range) MLV have been shown to enter the cell 
through endocytosis (17). Following viral fusion with the host membrane, viral core is 
delivered to the cytoplasm where uncoating and reverse transcription take place. Most 
retroviral reverse transcription occur during early stages of virus life cycle, except for 
spumaviruses, where the process takes place during assembly (16). During reverse 
transcription, complementary DNA (cDNA) is generated from the viral genomic RNA. 
The cDNA is then transported into the nucleus as a pre-integration complex (PIC). In the 
nucleus, the cDNA is integrated into the host genome, a process mediated by viral 
integrase protein. The integrated viral genome is now known as a provirus. 
During late stages of virus life cycle, viral genes are transcribed and translated to 
initiate the formation and release of new virions. For HIV-1, tat is one of the earliest 
genes to be expressed (18). Tat stands for trans-activator of transcription. As its name 
suggests, it increases transcription level of viral genes. Similar to tat, HTLV family 
encodes the tax gene, which, when expressed, also helps to increase expression level of 
other viral genes (19).  
Viral genomic RNA is transcribed in the nucleus and transported out of the 
nucleus in its unspliced form (20). In HIV-1, the transport of singly spliced or unspliced 
RNA out of the nucleus is assisted by the viral-encoded Rev protein. Rev binds to the 
rev-response element (RRE) found on the RNA. Rev binding to RRE recruits 
Crm1/RanGTP complex, which facilitates nuclear export (16). Rev-like proteins are also 
found in other retroviruses, such as Rem (MMTV), Rex (HTLV-1) and Rec (HERV-K) 
(21, 22).  
5 
 
Following enhanced viral mRNA transcription and nuclear export, viral structural 
proteins such as Gag, Gagpol and Env are synthesized in the cytoplasm and are 
subsequently targeted to the site of virus assembly (see Retroviral assembly). During 
assembly, viral genomic RNA is encapsidated into the forming virion. Specific 
incorporation of genomic RNA is mediated by the binding of Gag protein to the Psi 
packaging sequence found on the RNA (see Gag polyprotein) (23). In addition to viral 
RNA, many cellular RNA are also incorporated into the virus particle. For instance, 
tRNALys and 7SL RNA are highly enriched in HIV-1 particles (24-27). tRNA
Lys is used 
by HIV-1 as the primer during reverse transcription, thus it is selectively packaged into 
the virus particle. The concentration of tRNALys in HIV-1 virus particles is estimated to 
be ten times higher than in the cell cytoplasm (28), whereas 7SL RNA was estimated to 
be 250-fold enriched (27). Other RNA, such as mRNAs for ribosomal proteins, are also 
packaged non-specifically into the virions (23, 29). 
At late stages of the virus assembly, newly formed virus particles are released 
from the cell surface. This pinching-off process is facilitated by the endosomal-sorting 
complex required for transport (ESCRT) proteins (30). The ESCRT proteins interact with 
the assembling Gag proteins via the late domain motifs, which are highly conserved 
among retroviruses (see Gag polyprotein). Finally, the viral protease packaged within 
the virus particles cleaves viral proteins into their individual forms, thereby causing a 
structural changes of the virus particle. This mature virus is then able to infect the next 
susceptible host cell. 
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Retroviral assembly 
As mentioned above, retroviral assembly is driven by the Gag proteins. Viral core 
is made up of assembling Gag multimers, which appear as electron-dense sites under the 
electron microscope (EM). Based on the morphology and where these viral cores are 
found in the cell, the retroviral assembly can be further divided into four categories – 
Types A, B, C and D (31). Type A retroviruses, such as ERV-like elements, are 
intracellular-only viruses, where immature particles are seen to bud into the cytoplasm or 
the endoplasmic reticulum. Type B and D retroviruses form preassembled immature 
particles in the cytoplasm before being transported and released at the plasma membrane. 
B-type retroviruses usually display more prominent envelope spikes than D-type 
retroviruses. Examples of B- and D-type retroviruses include the MMTV and Mason-
Pfizer monkey virus (MPMV), respectively. Finally, in type C retroviruses, the Gag 
proteins are transported as precursors to the plasma membrane such that virus budding 
occurs simultaneously with virus assembly. The C-type retroviruses includes equine 
infectious anemia virus (EIAV), MLV, HERV-K, RSV as well as human pathogens like 
HIV and HTLV. For the remaining sections of my dissertation, I will be focusing on the 
assembly of the C-type retroviruses. 
The site of assembly of some retroviruses, such as that of HIV-1, is cell-type 
dependent. In HeLa cells and T cells, HIV-1 assembles at the plasma membrane (32). In a 
subset of T cells that adopts polarized morphology (such as those found in lymph nodes), 
HIV-1 is observed to assemble at one particular region of the plasma membrane, known 
as the uropod. Uropod is a region at the rear-end of a polarized T cell, and is found to 
contain numerous adhesion molecules for cell-to-cell contact (32, 33). In contrast to T 
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cells and HeLa cells, in primary macrophages, HIV-1 assembles and accumulates at 
seemingly intracellular compartments (32). These compartments, called the virus 
containing compartments (VCC), were thought to be endosomal compartments or 
multivesicular bodies (MVB) (34). While the exact nature of the VCC still remains 
unclear, some report that VCC is actually an invagination of the plasma membrane and 
contains unique structures and cellular markers that are distinct from the endosomal 
compartments/MVB. 
In addition to HIV-1, HTLV-1 Gag also shows different localization in different 
cell types. In T cells, HTLV-1 Gag localize mainly to the plasma membrane, whereas in 
cell lines such as HeLa cells, HTLV-1 Gag is found to localize to both plasma membrane 
and intracellular compartment (35, 36). The varied Gag localization pattern in different 
cells may suggest that different trafficking machinery is being used for transporting Gag 
to its ultimate location for assembly, the plasma membrane. 
Gag polyprotein 
Gag is synthesized as a multi-domain polyprotein. All retroviral Gag contains 
matrix (MA), capsid (CA) and nucleocapsid (NC) structural domains (Fig. 1.3A) (37-41). 
Each domain plays critical roles during assembly. The MA domain is mainly responsible 
for membrane binding as well as targeting Gag to the site of assembly. In addition to 
these roles, MA also binds RNA (35, 39, 42-52). CA contains two subdomains – the N-
terminal domain (NTD) and C-terminal domain (CTD). While the NTD is involved in 
viral core formation, the CTD is important in mediating Gag-Gag dimerization. The NC 
contains two zinc-finger domains, which bind to the Psi RNA packaging signal and 
encapsidate the genomic RNA during assembly. NC-RNA interaction also promotes 
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higher order Gag-Gag interaction by using RNA as a scaffold for Gag multimerization. 
Finally, B-, C- and D-type retroviruses also contain late domain (L) motifs to help in the 
release of virus particle from the plasma membrane. Since A-type retroviruses are 
considered as “intracisternal” particles and are not released from the cell surface, they are 
thought to not contain late domain motifs. There are three classes of L motif: PTAP, 
PPXY, YXXL (30, 38, 53, 54). For HIV-1, the main mechanism of release involves the 
interaction between the PTAP motif and Tsg101, a member of the ESCRT-1 complex, 
which recruits other ESCRT complexes to facilitate the pinching-off process (53).  
In addition to these well-defined functional domains and motifs, some Gag 
proteins also contain spacer peptides, which vary in location within the Gag protein and 
play various roles during assembly. For instance, HIV-1 Gag contains spacer peptides 1 
and 2 (SP1 and SP2) (37). While the role of SP2 is not well-understood, SP1 is important 
in proper particle formation. In RSV, the spacer peptide p10 contains nuclear export 
signal (NES), which, when mutated, prevents Gag from exiting the nucleus, resulting in 
inefficient assembly (55). 
The focus of my dissertation is to understand the role of MA in mediating 
retroviral Gag membrane binding and targeting to the site of assembly. This research was 
carried out broadly, by examining the membrane binding behavior of various retroviral 
MA, and also highly focused, by looking at the targeting mechanism of HIV-1 Gag to the 
VCC in primary macrophages. As membrane binding is the first key step in retroviral 
assembly, this process serves as an attractive drug target for inhibiting virus replication. 
Therefore, an extensive understanding of the molecular mechanisms of Gag membrane 
binding and targeting by retroviral MA is necessary for identifying important drug targets. 
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In the remaining parts of this chapter, I will be focusing on discussing the roles played by 
retroviral MA during assembly. 
The roles of retroviral MA in virus assembly 
(i) Structure of retroviral MA 
The retroviral MA domain makes up the N-terminus of the Gag protein (Fig. 
1.3A). Despite a lack in sequence homology, structures of currently solved MA domains 
are remarkably similar to one another (39). To date, there are nine solved retroviral MA 
structures (39). These MA domains contain a globular core which is made up for four -
helices [for a comparison of retroviral MA structures, see Alfadlhi et al 2014 (39)]. 
Moreover, all retroviral MA contain basic residues (56). In some retroviruses, such as 
that of HIV-1, the basic residues are more clustered, forming a basic patch known as the 
highly basic region (HBR) (57-59). In other retroviruses, such as in HTLV-1, there is no 
obvious highly basic region; rather, the basic patches are found to be smaller and more 
distributed on the MA domain (36, 60, 61).  
(ii) Myristate moiety of retroviral MA 
The role of MA in membrane binding is brought about by two important signals: 
the N-terminal myristate and the basic residues (39, 57-59). Myristoylation is a co-
translational modification process in which a saturated 14-carbon chain, the myristic acid, 
is covalently added to the surface-exposed glycine at the N-terminus of a forming protein. 
For HIV-1, myristate moiety is added to the first glycine residue (following methionine) 
of the Gag protein, following the cleavage of the first methionine amino acid from the 
forming polypeptide (57, 59). The myristate moiety allows the Gag protein to interact 
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with cellular membrane via hydrophobic interactions. Myristoylated Gag are found in 
most retroviruses such as HIV-1, HTLV-1, MLV, and HERV-K. Mutation of the N-
terminus glycine residue, which prevents the addition of myristoyl group, renders the Gag 
protein unable to bind to cellular membrane (59), suggesting that myristate moiety is 
essential for membrane binding of Gag.  
The presence of constitutively exposed myristate can be detrimental for the virus 
as random binding of Gag to different cellular membrane may occur. Therefore, it is 
important to sequester the myristate moiety until Gag reaches the site of assembly, where 
membrane binding should occur. In HIV-1, the “myristoyl switch” mechanism is 
proposed to explain how the myristate exposure is regulated (62-69). According to this 
hypothesis, the myristoyl moiety is buried inside the HIV-1 MA globular domain and is 
only exposed upon Gag conformational changes that are triggered by events happening at 
the site of assembly, such as Gag-Gag interaction and binding to specific lipid at the 
plasma membrane. Some myristoylated cellular proteins, such as ADP-ribosylation factor 
and recoverin, have also been described to use the “myristoyl switch” mechanism to 
regulate their membrane binding (70, 71). Interestingly, it was suggested that, despite 
being myristoylated, HTLV-1 Gag does not utilize this mechanism for its membrane 
binding regulation (72, 73). How HTLV-1 Gag regulates its myristoyl exposure is not 
well-understood. Furthermore, whether this mechanism is truly unique to HIV-1 Gag 
remains to be determined. 
(iii) Basic region of retroviral MA contributes to electrostatic interaction with cellular 
membrane 
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Despite the importance of the myristate moiety in membrane binding, intriguingly, 
not all C-type retroviral Gag are myristoylated. Both RSV and EIAV Gag are not 
myristoylated, yet, they are able to bind to the plasma membrane (74, 75). This suggests 
that other forms of protein-membrane interaction are sufficient to provide the critical 
binding energy for stable membrane binding. One likely candidate is the electrostatic 
interaction between the basic patches on the retroviral MA and the negatively charged 
cellular membrane (56, 74, 76). Indeed, when all basic residues within the HBR is 
mutated to alanine, HIV-1 Gag failed to bind to the plasma membrane or negatively 
charged liposomes in vitro, suggesting that for HIV-1 Gag, both myristate and HBR are 
required for stable protein-membrane interaction (46, 59). Thus, in the case of RSV and 
EIAV Gag, it is possible that the electrostatic interaction is the main attractive force 
between the MA domain and the cellular membrane.  
(iv) Cellular proteins that bind membrane also contain polybasic region 
Not only retroviral Gag, but many cellular proteins also contain polybasic regions 
and are found to interact with cellular membrane via electrostatic interaction. These 
interactions can be specific or simply charge-based (77). Proteins containing pleckstrin 
homology (PH), epsin N-terminal homology (ENTH) domain, and FYVE domain, for 
example, bind membrane via specific interaction between the basic amino acid residues 
on the protein and the unique structure of the phospholipid headgroup (78). Other 
membrane proteins such as the effector domain of Src protein and Myristoylated Alanine-Rich 
C Kinase Substrate (MARCKS)  bind to negatively charged membrane mainly by bulk 
charge interactions (78-80). 
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(v) HIV-1 MA and the PH domain of PLC1 bind PI(4,5)P2 
The PH domain of phospholipase C delta-1 (PLC1) binds specifically to 
phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2), a phospholipid that is predominantly 
found at the inner leaflet of the plasma membrane (Fig. 1.3B) (77). PI(4,5)P2 is a type of 
phosphoinositide that makes up 1% of the total phospholipid at the plasma membrane 
with an overall charge of -3 or -4 at pH 7.0 (78). Upon binding, PLC1 cleaves PI(4,5)P2 
into diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3), where both serve as 
secondary messengers for the activation of signaling pathways in the cell. DAG remains 
on the cell membrane and activates the protein kinase C (PKC) cascade, whereas IP3 
enters the endoplasmic reticulum (ER), leading to an efflux of Ca2+, which in turn 
activates other signaling cascades. In addition to activating cell signaling pathways, 
PI(4,5)P2 is also involved in cytoskeleton rearrangement and in membrane trafficking, 
such as clathrin-mediated endocytosis and phagocytosis (78, 81-83). 
The polybasic residues (Lys30 and Lys57) found in the PH domain of PLC1 is 
shown to interact with the phosphorylated inositol ring of PI(4,5)2 by stereospecific 
interaction. Mutations at these sites of the PH domain results in severe reduction in 
PI(4,5)P2 binding (84).  
HIV-1 Gag has also been shown to interact specifically with PI(4,5)P2 (46, 66, 85-
88). Several in vitro studies further support that HIV-1 MA, in particular the HBR, 
interacts specifically with PI(4,5)P2. In the first study, using NMR, Saad et al., 
demonstrated that HIV-1 MA interacts specifically with PI(4,5)P2 and this interaction 
triggers myristate exposure (66). In another study, mass-spectrometric protein 
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footprinting was used to demonstrate that Lysines 29 and 31 of HIV-1 MA interact with 
PI(4,5)P2 (88). However, there are major caveats to these structural studies. First of all, 
the HIV-1 Gag protein used for modeling was either non-myristylated or truncated. 
Secondly, soluble, short acyl-chain PI(4,5)P2 was used, which did not fully represent the 
PI(4,5)P2 found in the cells (Fig. 1.3B). Thus, in order to fully study the interaction of full-
length myristylated Gag and PI(4,5)P2 with long acyl chains, our lab reported the use of 
in vitro liposome binding assay. Using this assay, we showed that HIV-1 Gag binds 
specifically to PI(4,5)P2-containing liposomes. Furthermore, mutating either the 
myristoylation site or the HBR of HIV-1 MA severely reduced HIV-1 Gag binding 
efficiency (87). These data provide in vitro evidence that HIV-1 Gag interacts 
specifically with PI(4,5)P2 via its MA domain. 
(vi) The role of PI(4,5)P2 in retroviral assembly in cells 
PI(4,5)P2 present at the plasma membrane can be depleted or mistargeted to 
intracellular compartments by overexpressing either phosphatidylinositol polyphosphate 
5 phosphatase (5ptaseIV) or the constitutively active Arf6 construct, respectively (89). 
PI(4,5)P2 depletion by 5ptaseIV overexpression in HeLa cells was found to severely 
reduced plasma membrane localization of HIV-1 Gag and HIV-1 release efficiency (87, 
89). Furthermore, expression of constitutively active Arf6 relocates HIV-1 Gag from the 
plasma membrane to the intracellular compartments. These results demonstrate that 
PI(4,5)P2 is important for HIV-1 assembly and Gag targeting to the site of assembly.  
The discovery of the role of PI(4,5)P2 in HIV-1 assembly has prompted more 
studies to examine the role of phospholipids in other retroviral assembly. To date, MLV 
MA, HIV-2 MA, RSV MA and EIAV MA have been shown to bind to PI(4,5)P2 (90-93), 
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although for EIAV, PI(3,5)P2 seems to play a more important role in virus assembly (94). 
Significant reduction in virus release efficiency of RSV, MLV, MPMV and HIV-2 are 
also observed upon 5ptaseIV overexpression in cells (93, 95-97). Interestingly, HTLV-1 
Gag as well as the HIV-1 Gag chimeric protein, which contains HTLV-1 MA in place of 
HIV-1 MA (HTMA Gag), do not require PI(4,5)P2 for efficient binding and that PI(4,5)P2 
depletion only modestly reduces their release from the cells (35).  
(vii) Retroviral MA target Gag to the site of assembly 
As mentioned previously, retroviral MA is also responsible in targeting Gag to the 
site of assembly. For HIV-1, some mutations in the HBR, such as mutating Lysines 29 
and 31 (29/31 KE), results in mislocalization of Gag to the intracellular compartments 
and inefficient virus release (34, 87). This suggests that proper Gag targeting to the site of 
assembly is important for efficient virus release. Similarly, mutations of some of the 
basic residues in other retroviral MA, such as that of HTLV-1, RSV and MLV, also lead 
to altered Gag localization and/or reduced virus release (36, 98, 99). Thus, the basic 
residues of retroviral MA play dual roles during virus assembly: (i) facilitating membrane 
binding and (ii) targeting Gag to the site of assembly.   
However, while it is true that HIV-1 MA plays a major role in targeting Gag to 
the plasma membrane in HeLa and T cells, the mechanism of Gag targeting to the uropod, 
a specialized region of the plasma membrane, in polarized T cells seems to be dependent 
more on Gag-Gag multimerization (100). Similarly, targeting of HIV-1 Gag to the VCC 
in primary macrophages seems to require higher-order multimerization by HIV-1 NC. 
The cell-type-dependent molecular mechanisms of HIV-1 Gag targeting to the site of 
assembly will be further discussed in Chapter IV of my dissertation. 
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(viii) The RNA-binding role of retroviral MA 
Most retroviral MA contain an overall positive charge (56). This basic charge 
allows retroviral MA to bind to the negatively charged cellular membrane as well as 
nucleic acids (NA). Both BLV MA and HIV-1 MA have been shown to have NA-binding 
abilities (101, 102). For BLV, it is thought that the MA domain plays a role in RNA 
encapsidation (101). HIV-1 MA, in particular, Lysine residues 25 and 26 in the HBR, has 
been implicated DNA/RNA binding (47, 48, 51). A recent RNA-seq study show that 
HIV-1 MA binds RNA, in particular, specific types of tRNAs, in cells (103). In vitro 
analysis of HIV-1MA further shows that some residues that binds RNA within the HBR 
overlap with those binding PI(4.5)P2 (104). Overall, these study support that HIV-1 MA, 
particularly the HBR, can bind NA. However, it was not known whether RNA had any 
regulatory effect on HIV-1 assembly, especially in membrane binding. Thus, to examine 
the role of HIV-1 MA and RNA interaction, our lab utilized the in vitro liposome binding 
assay and analyzed the effect of RNase treatment of HIV-1 Gag on membrane binding. 
Surprisingly, we found that RNase treatment enables HIV-1 Gag to bind to negatively 
charged liposomes (PC:PS) that does not contain PI(4,5)P2 (46). The PC:PS liposomes 
are made up of neutral lipid phosphatidylcholine (PC) and an acidic lipid 
phosphatidylserine (PS) at 2:1 ratio. Importantly, deletion of NC, the major RNA-binding 
domain, still renders HIV-1 Gag responsive to RNase treatment, suggesting that MA-
bound RNA is the one responsible for liposome binding inhibition (46). Based on these 
results and previous studies looking at HIV-1 MA ability to bind RNA, we hypothesize 
that the MA-bound RNA prevents HIV-1 Gag from binding non-specifically to the 
abundant negatively charged cellular membranes and only allows binding to membranes 
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that contain PI(4,5)P2, such as the plasma membrane (Fig. 1.4). In other words, RNA 
regulates HIV-1 Gag membrane binding by HIV-1 Gag specific binding to the plasma 
membrane where assembly takes place.  
In contrast to HIV-1 Gag, HTLV-1 Gag was found to be able to bind non-
PI(4,5)P2-containing (PC:PS) liposomes efficiently (35). Furthermore, unlike HIV-1 Gag, 
HTLV-1 Gag binding to PC:PS liposomes is not responsive to RNase treatment as 
efficient binding can already be achieved even in the absence of RNase treatment (35). 
HTLV-1 Gag provides the first evidence that PI(4,5)P2 and RNA do not regulate the 
membrane binding of all retroviral Gag. However, while it is likely that the difference in 
membrane binding properties of HIV-1 Gag and HTLV-1 Gag is due to the MA domain, 
we were not able to specifically identify which retroviral domain in HTLV-1 Gag confers 
this lack of sensitivity to PI(4,5)P2 and RNA. Moreover, it is unknown whether other 
retroviral MA can be similarly or differentially regulated by PI(4,5)P2 and RNA. Thus, to 
address these issues, I conducted a broad analysis of different retroviral MA in their Gag 
membrane binding and targeting properties. By constructing protein chimeras (GagLZ), 
where each contain different retroviral MA, I was able to analyze specifically the role of 
MA-PI(4,5)P2 and MA-RNA interactions during Gag assembly (60). The analyses and 
discussion of this part of my thesis can be found in Chapter II of my dissertation. 
The data collected so far indicates that RNA-mediated membrane binding 
inhibition of HIV-1 Gag exists in vitro. While it is compelling to think that RNA can also 
regulate the interaction between HIV-1 MA and membrane in the cell, there is no direct 
evidence to show that this mechanism exists in the cell. Thus, to examine if RNA-
mediated membrane binding inhibition of HIV-1 Gag can happen in cells, our lab 
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developed the cell-derived liposome binding assay (45). In these experiments, we 
harvested HIV-1 Gag from transfected HeLa cells and demonstrated that these HIV-1 
Gag proteins are able to bind to PC:PS liposomes upon RNase treatment. Furthermore, to 
examine if RNA can indeed block HIV-1 Gag binding to PC:PS liposomes, we added 
back RNA to HIV-1 Gag that was previously RNase-treated and then RNase-inactivated.  
As expected, we found that RNA can re-establish the inhibition on Gag binding to these 
non-PI(4,5)P2-containing liposomes (45). The results of the cell-derived liposome 
binding assays and the RNA add-back assays will be further discussed in Chapter III of 
the dissertation.  
Overview of thesis 
Retroviral assembly is driven by its structural Gag protein. Assembly is a key step 
in virus replication as it leads to the production of new virions in the cell. Since Gag is 
the main driver of this important process, it serves as an attractive drug target to inhibit 
viral replication. In this introduction, we have discussed some similarities between 
retroviral Gag and cellular proteins in their membrane binding properties. We have also 
considered the importance of cellular phospholipids and RNA in regulating Gag 
membrane binding. Membrane binding regulation by RNA is a new concept. Given that 
both retroviral MA and membrane-binding cellular proteins contain polybasic regions, it 
is likely cellular proteins can also bind RNA and that the RNA-mediated regulation is not 
only limited to retroviral proteins. Thus, a more in-depth analysis of how retroviral Gag 
bind to cellular membrane will potentially reveal important (cellular or viral) players in 
the assembly step and also further our understanding of how membrane binding of 
various cellular proteins are regulated.   
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My dissertation involves the study of roles of lipids and RNA in regulating 
retroviral assembly. The first aim of my thesis is to broadly examine the roles of lipid and 
RNA in regulating the membrane binding of retroviral Gag. This work is presented in 
Chapter II, which shows that membrane binding of retroviral Gag can be distinctly 
categorized into those that are PI(4,5)P2-dependent, RNAse-responsive and those that are 
PI(4,5)P2-independent and RNase non-responsive. Furthermore, towards better 
understanding of the role of RNA in regulating retroviral Gag membrane binding in the 
cell, in Chapter III, I have developed a cell-based liposome binding assay. I was able to 
validate our previous in vitro liposome binding results using cell-derived Gag in place od 
the in vitro-synthesized Gag. These results supports the idea that cellular RNA can 
interact with HIV-1 Gag and that RNA-mediated inhibition of HIV-1 Gag membrane 
binding can exist in the cell.  
The second aim of my thesis is to elucidate the molecular mechanism of HIV-1 
assembly in primary macrophages, a topic that remains poorly understood. In Chapter 
IV of my dissertation, I described the roles of PI(4,5)P2 and RNA in determining the 
localization of HIV-1 Gag to VCC in macrophages. My results suggest that HIV-1 Gag 
localization to the VCC requires NC-mediated multimerization. 
Finally, in Chapter V, I will summarize results of Chapters II, III, IV, propose 
future directions by providing some of the preliminary results pertaining to these projects, 
and discuss the future of the antiretroviral treatments based on the work of my 
dissertation. 
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Fig. 1.1. Retroviral genome organization. A comparison of simple versus complex retroviral 
genome, as exemplified by MLV and HIV-1, respectively. Simple retroviruses only contain four 
essential genes – gag, pro, pol and env; whereas complex retroviruses contain additional 
accessory genes such as tat, rev, vif, vpr, vpu and nef. 
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Accessory protein Major function 
Nef MHC-I and CD4 downregulation. 
Rev Binds rev response elements (RRE) found on viral RNA, transport of 
unspliced or incompletely spliced RNA out of nucleus. 
Tat Activation of HIV-1 gene transcription. 
Vif Counteracts the restriction factor APOBEC3G and prevents G-to-A 
hypermutation. 
Vpr Cell cycle arrest; rescues Env expression in macrophages by 
counteracting an unknown restriction factor. 
Vpu Downregulates tetherin to increase virus release from the cell surface. 
 
Table 1.1. Functions of HIV-1 accessory proteins. HIV-1 genome contains genes that encode 
different accessory proteins that ensure its survival in the host. These proteins help in immune 
evasion, host restriction factor downregulation and also in increasing viral gene expression. For 
review, refer to (105-107). 
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Fig. 1.2. An overview of retrovirus lifecycle. Retrovirus lifecycle, as exemplified by HIV-1 
lifecycle, is broadly divided into early and late events. Early events include virus attachment, 
entry, membrane fusion, reverse transcription and integration. Late events of retrovirus 
replication include transcription and translation of viral genes, virus assembly, virus release and 
maturation. 
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Fig.1.3. HIV-1 Gag structural and functional domains and PI(4,5)P2 structure. (A) All 
retroviral Gag are synthesized as polyprotein containing matrix (MA), capsid (CA) and 
nucleocapsid (NC) structural domains. Each domain play essential roles during assembly. 
Retroviral Gag also contain late domain motif to help in virus release from cell surface. For HIV-
1, late domain motif is found in the p6 region. Other retroviruses, such as HTLV-1 and MLV, the 
late domain motif is found in the MA region [for review, refer to (54)]. In addition to these 
structural domains, some retroviral Gag, such as HIV-1, also contain spacer peptides. (B) 
PI(4,5)P2 is found in the inner leaflet of the plasma membrane. Its inositol ring is phosphorylated 
at the fourth and fifth position, making PI(4,5)P2 a highly negatively charged phospholipid. 
Natural PI(4,5)P2 contains long acyl chains (C16 to C20). 
 
O
P
O
-
O
-
O
-
O
P
O
-
O
O
O
P
O
-
O
O
HO
OH
OH
CH
2
OO
CC
OO
1
2
4
3
6 5
CH CH
Plasma membrane
outer leaflet
inner leaflet
A
B
23 
 
 
Fig. 1.4. A working model for RNA-mediated regulation of HIV-1 Gag membrane binding. 
The interaction between HIV-1 MA and RNA prevents HIV-1 Gag from binding to non-specific 
cellular membranes, i.e., membranes that do not contain PI(4,5)P2. However, upon encountering 
PI(4,5)P2-containing membrane, such as the plasma membrane, the HBR of HIV-1 MA interacts 
with PI(4,5)P2, facilitating Gag membrane binding. It is not known at this point whether the RNA 
is displaced upon HIV-1 MA binding to PI(4,5)P2 or remains bound to the MA domain. 
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CHAPTER II 
Membrane Binding and Subcellular Localization of Retroviral Gag Proteins are 
Differentially Regulated by MA Interactions with PI(4,5)P2 and RNA 
 
ABSTRACT 
The matrix (MA) domain of HIV-1 mediates proper Gag localization and 
membrane binding via interaction with a plasma-membrane(PM)-specific acidic 
phospholipid, phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]. HIV-1 MA also 
interacts with RNA, which prevents Gag from binding to membranes containing 
phosphatidylserine, a prevalent cellular acidic phospholipid. These results suggest that 
the MA-bound RNA promotes PM-specific localization of HIV-1 Gag by blocking non-
specific interactions with cellular membranes that do not contain PI(4,5)P2. To examine 
whether PI(4,5)P2 dependence and RNA-mediated inhibition collectively determine MA 
phenotypes across a broad range of retroviruses and elucidate the significance of their 
interrelationships, we compared a panel of Gag-leucine-zipper constructs (GagLZ) 
containing MA of different retroviruses. We found that in vitro membrane binding of 
GagLZ via HIV-1 MA and RSV MA is both PI(4,5)P2-dependent and susceptible to 
RNA-mediated inhibition. The PM-specific localization and virus-like particle (VLP) 
release of these GagLZ proteins are severely impaired by overexpression of a PI(4,5)P2-
depleting enzyme, polyphosphoinositide 5-phosphatase IV (5ptaseIV). In contrast, 
membrane binding of GagLZ containing HTLV-1, MLV, and HERV-K MA is PI(4,5)P2-
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independent and not blocked by RNA. The PM localization and VLP release of these 
GagLZ chimeras were much less sensitive to 5ptaseIV expression. Notably, single amino 
acid substitutions that confer a large basic patch rendered HTLV-1 MA susceptible to the 
RNA-mediated block, suggesting that RNA readily blocks MA containing a large basic 
patch, such as HIV-1 and RSV MA. Further analyses of these MA mutants suggest a 
possibility that HIV-1 and RSV MA acquired PI(4,5)P2 dependence to alleviate 
membrane binding block imposed by RNA. 
 
INTRODUCTION 
Assembly and release of retrovirus particles are mediated by the viral structural 
protein, Gag. Human immunodeficiency virus type-1 (HIV-1) Gag is synthesized as a 
precursor polyprotein, comprising four major structural domains: matrix (MA), capsid 
(CA), nucleocapsid (NC) and p6; and two spacer peptides: SP1 and SP2 (1-3). Each of 
these domains plays essential roles during assembly. MA is responsible for targeting and 
binding of HIV-1 Gag to the plasma membrane (PM), the site where virus assembly 
occurs. The N-terminal domain of CA is implicated in Gag lattice arrangement during 
virus particle formation, while the C-terminal domain contains CA dimer interface. 
Specific encapsidation of viral genomic RNA is determined by zinc finger motifs in NC, 
while NC binding to RNA also promotes Gag multimerization. The late domain motifs 
within NC and p6 recruit cellular ESCRT complexes that facilitate release of virus 
particles from the cell surface (4-6). 
HIV-1 MA contains bipartite signals that mediate Gag binding to the PM: the N-
terminal myristoyl moiety and the highly basic region (HBR), which spans residues 17 to 
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31 in the MA domain (7-9). The myristoyl moiety is sequestered within a hydrophobic 
pocket of HIV-1 MA. Structural changes caused by events such as Gag multimerization 
and Gag-PI(4,5)P2 interactions trigger exposure of the myristoyl moiety, facilitating 
hydrophobic interactions between MA and lipid bilayer membranes (10-17). The HBR 
contributes to membrane binding via electrostatic interactions with the acidic 
phospholipids. Several studies based on a variety of approaches including protein 
footprinting, NMR and liposome binding showed that the HIV-1 MA HBR interacts with 
phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2], a phosphoinositide that is found 
predominantly at the cytoplasmic leaflet of the PM (14, 18-23). It has also been shown 
that mutations in the HBR result in alterations of HIV-1 Gag localization from the PM to 
either the intracellular compartments or the cytosol (21, 22, 24-28). These findings 
suggest that HBR also plays a role in targeting HIV-1 specifically to the PM. Notably, 
when cellular PI(4,5)P2 is depleted by overexpression of polyphosphoinositide 5-
phosphatase IV (5ptase IV), HIV-1 Gag fails to bind PM efficiently and either remains in 
the cytosol or localizes to intracellular compartments, resulting in a significant reduction 
in HIV-1 release (20, 21, 27, 29, 30). These results suggest that HIV-1 MA-PI(4,5)P2 
interactions are important for PM binding of HIV-1 Gag. 
Using an in vitro liposome binding assay, we previously showed that HIV-1 Gag 
synthesized in vitro in rabbit reticulocyte lysates is unable to bind liposomes consisting of 
a neutral phospholipid phosphatidylcholine (PC) and an acidic phospholipid 
phosphatidylserine (PS) in a 2:1 ratio [PC:PS (2:1)], unless PI(4,5)P2 is also present in the 
liposomes (21). These results suggest that bulk negative charge of liposomes is 
insufficient for efficient Gag-membrane interaction in the presence of mammalian cell 
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lysates and that Gag membrane binding under these conditions requires the presence of 
PI(4,5)P2. In addition to PI(4,5)P2, HIV-1 MA binds RNA (22, 30-41). Using the same 
liposome binding assay described above, we found that HIV-1 Gag can bind PC:PS (2:1) 
liposomes when it is first treated with RNase. These and other results suggest that the 
MA-RNA interaction negatively regulates HIV-1 Gag membrane binding in the absence 
of PI(4,5)P2 by inhibiting HBR interaction with acidic lipids (22, 33, 42-44). The RNase 
responsiveness of Gag membrane binding is also observed for HIV-1 Gag derived from 
the cytosol of transfected HeLa cells, indicating that RNA present in human cells is 
capable of preventing Gag from binding to membrane in cells (33). Based on these 
results, we hypothesized that the interaction of MA HBR with RNA prevents premature 
or non-specific binding of HIV-1 Gag to membranes containing prevalent acidic lipids 
such as PS and thereby consequentially ensures its specific binding to the PM, which 
contains PI(4,5)P2.  
Basic surface patches are present not only on HIV-1 MA but on all retroviral MA 
domains for which structures have been determined. These surface patches are proposed 
or shown to interact electrostatically with phospholipid headgroups (45-49). Like HIV-1 
MA, the MA domains of other retroviruses are also known to interact with RNA either in 
cells or in vitro (39, 50-53). Furthermore, in addition to HIV-1 Gag, Gag proteins of 
many retroviruses including HIV-2, equine infectious anemia virus (EIAV), murine 
leukemia virus (MLV), Rous sarcoma virus (RSV), and Mason-Pfizer monkey virus were 
shown to either interact with PI(4,5)P2 via MA or produce virions in a manner that is 
susceptible to 5ptaseIV overexpression, suggesting that PI(4,5)P2 is involved in efficient 
assembly and release of these viruses (20, 29, 54-58). However, the degree of 
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PI(4,5)P2 dependence may vary among different retroviruses. For instance, a study 
showed that even though EIAV MA can bind both PI(3,5)P2 and PI(4,5)P2, EIAV 
assembly was sensitive to an inhibitor of PI(3,5)P2 synthesis, but not to 5ptaseIV 
overexpression (59).  As for RSV, while PI(4,5)P2 was observed to promote Gag binding 
to liposome membranes (29), it remains unclear to what extent PI(4,5)P2 plays a role in 
PM localization of Gag and virus assembly in cells, since previous studies yielded 
inconsistent results on RSV Gag sensitivity to 5ptaseIV overexpression (29, 56). In this 
regard, a comparative study of various retroviruses in the same experimental systems 
should allow us to determine the spectrum of PI(4,5)P2 dependence for membrane 
binding, subcellular localization, and virus particle production.   
Using the in vitro liposome binding assay, we previously found that, unlike HIV-1 
Gag, HTLV-1 Gag does not require PI(4,5)P2 for efficient membrane binding to PC:PS 
(2:1) liposomes (30). We also observed that RNase treatment of HTLV-1 Gag does not 
increase its binding to PC:PS (2:1) liposomes, unlike HIV-1 Gag, which is highly 
responsive to RNase treatment. These results suggest that HTLV-1 Gag membrane 
binding is not inhibited by RNA, unlike that of HIV-1 Gag. However, in that study, the 
presence of viral RNA and the downstream NC domain complicated the interpretation of 
the results as to the intrinsic properties of HTLV-1 MA relative to those of HIV-1 MA. 
As such, several major questions including the following remain to be answered. (i) Is the 
RNA susceptibility (or lack thereof) primarily determined by MA? If so, which feature of 
MA determines its susceptibility to RNA? (ii) What is the relationship between PI(4,5)P2 
interaction and RNA binding of HIV-1 MA? Are they inseparable or regulated 
differently? (iii) What is the significance of such relationships in assembly? For example, 
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was RNA recruited to enhance the specificity for PI(4,5)P2 or did RNA-mediated block 
necessitate PI(4,5)P2 interaction? Lastly, (iv) can PI(4,5)P2 dependence and susceptibility 
to RNA (or lack thereof) serve as a general principle that can explain membrane binding 
and subcellular localization phenotypes of a broad range of retroviral MA domains?  
In this study, in order to broadly analyze the specific roles of MA-PI(4,5)P2 and 
MA-RNA interactions in membrane binding, we analyzed chimeric HIV-1 Gag 
derivatives where HIV-1 MA is replaced with MA domains of other retroviruses, each 
representing a retroviral genus, i.e., HTLV-1 (deltaretrovirus), MLV (gammaretrovirus), 
RSV (alpharetrovirus) and human endogenous retrovirus-K (HERV-K) (betaretrovirus). 
In this analyses, we focused on retroviruses that follow Type C assembly pathway, in 
which the most part of virus particle assembly process takes place at membrane (e.g., the 
PM) (60). To eliminate the effect of NC-RNA binding while allowing Gag 
multimerization, we replaced the HIV-1 NC, the major RNA-binding domain, with a 
leucine zipper motif in these constructs (GagLZ) (61). We examined their localization 
and VLP release efficiencies in cells as well as their membrane binding properties using 
both cell-based and in vitro methods. Our data demonstrate that PI(4,5)P2 dependence 
and RNA-mediated inhibition are highly correlated properties among the five different 
retroviral MA domains. We found that there are two distinct groups among the retroviral 
MA domains that differ in their membrane binding phenotypes: those that are PI(4,5)P2-
dependent and RNase-responsive (MA of HIV-1 and RSV) and those that are neither 
PI(4,5)P2-dependent nor RNase-responsive (MA of HTLV-1, MLV and HERV-K). Using 
structure-guided mutagenesis approach, we also elucidated an MA determinant for RNA 
susceptibility. We found that, strikingly, single point mutations that increase the size of 
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an MA basic patch convert HTLV-1 MA to MA that is sensitive to RNA-mediated 
inhibition of membrane binding. However, unlike for HIV-1 MA and RSV MA, which 
also have a large basic patch, PI(4,5)P2 failed to reverse the RNA-mediated inhibition for 
these HTLV-1 MA mutants, suggesting that PI(4,5)P2 dependence and RNA 
susceptibility are genetically separable. These results support the model that that 
PI(4,5)P2 dependence is an adaptation of retroviruses that contain a large basic patch on 
the MA surface, such as HIV-1 and RSV, to overcome the strong membrane binding 
block imposed by RNA. Other retroviruses such as HTLV-1 and MLV may have adopted 
smaller basic patches on their MA surface to avoid RNA-mediated membrane binding 
inhibition. 
 
MATERIALS AND METHODS 
Plasmids. pCMV-RRE-HIV-1 GagLZ was constructed from pCMV-RRE-HIV1.5-Gag 
which was described previously (30). To focus specifically on the role of MA-RNA 
interaction in Gag localization, the NC region of HIV-1 Gag, which also contain an 
RNA-binding domain, was replaced with leucine zipper dimerization motif (LZ) from 
yeast GCN4 activator (a kind gift from H. Gottlinger) (61). This construct, called HIV-1 
GagLZ, is able to multimerize and form virus-like particles similar to wild-type HIV-1 
Gag. pCMV-RRE-HTLV-1 MA GagLZ was constructed by replacing HIV-1 MA of 
pCMV-RRE-HIV-1 GagLZ with HTLV-1 MA spanning residues 1 to 116. pCMV-RRE-
RSV MA GagLZ contains RSV MA-p2-p10 (RSV Gag residues 1-239) of the RHR 
construct (a kind gift from V. Vogt) (78) in place of HIV-1 MA. pCMV-RRE-MLV MA 
GagLZ was constructed by substituting HIV-1 MA with MLV MA (residues 1-131) from 
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pNCA (a kind gift from A. Telesnitsky) (79). Finally, pCMV-RRE-HERV-K MA GagLZ 
contains HERV-K MA-SP1 (residues 1-148) of pCRVI/HERV-K/GagPro (a kind gift 
from P. Bieniasz) (80, 81) in place of HIV-1 MA. Acidic-to-basic point mutants of 
HTLV-1 MA GagLZ (D42K, E55K, D42K/E55K) were constructed using standard 
molecular cloning techniques. 
pCMV-RRE-HIV-1 Gag-eCFP and pCMV-RRE-HTLV-1 Gag-eCFP were 
described previously (30). pCMV-RRE-RSV Gag-eCFP, pCMV-RRE-MLV Gag-eCFP, 
and pCMV-RRE-HERV-K Gag-eCFP  were constructed by replacing the HIV-1 gag 
reading frame in pCMV-RRE-HIV-1 Gag-eCFP with that of RSV gag in an expression 
plasmid (78), MLV gag in pNCA (79) and HERV-K gag in pCRVI/HERV-K/GagPro 
(80, 81), respectively, using standard molecular cloning techniques. 
GagLZ proteins were C-terminally fused to a linker (Ala-Gly-Ser-Pro-Ala) and either an 
eCFP or the Venus variant of YFP to yield fluorescently-tagged chimeric GagLZ 
constructs. The first methionine residue of eCFP and YFP were deleted to prevent the 
fluorescent protein from being translated by internal ribosomal entry. The 5ptaseIV 
expression plasmid, pcDNA4TO/Myc5ptaseIV, and its derivative that lacks a functional 
phosphatase domain (pCDNA4TO/5ptaseIV ∆1) were previously described (21, 27, 82). 
pRS-HRevX plasmid (a gift from D. Derse) is derived from the pKS-Bluescript vector 
encoding the HIV-1 rev gene driven by an RSV promoter. pCMV-Vphu, which encodes 
the codon-optimized HIV-1 vpu gene, was kindly provided by K. Strebel (83). The Gag 
expression plasmids used for in vitro transcription-translation-coupled reactions, pGEM-
HIV-1 GagLZ, pGEM-HTLV-1 MA GagLZ, pGEM-RSV MA GagLZ, pGEM-MLV MA 
GagLZ, and pGEM-HERV-K MA GagLZ were constructed using pGEM-1 (Promega) as 
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a vector plasmid and Gag-encoding fragments derived from pCMV-RRE-HIV-1 GagLZ, 
pCMV-RRE-HTLV-1 MA GagLZ, pCMV-RRE-RSV MA GagLZ, pCMV-RRE-MLV 
MA GagLZ and pCMV-RRE-HERV-K MA GagLZ, respectively, using standard 
molecular cloning techniques. The resulting plasmids encode the Kozak sequence, 
followed by HIV-1 GagLZ, HTLV-1 MA GagLZ, RSV MA GagLZ, MLV MA GagLZ 
and HERV-K MA GagLZ. 
Cells and transfection. HeLa cells were cultured as described previously (21, 22, 25, 
84). For microscopy, 4.2 x 104 cells were plated into each well of eight-well chamber 
slides (Lab-Tek; Nalge Nunc International), grown for 24 h, and transfected with DNA 
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. For 
VLP release, 5.6 x 105 cells were plated into each well of six-well plates (Corning), 
grown overnight, and transfected as described above. For microscopy, Gag expression 
plasmids were transfected along with pRS-HRevX. For VLP release assays, Gag 
expression plasmids were transfected along with pRS-HRevX and pCMV-Vphu. Co-
expression of pCMV-Vphu does not lead to any change in chimeric GagLZ localization 
(unpublished data). 
VLP release assay and immunoblotting. VLP release assay using immunoblotting was 
previously described (30). In some experiments, VLP release was examined using 
metabolic labeling and immunoprecipitation as previously described with modifications 
(21, 27, 85). Briefly, HeLa cells were transfected with CMV-driven plasmid encoding a 
chimeric GagLZ construct, along with pRS-HRevx and pCMV-Vphu. Sixteen hours post-
transfection, culture medium was changed to RPMI-1640 lacking both methionine (Met) 
and cysteine (Cys) and supplemented with 2% FBS [RPMI-2 (−Met/−Cys)] and 
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incubated for 30 min. Subsequently, these cells were metabolically labeled with [35S] 
Met/Cys (Perkin-Elmer) in fresh RPMI-2 (−Met/−Cys) for 4 h. Cell and virion lysates 
were prepared and subjected to immunoprecipitation with HIV-Ig antiserum (NIH AIDS 
Research and Preference Reagent Program). The virus release efficiency was calculated 
as the amount of virion-associated Gag as a fraction of the total amount of Gag 
synthesized during the labeling period. 
Immunostaining and fluorescence microscopy. Fixation and immunostaining of 
transfected HeLa cells expressing Gag or Gag-fluorescent protein fusions were performed 
as described previously (27, 30). The presence of 5ptaseIV in cells was visualized by 
immunostaining with mouse anti-Myc antibody (clone 9E10; Santa Cruz 
Biotechnologies). For visualization of the plasma membrane, cells were incubated with 
Alexa Fluor 594-conjugated concanavalin A (ConA; Invitrogen) for 2 min after fixation. 
Cells were then imaged using Leica confocal fluorescence microscope. Pearson’s 
correlation coefficients of ConA and Gag-YFP were calculated using the Coloc2 plugin 
in ImageJ. Twenty to fifty cells were analyzed for each condition. For determining the 
distribution of Gag localization patterns, images of about 20 fields were recorded by 
using an Olympus IX70 inverted fluorescence microscope at 100x magnification, and a 
range of 80 to 150 cells that were positive for both Gag and 5ptaseIV (either full-length 
[FL] or the ∆1 derivative) were evaluated for the Gag localization pattern in each 
condition in a blind manner. Classification of Gag localization patterns was validated 
using line profiles generated using ImageJ. 
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Liposome-binding assay. Preparation of liposomes, in vitro Gag translation, and sucrose 
gradient flotation centrifugation were performed as described previously (21, 30, 33). The 
RNase treatment experiments were also performed as previously described (30, 33).  
Electrostatic potential calculations. The calculations of electrostatic potential of 
previously solved retroviral MA domains were performed using the DelPhi program (86). 
The electrostatic potentials were then mapped to molecular surface and visualized using 
the Chimera program (87). The retroviral MA structures used for comparison are as 
follow: HIV-1 MA (PDB: 2HMX), RSV MA (PDB: 1A6S), HTLV-2 (PDB: 1JVR) and 
MLV MA (PDB: 1MN8) (45, 63-65). The HTLV-1 MA structure was predicted based on 
the NMR structure of HTLV-2 MA (PDB: 1JVR) (45) using the SWISS-MODEL server 
(66, 67). The molecular surface of HIV-1 MA and HTLV-1 MA was visualized using 
Protean 3D. 
Statistical analysis. Two-tailed Student t-tests were performed using Microsoft Excel. 
The paired t test was used for comparing data obtained from the same set of experiments. 
P values of <0.05 were considered statistically significant. 
 
RESULTS 
MA domains of different retroviruses determine subcellular localization patterns of 
Gag chimeras 
As a first step to compare the properties of different retroviral MA domains, we 
tested the subcellular localization of eCFP-tagged full-length Gag proteins of different 
retroviruses in transfected HeLa cells. The cell surface was stained using Concanavalin A 
(ConA) labeled with AlexaFluor 594 to better distinguish Gag at the PM from those at 
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intracellular sites. As evident in the intensity profiles of ConA and Gag-eCFP, cells 
expressing eCFP-tagged HIV-1 Gag, RSV Gag or HERV-K Gag displayed highest Gag-
eCFP signals at cell periphery (Fig. 2.1), indicating that these Gag-eCFP proteins localize 
predominantly to the PM. In contrast, cells expressing eCFP-tagged HTLV-1 Gag, MLV 
Gag and EIAV Gag showed eCFP intensity peaks at both cell periphery and cytoplasmic 
regions, indicating that these Gag-eCFP proteins localize to both PM and intracellular 
compartments (Fig. 2.1). To test whether the differential localization patterns can be 
attributed primarily to MA domains and not downstream sequences, we constructed a 
panel of Gag chimera by replacing the MA domain of HIV-1 Gag with that of RSV, 
HTLV-1, MLV, HERV-K or EIAV (Fig. 2.2A). In these experiments, to eliminate the 
effect of NC-RNA binding so as to focus on the direct effect of the MA-RNA interaction, 
we replaced NC with a leucine zipper motif (GagLZ) in these constructs (Fig. 2.2A) (61). 
HIV-1 Gag chimeras containing HIV-1 CA and this LZ sequence were previously shown 
to support wild-type-level VLP formation in the absence of NC (61). Like their full-
length counterparts, eCFP-tagged HIV-1 GagLZ, RSV MA GagLZ and HERV-K MA 
GagLZ localized predominantly at the PM in HeLa cells (Fig. 2.1).  In contrast, eCFP-
tagged HTLV-1 MA GagLZ and MLV MA GagLZ localized to both the PM and 
intracellular compartments, as observed with their full-length versions. Altogether, these 
results suggest that the MA domains of HIV-1, HTLV-1, RSV, MLV, and HERV-K 
determine the subcellular localization of Gag regardless of the downstream sequences. 
Unlike other chimeric GagLZ constructs tested, however, EIAV MA GagLZ and its full-
length counterpart, EIAV Gag, showed different localization patterns. We found that 
EIAV MA GagLZ localized mainly to PM, unlike wild type EIAV Gag, which localized 
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to both the PM and intracellular compartments (Fig. 2.1) (59). This suggests that the MA 
domain of EIAV Gag is not the sole determinant of Gag localization and that the 
downstream sequences of EIAV MA play a role as well. For this reason, we chose not to 
pursue EIAV MA GagLZ in subsequent comparative analyses of retroviral MA domains. 
Differential effects of PI(4,5)P2 depletion on subcellular localization of GagLZ 
chimeras in HeLa cells   
We and others previously reported that 5ptaseIV overexpression abolishes 
localization of HIV-1 Gag to the PM and instead increases the hazy cytosolic localization 
in HeLa cells (21, 27, 29, 30). To assess the effect of PI(4,5)P2 depletion on subcellular 
localization of chimeric GagLZ proteins described above, HeLa cells were transfected 
with a plasmid encoding YFP-tagged chimeric GagLZ constructs (GagLZ-YFP), along 
with a plasmid encoding either Myc-tagged full-length (FL) 5ptaseIV or its ∆1 derivative, 
and were examined by fluorescence microscopy (Fig. 2.2B and 2.4). The 5ptaseIV ∆1 
derivative lacks the functional phosphatase domain and therefore does not deplete 
cellular PI(4,5)P2 (21, 27, 29, 30). We used YFP-tagged chimeric GagLZ constructs in 
this experiment because they display higher signal-to-background ratios than eCFP-
tagged ones. Substitution of FP in these chimeric GagLZ constructs did not alter their 
subcellular localizations (compare Fig. 2.4, 5ptaseIV ∆1, with Fig. 2.1). To measure the 
effect of 5ptaseIV expression on localization of the chimeric GagLZ constructs 
quantitatively, we analyzed 80-150 cells expressing both Myc-tagged and YFP-tagged 
proteins per condition and categorized them in a blind manner into 3 different groups 
based on GagLZ-YFP localization patterns: (i) predominant localization at the PM (black 
bar), (ii) localization to both PM and intracellular compartments (white bar), and (iii) 
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hazy cytosolic localization (grey bar) (Fig. 2.4A). These three localization patterns were 
also validated via comparison of the GagLZ-YFP signal intensity profiles with the signal 
intensity profiles of ConA-AlexaFluor 594, the PM marker (Fig. 2.4B). In 5ptaseIV ∆1-
expressing cells, a majority of HIV-1 GagLZ, RSV MA GagLZ, and HERV-K MA 
GagLZ showed punctate PM localizing pattern. However, when 5ptaseIV FL was 
expressed, most cells expressing HIV-1 GagLZ and RSV MA GagLZ displayed hazy 
cytosolic signals, indicating a defect in Gag membrane binding. In contrast, HERV-K 
MA GagLZ still localized to the PM with a modest increase in the population of cells 
showing dual localization to the PM and intracellular compartments in 5ptaseIV FL-
expressing cells. On the other hand, 5ptaseIV overexpression did not drastically alter 
localization of HTLV-1 MA GagLZ and MLV MA GagLZ; most cells showed GagLZ 
localized to both the PM and intracellular compartments regardless of whether they 
expressed 5ptaseIV ∆1 or FL. While localization of these GagLZ proteins to intracellular 
compartments appeared to be increased in some of the cells expressing 5ptaseIV FL, PM 
localization was still observed in these cells.  
In addition to the analysis of cell populations described above, we also sought to 
measure quantitatively the effect of 5ptaseIV expression on the chimeric GagLZ 
localization on single cell bases. To this end, we acquire images using confocal 
microscopy and calculated the Pearson’s correlation coefficient (PCC) between YFP-
tagged GagLZ constructs and ConA- Alexa Fluor 594. Confocal imaging (Fig. 2.2B) 
showed qualitatively same localization patterns for GagLZ chimeras as observed by 
epifluorescence microscopy (Fig. 2.4) but eliminated out-of-focus signals. In the PCC 
analysis (Fig. 2.3A), we used the distributions of wild type HIV-1 Gag-YFP, a chimeric 
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HIV-1 Gag-YFP which contains HTLV-1 MA (HTMA Gag-YFP) (30), and membrane-
binding-defective HIV-1 mutant (1GA Gag-YFP) as controls (Fig. 2.3A). These Gag 
constructs were previously determined to display predominantly PM, PM+intracellular 
and hazy cytosolic localizations, respectively. The PCC of ConA with HIV-1 Gag-YFP 
was found to be above 0.6; ConA with HTMA Gag-YFP was around 0.5; and ConA with 
1GA Gag-YFP was below 0.1 (Fig. 2.3B). In this analysis, we found that in 5ptaseIV ∆1-
expressing cells, HIV-1 GagLZ and RSV MA GagLZ showed high PCC values with 
ConA (above 0.6) (Fig. 2.3B). When 5ptaseIV FL was expressed, HIV-1 GagLZ and 
RSV MA GagLZ showed great reductions in PCC with ConA (below or near 0). In 
contrast, only modest (while statistically significant) changes were observed in PCC 
values for HTLV-1 MA GagLZ, MLV MA GagLZ, or HERV-K MA GagLZ with ConA 
between 5ptaseIV ∆1- and FL-expressing cells. These data (Fig. 2.3B) quantitatively 
support our observation shown in Fig. 2.4, which revealed that GagLZ chimeras 
containing HTLV-1 MA, MLV MA, and HERV-K MA are able to localize at the PM 
regardless of the 5ptaseIV expression. 
Altogether, these results suggest that while PI(4,5)P2 is required for localization 
of HIV-1 GagLZ and RSV MA GagLZ to the PM, it is not essential for PM localization 
of chimeric GagLZ constructs containing HERV-K MA, HTLV-1 MA or MLV MA in 
HeLa cells. 
Virus-like particle production of HIV-1 GagLZ and RSV MA GagLZ, but not that 
of HTLV-1 MA GagLZ, MLV MA GagLZ and HERVK MA GagLZ, is severely 
inhibited upon cellular PI(4,5)P2 depletion in HeLa cells 
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In parallel with the microscopy analysis, we also sought to determine the effect of 
PI(4,5)P2 depletion on the virus-like particle (VLP) release of the GagLZ chimeras with 
different retroviral MA domains. To this end, we examined the effect of 5ptaseIV 
expression on VLP production of the untagged GagLZ constructs. We transfected HeLa 
cells with a plasmid encoding one of the GagLZ chimeras, along with expression 
plasmids for Rev, humanized Vpu (Vphu), and either 5ptaseIV FL or the Δ1 derivative. 
Sixteen hours post-transfection, cell and viral lysates were collected. GagLZ proteins in 
lysates were then detected by immunoblotting using HIV-immunoglobulin, and the virus 
release efficiency was calculated. Consistent with the diminished PM localization, we 
observed that VLP release efficiency of HIV-1 GagLZ and RSV MA GagLZ was greatly 
reduced (~3-10 fold) upon coexpression of 5ptaseIV FL relative to when co-expressed 
with 5ptaseIV Δ1 (Fig. 2.5). In contrast, the VLP production of HTLV-1 MA GagLZ, 
MLV MA GagLZ and HERV-K MA GagLZ was only modestly reduced (less than 2 
fold) upon 5ptaseIV FL co-expression, consistent with the PM localization of these 
GagLZ proteins, which was not visibly altered upon 5ptaseIV FL expression (Fig. 2.5). 
We noticed that the expression levels of RSV MA GagLZ in cells (and hence in VLPs) 
were much higher than other GagLZ tested (such as MLV MA GagLZ), potentially 
affecting quantification of RSV MA GagLZ (Fig. 2.5A). However, when reduced 
amounts of lysates were loaded, VLP release of RSV MA GagLZ still showed significant 
sensitivity to 5ptaseIV FL, whereas MLV MA GagLZ VLP release did not (Fig. 2.6A, 
2.6B). Consistent with the immunoblotting experiments described above, analyses of 
VLP release efficiency using metabolic labeling followed by radioimmunoprecipitation 
showed that VLP release efficiency of RSV MA GagLZ was reduced 5 fold in cells 
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expressing 5ptaseIV FL relative to cells expressing 5ptaseIV Δ1, whereas that of HTLV-
1 MA GagLZ was reduced only 2 fold (unpublished data). Of note, the lower molecular 
weight band of RSV MA GagLZ, which has been also observed with its full-length 
counterpart (62), is likely due to internal initiation from methionine residue 139. Deletion 
of this site led to the elimination of this band but did not affect sensitivity of VLP release 
to 5ptaseIV FL expression (Fig. 2.6C). Overall, these results indicate that cellular 
PI(4,5)P2 is essential for efficient VLP production in HeLa cells for GagLZ chimeras 
containing HIV-1 MA or RSV MA but not for those containing HTLV-1, MLV, or 
HERV-K MA.  
MA domains of HIV-1 and RSV, but not those of HTLV-1, MLV and HERV-K, 
mediate membrane binding of GagLZ in a PI(4,5)P2-dependent manner 
The results described above demonstrate that there are two groups of retroviral 
MA domains that differ from each other in terms of PI(4,5)P2 dependence: while 
PI(4,5)P2 is essential for the PM localization of GagLZ and VLP production mediated by 
some retroviral MA domains (HIV-1 and RSV), it is dispensable for those facilitated by 
other retroviral MA domains (HTLV-1, MLV and HERV-K). To further examine the role 
of PI(4,5)P2 in mediating membrane binding via retroviral MA domains, we performed 
an in vitro liposome binding assay. We observed that similar to full-length HIV-1 Gag, 
HIV-1 GagLZ bound poorly to control liposomes containing PC and PS in a 2:1 ratio 
[hereafter PC:PS (2:1) liposomes], but its binding efficiency increased significantly when 
7.25 mol% of PI(4,5)P2 was included in PC:PS (2:1) liposomes (Fig. 2.7). Similarly, RSV 
MA GagLZ bound poorly to PC:PS (2:1)  liposomes, but inclusion of PI(4,5)P2 
significantly enhanced its binding (Fig. 2.7). In contrast, HTLV-1 MA GagLZ bound 
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readily to PC:PS (2:1) liposomes, and the presence of PI(4,5)P2 did not significantly 
increase its binding efficiency (Fig. 2.7), as was the case with full-length HTLV-1 Gag 
(30). Interestingly, GagLZ chimeras containing MLV MA or HERV-K MA also bound 
readily to liposomes in the absence of PI(4,5)P2 (Fig. 2.7). Overall, these results indicate 
that membrane binding mediated by HTLV-1 MA, MLV MA and HERV-K MA does not 
require the presence of PI(4,5)P2, whereas PI(4,5)P2 is important for efficient membrane 
binding of HIV-1 MA and RSV MA. 
PC:PS (2:1) liposome binding of GagLZ chimera via HIV-1 MA or RSV MA, but 
not via HTLV-1 MA, MLV MA or HERV-K MA, is susceptible to RNA-mediated 
block 
We recently showed that binding of full-length HTLV-1 Gag to PC:PS (2:1)  
liposomes is not inhibited by RNA, unlike that of full-length HIV-1 Gag (30). To 
determine whether HTLV-1 MA is responsible for this lack of sensitivity to RNA-
mediated inhibition and whether other retroviral MA domains are susceptible to such 
RNA-mediated inhibition as well, we compared GagLZ chimeras for RNase 
responsiveness in their binding to PC:PS (2:1) liposomes. We observed that, like full-
length HIV-1 Gag, HIV-1 GagLZ is responsive to RNase treatment, indicating that MA-
bound RNA rather than NC-bound RNA is likely responsible for the membrane binding 
block to PC:PS (2:1)  liposomes (Fig. 2.8). Similar to HIV-1 GagLZ, binding of RSV 
MA GagLZ to PC:PS (2:1) liposomes was poor, and its binding efficiency increased 
greatly upon RNase treatment (Fig. 2.8). In contrast, chimeric GagLZ containing either 
HTLV-1 MA, MLV MA, or HERV-K MA, which bound to PC:PS (2:1) liposomes 
efficiently in the absence of PI(4,5)P2, did not respond to RNase treatment (Fig. 2.8). 
 50 
These results indicate that while RNA suppresses membrane binding via HIV-1 MA and 
RSV MA, the membrane binding mediated by HTLV-1 MA, MLV MA, and HERV-K 
MA are insensitive to RNA-mediated suppression. 
 Altogether, we observed a striking correlation between PI(4,5)P2 dependence and 
susceptibility to RNA-mediated block of membrane binding across MA domains of  
different retroviruses. A retroviral MA that requires PI(4,5)P2 for efficient membrane 
binding is responsive to RNase treatment. Conversely, if a retroviral MA binds 
membrane in a PI(4,5)P2-independent manner, its membrane binding does not change 
upon RNase treatment. This correlation also extends to the GagLZ behaviors in cells. 
While PM localization and VLP release efficiency of PI(4,5)P2-dependent, RNase-
responsive GagLZ (containing HIV-1 MA or RSV MA) are highly sensitive to 5ptaseIV 
overexpression, the PI(4,5)P2-independent and RNase-non-responsive GagLZ (containing 
HTLV-1 MA, MLV MA or HERV-K MA) are minimally sensitive to 5ptaseIV 
overexpression. 
RNA serves as an inhibitor for the membrane binding of retroviral MA with a large 
basic surface patch 
Our results thus far suggest that there is a correlation between PI(4,5)P2 
dependence and sensitivity to RNA-mediated inhibition in the membrane binding of 
retroviral MA domains. To examine whether these properties could be attributed to a 
feature in the retroviral MA structures, we compared the basic patch distribution on 
surfaces of previously solved retroviral MA structures, namely, HIV-1 MA, RSV MA, 
MLV MA and HTLV-2 MA (63-65), as done previously (49) (Fig. 2.9). The comparison 
of electrostatic potential maps suggests that both HIV-1 MA and RSV MA contain a 
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large basic patch on their surfaces, whereas HTLV-2 MA and MLV MA contain several 
smaller basic patches. We also modeled the structure of HTLV-1 MA based on the 
HTLV-2 MA structure (PDB: 1JVR) (45) using SWISS-MODEL, a protein structure 
homology-modeling server (66, 67). When we compared distribution of basic amino 
acids between the predicted model of HTLV-1 MA and an NMR structure of HIV-1 MA 
(2HMX), we found that HIV-1 MA contains a larger basic surface patch than those found 
on HTLV-1 MA (Fig. 2.10). To further examine whether the size of a surface basic patch 
on retroviral MA plays a role in regulating membrane binding, we introduced acidic-to-
basic substitutions for two amino acid residues close to a small basic patch (D42 and 
E55) in HTLV-1 MA.  These changes were made in the HTLV-1 MA GagLZ context and 
tested for their effects on binding to PC:PS (2:1) liposomes with or without RNase 
treatment. Despite the increased positive charge, which could enhance electrostatic 
interaction with negatively charged liposomes, we found that all mutants show reduced 
binding to PC:PS (2:1) liposomes relative to wild-type HTLV-1 MA GagLZ (Fig. 2.11). 
While the E55K mutation reduced liposome binding only slightly, the reduction in 
liposome binding was prominent with mutants with the D42K change. Upon RNase 
treatment, however, all mutants bound to PC:PS (2:1)  liposomes as efficiently as wild-
type HTLV-1 MA GagLZ (Fig. 2.11). These results indicate that the mutant MA domains 
retain the ability to bind membrane as revealed by RNase treatment and hence are 
unlikely to be grossly misfolded. More importantly, these results demonstrate that single 
or double amino acid substitutions, which increase the size of a basic patch, can readily 
convert an otherwise RNA-insensitive MA to one that is susceptible to RNA-mediated 
inhibition. Altogether, these results suggest that the size of MA basic patches is a 
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determinant for susceptibility of retroviral-MA-mediated membrane binding to the RNA-
mediated inhibition. 
PI(4,5)P2 fails to facilitate membrane binding of HTLV-1 MA GagLZ containing 
acidic-to-basic point mutations  
Unstructured polybasic peptides can display a specificity for PI(4,5)P2 over PS 
due to the higher charge density (68). Therefore, we further tested whether increasing the 
size of basic surface patch of HTLV-1 MA GagLZ also increases its PI(4,5)P2 
dependence in membrane binding in vitro. We observed that, unlike HIV-1 GagLZ, 
which significantly increased liposome binding in the presence of PI(4,5)P2, the HTLV-1 
MA GagLZ mutants did not show a significant enhancement of membrane binding in a 
PI(4,5)P2-dependent manner (Fig. 2.11). This was especially clear with D42K and 
D42K/E55K, which failed to bind efficiently to both non-PI(4,5)P2-containing and 
PI(4,5)P2-containing liposomes (Fig. 2.11). We further tested by microscopy whether 
such membrane binding defect is reflected in the localization of HTLV-1 MA GagLZ 
mutants in cells. While YFP-tagged wild-type HTLV-1 MA GagLZ displayed PM 
localization in addition to intracellular localization, the D42K/E55K mutant showed no 
PM signal in HeLa cells, indicating that this mutant fails to bind the PM even in the 
presence of PI(4,5)P2  (Fig. 2.12). Consistent with this observation, the PCC analysis 
revealed a stark difference in the extent of colocalization with ConA between WT 
HTLV-1 GagLZ (PCC > 0.3) and the mutant (PCC < - 0.1) (Fig 2.12). Overall, our data 
suggest that an increase in size of a basic surface patch of a retroviral MA results in a 
stronger block by RNA in membrane binding, but such change alone is insufficient to 
confer PI(4,5)P2-dependent membrane binding ability to the retroviral MA. 
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DISCUSSION 
In this work, we have revealed a clear correlation between PI(4,5)P2 dependence 
and RNA-mediated inhibition of the membrane binding mediated by various retroviral 
MA domains. Using chimeric GagLZ constructs that differ only in MA domains allowed 
us to compare intrinsic properties of different MA domains without the potentially 
differential effects of the downstream regions, while allowing the Gag chimeras to 
multimerize and form VLPs (61, 69, 70). Using this approach, we demonstrated that 
GagLZ chimeras that are PI(4,5)P2-dependent (those containing HIV-1 MA and RSV 
MA) in their membrane binding are susceptible to RNA-mediated inhibition. In contrast, 
GagLZ chimeras that do not require PI(4,5)P2 for efficient membrane binding (those 
containing HTLV-1 MA, MLV MA and HERV-K MA) are not inhibited by RNA. Since 
the chimeric GagLZ constructs displayed subcellular localization patterns that were 
indistinguishable from their full-length counterparts, membrane binding properties of the 
different retroviral MA in the GagLZ backbone examined in this study are likely to 
reflect those in the native contexts. Consistent with our results, a recent fluorescence 
fluctuation spectroscopy study showed that unlike HIV-1 MA, which is known to be 
inefficient in membrane binding, HTLV-1 MA can readily bind membrane in cells (71). 
It should be noted that our assays are designed to analyze PI(4,5)P2 dependence of Gag 
proteins in the presence of RNA and mammalian cell components. Therefore, the lack of 
observed PI(4,5)P2 dependence for GagLZ membrane binding via MLV MA does not 
necessarily contradict with previous analyses of the interaction between PI(4,5)P2 and 
purified unmyristylated MLV MA, which were focused on the affinity between the 
purified components (55).   
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A comparison of the electrostatic potential of previously solved retroviral MA 
structures showed that HIV-1 MA and RSV MA contain a large basic surface patch 
compared to HTLV-2 MA and MLV MA. Furthermore, point mutations in HTLV-1 MA, 
which increase the size of a small basic patch on the MA surface, rendered the protein 
defective in binding to PC:PS (2:1) liposomes and RNase-responsive, the membrane 
binding phenotypes reminiscent of those of HIV-1 GagLZ and RSV MA GagLZ. 
Conversely, we previously observed that multiple single point mutations that reduce the 
size of the basic surface patch of HIV-1 MA enhanced binding of HIV-1 MA mutants to 
PC:PS (2:1) liposomes (22). The susceptibility of Gag membrane binding to RNA-
mediated inhibition does not appear to be a mere consequence of the increased total 
charge of MA. The net charges of HIV-1 MA and HTLV-1 MA (residues 1-116, which 
are present in our GagLZ chimeras) are similar (+4.16 and +4.39, respectively, at pH7) 
even though RNA suppresses membrane binding of only the former but not the latter, 
highlighting the importance of how basic residues are distributed over the MA surface. 
Altogether, these results suggest that an increase in the size of a basic surface patch on 
retroviral MA results in an increase in stable RNA binding, which in turn imposes a 
stronger block on retroviral MA membrane binding.  
Interestingly, HTLV-1 MA GagLZ mutants (D42K and D42K/E55K), which have 
larger basic patches and are susceptible to RNA-mediated inhibition, were unable to bind 
efficiently to PI(4,5)P2-containing liposomes unlike HIV-1 MA GagLZ and RSV MA 
GagLZ. The inability to bind PI(4,5)P2 and the susceptibility to RNA block were also 
observed with an HIV-1 Gag mutant, HBR/RKswitch, where all lysine and arginine 
residues within HIV-1 HBR are substituted with each other (72). The failure of the 
 55 
HTLV-1 MA GagLZ mutants and HBR/RKswitch in utilizing PI(4,5)P2 for membrane 
binding indicates that the presence of a large basic surface patch is insufficient for 
PI(4,5)P2 interaction, yet is sufficient for MA-RNA interaction. Therefore, it appears 
likely that HIV-1 MA and RSV MA, which contain a large basic surface patch, have 
evolved to counteract the RNA-mediated inhibition by interacting specifically with 
PI(4,5)P2. On the other hand, HTLV-1 MA and MLV MA avoid strong RNA-mediated 
suppression of membrane binding possibly due to their smaller basic patches. In light of 
the observation that both PI(4,5)P2-dependent and -independent MA domains mediate 
efficient VLP production, the significance of the PI(4,5)P2 dependence for HIV-1 and 
RSV may be to counteract the RNA-mediated suppression rather than to direct PM-
specific localization.  
The model described above also suggests an alternative mechanism for 
localization of Gag to intracellular vesicles observed for several retroviruses. Such 
intracellular localization has been explained as the consequence of nonspecific 
endocytosis of virions formed at the PM (73, 74). However, in our comparison, while 
HIV-1 GagLZ and RSV MA GagLZ were found almost exclusively at the PM where 
PI(4,5)P2 localizes in cells, HTLV-1 MA GagLZ and MLV MA GagLZ localized both at 
the PM and intracellular compartments despite the fact that they all share the same 
multimerization domains. This suggests that intracellular localization via VLP 
endocytosis for these GagLZ would have to be an MA-specific process rather than non-
specific internalization. Alternatively, according to our model, due to the weaker RNA-
mediated block of membrane binding, HTLV-1 MA GagLZ and MLV MA GagLZ are 
able to bind to different cellular membranes via prevalent acidic lipids, thus localize to 
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both PM and intracellular compartments in cells. We observed that HTLV-1 MA GagLZ 
and MLV MA GagLZ bind liposomes containing PS or other acidic lipids 
(phosphatidylglycerol or phosphatidic acids) with similar efficiencies (unpublished data). 
Nevertheless, because of the relative abundance and broad subcellular distribution (75, 
76), it is still quite possible that PS mediates Gag membrane binding via HTLV-1 MA or 
MLV MA in cells and thus leads to their intracellular localization.  
Subcellular localization patterns and the severity of the effect of 5ptaseIV 
expression on VLP production generally correlated well with the membrane binding 
phenotypes of GagLZ chimeras in this study. However, subcellular localization of 
HERV-K MA GagLZ was inconsistent with membrane binding and VLP production 
phenotypes of this GagLZ protein. HERV-K MA GagLZ localized predominantly to the 
PM, and upon 5ptaseIV expression, a substantial fraction localized to intracellular 
compartments, even though in vitro membrane binding of this GagLZ derivative and its 
VLP release in cells are independent of the presence of PI(4,5)P2. One can speculate that 
in cells HERV-K MA GagLZ may be able to bind both PI(4,5)P2 and another PM-
specific molecule, only the latter of which promotes productive assembly.  
 The direct comparison of 5 different retroviral MA domains in this study 
highlighted the difference in severity of VLP release inhibition by 5ptaseIV expression. 
In particular, it is of note that 5ptaseIV overexpression inhibits GagLZ particle 
production mediated by RSV MA but not as severely as that by HIV-1 MA. While the 
cause of the difference between the two GagLZ chimeras remains unknown, these results 
potentially reconcile two apparently contradicting previous studies; while Chan et al. 
reported that 5ptaseIV has minimal effect on full length RSV Gag VLP production when 
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compared to HIV-1 Gag (29), Nadaraia-Hoke et al. reported that PM localization and 
virus release are reduced upon 5ptaseIV overexpression (56). Thus, as was the case with 
RSV MA GagLZ in this study, it is possible that the effect of 5ptaseIV overexpression on 
full-length RSV Gag may be less severe than that on HIV-1 Gag but still detectable in a 
sensitive assay (as speculated in a recent review (77)).   
Our current study demonstrated that VLP release efficiency of MLV MA GagLZ 
is only modestly reduced upon 5ptaseIV overexpression (less than 2 fold), whereas 
previous studies showed that full-length MLV Gag VLP production is greatly reduced by 
5ptaseIV overexpression (3-8 fold) (20, 55). Such discrepancies exist possibly due to the 
difference in downstream sequences and/or the difference in the type of cell lines in 
which the experiments were carried out. In particular, the native NC domain may 
modulate membrane binding phenotypes possibly by facilitating capture of RNA that can 
in turn bind to MA and necessitate PI(4,5)P2 interaction for efficient membrane binding. 
While this study focused on intrinsic properties of various retroviral MA domains when 
compared in the same context, ongoing studies are aimed at the modulatory role of NC-
mediated RNA interactions in lipid-RNA competition over MA domains.  
In summary, this study has demonstrated that membrane binding of retroviral MA 
can be either PI(4,5)P2-dependent and sensitive to RNA-mediated inhibition or PI(4,5)P2-
independent and RNA-insensitive. We also showed that RNA-insensitive MA can be 
readily converted to an RNA-sensitive one by expanding an MA surface basic patch, but 
such expansion is insufficient for the ability to utilize PI(4,5)P2 for efficient membrane 
binding in the presence of the RNA block. Based on our study, we propose that the block 
imposed by RNA on membrane binding has driven retroviruses with a large basic patch 
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on the MA surface to acquire the ability to use PI(4,5)P2, whereas other retroviruses may 
have maintained smaller basic patches on their MA domains to evade this inhibition. Our 
study also highlights a potential role for RNA as a broad inhibitor that negatively 
regulates membrane binding of cytoplasmic proteins that have basic patches.  
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Fig. 2.1. Retroviral MA determines localization of Gag chimeras in HeLa cells. HeLa cells 
expressing Gag-eCFP or GagLZ-eCFP constructs were fixed and analyzed using an epi-
fluorescence microscope. PM was detected by staining with Concanavalin A (ConA) conjugated 
with Alexa Fluor 594. Fluorescence intensity profiles along the lines drawn in merged images are 
shown on the right. Gag-eCFP, green line; ConA-Alexa Fluor 594, red line. Gag-eCFP constructs 
that localize only at the PM have fluorescence intensity peaks only at the same locations as 
ConA-Alexa Fluor 594 (i.e., at cell periphery). In contrast, Gag-eCFP constructs that localize 
both at the PM and intracellular compartments have intensity peaks at inner locations of the cell 
in addition to the peaks matching those of ConA-Alexa Fluor 594 at cell periphery. Note that 
HIV-1 Gag-eCFP, HIV-1 GagLZ-eCFP, RSV Gag-eCFP, RSV MA GagLZ-eCFP, HERV-K 
Gag-eCFP, HERV-K MA GagLZ-eCFP and EIAV MA GagLZ-eCFP localized predominantly on 
the PM, whereas HTLV-1 Gag-eCFP, HTLV-1 MA GagLZ-eCFP, MLV Gag-eCFP, MLV MA 
GagLZ-eCFP and EIAV Gag-eCFP localized to both PM and intracellular compartments. 
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 Fig. 2.2. PM localization of HTLV-1 MA GagLZ, MLV MA GagLZ, and HERV-K MA 
GagLZ persists upon 5ptaseIV overexpression, unlike that of HIV-1 GagLZ and RSV MA 
GagLZ. (A) Schematic illustrations of HIV-1 Gag, HIV-1 GagLZ, RSV MA GagLZ, HTLV-1 
MA GagLZ, MLV MA GagLZ, and HERV-K MA GagLZ are shown. The first amino acid, 
methionine, is included in the numbering of MA residues although the methionine is removed 
upon N-terminal myristylation. All Gag proteins were expressed from the same CMV-promoter-
driven vector backbone. (B) HeLa cells expressing YFP-tagged HIV-1 GagLZ, RSV MA GagLZ, 
HTLV-1 MA GagLZ, MLV MA GagLZ or HERV-K MA GagLZ, along with Myc-tagged full-
length (FL) 5ptaseIV or the ∆1 derivative, were stained with ConA labeled with Alexa Fluor 594 
(not shown), immunostained with mouse monoclonal anti-Myc antibody and anti-mouse IgG 
conjugated with Alexa Fluor 647 (anti-Myc), and analyzed using a confocal fluorescence 
microscope. Note that overexpression of 5ptaseIV FL induced mislocalization of HIV-1 GagLZ 
and RSV MA GagLZ to the cytosol and abolished PM localization. In contrast, 5ptaseIV FL 
overexpression did not drastically alter localization of HTLV-1 MA GagLZ and MLV MA 
GagLZ to the PM and intracellular compartments. Overexpression of 5ptaseIV increased the 
localization of HERV-K MA GagLZ to intracellular compartments, but PM localization persisted 
regardless of the intracellular localization.  
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Fig. 2.3. Pearson’s Correlation Coefficient for colocalization of chimeric GagLZ with ConA 
in cells expressing 5ptaseIV ∆1 or full-length 5ptaseIV. (A) HeLa cells expressing YFP-tagged 
HIV-1 Gag, HTMA Gag and HIV-1 (1GA) Gag were stained with ConA labeled with Alexa 
Fluor 594. Cells were then fixed and analyzed using a confocal fluorescence microscope.  (B) 
Pearson’s correlations coefficients (PCC) for colocalization of Gag-YFP or GagLZ-YFP with 
ConA were calculated and are shown as means ± SEM. Twenty to fifty cells were analyzed per 
condition. **, P<0.005; ***, P<0.001. 
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Fig. 2.4. The effect of 5ptaseIV overexpression on subcellular localization of chimeric 
retroviral MA GagLZ in HeLa cells. (A) The number of cells with (i) Gag localized 
predominantly at the PM (black), (ii) Gag localized at both PM and intracellular compartments 
(white), and (iii) Gag localized in the cytosol (grey) were counted. A range of 80 to 150 cells, 
which were positive for both 5ptaseIV and Gag, were examined for each condition. (B) HeLa 
cells expressing YFP-tagged HIV-1 GagLZ, RSV MA GagLZ, HTLV-1 MA GagLZ, MLV MA 
GagLZ or HERV-K MA GagLZ, along with Myc-tagged full-length (FL) 5ptaseIV or the ∆1 
derivative, were stained with ConA labeled with Alexa Fluor 594, immunostained with mouse 
monoclonal anti-Myc antibody and anti-mouse IgG conjugated with Alexa Fluor 350 (anti-Myc) 
(not shown), and analyzed using an epi-fluorescence microscope. Intensity profiles of ConA and 
Gag-YFP were plotted. Note that overexpression of 5ptaseIV FL but not ∆1 induced 
mislocalization of HIV-1 GagLZ and RSV MA GagLZ to the cytosol and abolished PM 
localization. In contrast, 5ptaseIV FL overexpression did not substantially alter localization of 
HTLV-1 MA GagLZ and MLV MA GagLZ to the PM and intracellular compartments. 
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Fig. 2.5. VLP release of HTLV-1 GagLZ, MLV MA GagLZ and HERV-K MA GagLZ is not 
as sensitive to full-length 5ptaseIV overexpression as that of HIV-1 GagLZ and RSV MA 
GagLZ. (A) Cell and VLP lysates of HeLa cells expressing HIV-1 GagLZ, RSV MA GagLZ, 
HTLV-1 MA GagLZ, MLV MA GagLZ or HERV-K MA GagLZ, along with 5ptaseIV FL or its 
∆1 mutant, were subjected to SDS-PAGE and analyzed by immunoblotting using HIV-
immunoglobulin. (B) Relative virus release efficiency was calculated as the amount of VLP-
associated GagLZ as a fraction of total GagLZ present in cell and VLP lysates and normalized to 
the virus release efficiency in 5ptaseIV ∆1-expressing cultures. The average VLP release 
efficiencies by cells expressing HIV-1 GagLZ, RSV MA GagLZ, HTLV-1 MA GagLZ, MLV 
MA GagLZ and HERV-K MA GagLZ along with 5ptaseIV ∆1 were 11.6%, 41.0%, 21.2%, 
28.9%, 14.4%, respectively. Note that the average VLP release efficiencies in the control condition do not correlate with the 
extents of sensitivity to full-length 5ptaseIV. Data from at least 7 different experiments are shown 
as means ± standard deviations. P values were determined using Student’s t-test using raw data. 
***, P<0.001; **. P<0.005; *, P<0.05. 
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Fig. 2.6. VLP release of MLV MA GagLZ is not as sensitive to 5ptaseIV overexpression as 
that of RSV MA GagLZ. (A) Cell and VLP lysates of HeLa cells expressing RSV MA GagLZ 
or MLV MA GagLZ, along with 5ptaseIV FL or its ∆1 mutant, were subjected to SDS-PAGE and 
analyzed by immunoblotting using HIV-immunoglobulin. In Figure 2.5, 1/5 of total cell lysates 
and the whole VLP lysates derived from one well of 6-well plates were loaded per lane (standard 
condition). Here, smaller fractions of lysates (1/20 of cell and 1/4 of VLP lysates) are loaded for 
comparison. (B) Virus release efficiencies of GagLZ were calculated as in Fig. 2.5B. Data from at 
least 3 different experiments are shown as means ± standard deviations. P values were determined 
using Student’s t-test using raw data. ***, P<0.001; **, P<0.005; *, P<0.05; ns, not significant. 
(C) Cell and VLP lysates of HeLa cells expressing WT RSV MA GagLZ or the ∆M139 mutant, 
along with full-length (FL) 5ptaseIV or the ∆1 derivative, were subjected to SDS-PAGE and 
analyzed by immunoblotting using HIV-immunoglobulin. Note that the prominent lower 
molecular weight band was absent in the lanes of the ∆M139 mutant. 
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 Fig. 2.7. HTLV-1 MA GagLZ, MLV MA GagLZ and HERV-K MA GagLZ proteins, unlike 
HIV-1 Gag LZ and RSV MA GagLZ, bind efficiently to liposomes in the absence of 
PI(4,5)P2. (A) [35S]-labeled HIV-1 GagLZ, RSV MA GagLZ, HTLV-1 MA GagLZ, MLV MA 
GagLZ and HERV-K MA GagLZ were synthesized in vitro using rabbit reticulocyte lysates and 
incubated with control liposomes [PC:PS (2:1)] or liposomes containing 7.25 mol% PI(4,5)P2 
[PC:PS (2:1) + PI(4,5)P2]. The reaction mixtures were then subjected to membrane flotation 
centrifugation, and a total of five 1-ml fractions were collected from each sample. M, membrane-
bound Gag; NM, non-membrane-bound Gag. Note that RSV MA GagLZ is synthesized as two 
predominant bands, but only the top band corresponding to the size of full-length RSV MA 
GagLZ is quantified. (B) The liposome binding efficiency is presented as the percentage of 
membrane-bound Gag versus the total Gag synthesized in the reaction. Each reaction is 
normalized to the binding efficiency to PI(4,5)P2-containing liposomes. The average liposome 
binding efficiencies of HIV-1 GagLZ, RSV MA GagLZ, HTLV-1 MA GagLZ, MLV MA GagLZ 
and HERV-K MA GagLZ to PI(4,5)P2-containing liposomes were 53.0%, 31.7%, 33.1%, 73.6%, 
51.1%, respectively. Data from at least three experiments are shown as means ± standard 
deviation. P values were determined by Student’s t-test. **, P<0.005; *, P<0.05; ns, not 
significant.  
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 Fig. 2.8. Membrane binding of HTLV-1 MA GagLZ, MLV MA GagLZ and HERV-K MA 
GagLZ proteins are not susceptible to RNA-mediated inhibition, unlike that of HIV-1 Gag 
LZ and RSV MA GagLZ. (A) HIV-1 GagLZ, RSV MA GagLZ, HTLV-1 MA GagLZ, MLV 
MA GagLZ and HERV-K MA GagLZ proteins were synthesized using rabbit reticulocyte lysates 
and either treated or not treated with RNase A. The reaction mixtures were incubated with the 
PC:PS [2:1] liposomes and were subsequently subjected to membrane flotation centrifugation. 
Five 1-ml fractions were collected from each sample. M, membrane-bound Gag; NM, non-
membrane bound Gag. Note that RSV MA GagLZ is synthesized as two predominant bands, but 
only the top band corresponding to the size of full-length RSV MA GagLZ is quantified. (B) The 
relative liposome binding efficiency was calculated as the percentage of membrane-bound versus 
the total Gag synthesized in the reaction and normalized to binding efficiencies in RNase-treated 
samples. The average liposome binding efficiencies of HIV-1 GagLZ, RSV MA GagLZ, HTLV-1 
MA GagLZ, MLV MA GagLZ and HERV-K MA GagLZ to RNase-treated conditions were 
56.7%, 22.9%, 44.5%, 56.5%, 51.4%, respectively. Data from at least six different experiments 
are shown as means ± standard deviations. P values were determined using Student’s t-test. ***, 
P<0.001; *, P<0.05, ns, not significant. 
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Fig. 2.9. Distribution of basic surface patches on retroviral MA structures. Previously solved 
retroviral MA domains are represented by their molecular surfaces. The electrostatic potentials 
were calculated using DelPhi, mapped to the molecular surfaces, and are visualized using 
Chimera. Blue represents basic patches, whereas red represents acidic patches on the MA 
domains. Note that HIV-1 MA and RSV MA contain large basic surface patches than HTLV-2 
MA and MLV MA, whose basic patches are smaller and distributed all over the MA domain. 
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 Fig. 2.10. A comparison of HIV-1 MA and HTLV-1 MA as represented by their molecular 
surfaces. HIV-1 MA was obtained from a previously solved structure (PDB: 2HMX). The 
structure of HTLV-1 MA was modeled based on the NMR structure of HTLV-2 matrix (PDB: 
1JVR) using the Swiss-Model server. Basic residues are represented in blue, while acidic residues 
are represented in red. Note that HIV-1 MA contains a larger basic patch than those present in 
HTLV-1 MA. The red arrows identify residues D42 and E55 of HTLV-1 MA, which are mutated 
to lysine in the experiments shown in the following panels.  
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Fig. 2.11. RNA inhibits membrane binding of HTLV-1 MA GagLZ mutants that contain an 
expanded basic patch in the MA domain. (A) [35S]-labeled WT and mutant HTLV-1 MA 
GagLZ proteins were synthesized using rabbit reticulocyte lysates and either treated or not treated 
with RNase A. The reaction mixtures were incubated with the control liposomes [PC:PS (2:1)] 
and were subsequently subjected to membrane flotation centrifugation. Five 1-ml fractions were 
collected from each sample. M, membrane-bound Gag; NM, non-membrane-bound Gag. The 
liposome binding efficiency is presented as the percentage of membrane-bound Gag versus the 
total Gag synthesized in the reaction. Data from at least three experiments are shown as means ± 
standard deviation. P values were determined by Student’s t-test. ***, P<0.001; **, P<0.005; *, 
P<0.05; ns, not significant. (B) [35S]-labeled WT and mutant HTLV-1 MA GagLZ were 
synthesized in vitro using reticulocyte lysates and incubated with control liposomes [PC:PS (2:1)] 
or liposomes containing 7.25 mol% PI(4,5)P2 [PC:PS (2:1) + PI(4,5)P2]. The reaction mixtures 
were then subjected to membrane flotation centrifugation, and a total of five 1-ml fractions were 
collected from each sample. M, membrane-bound Gag; NM, non-membrane-bound Gag. Each 
reaction is normalized to the binding efficiency of WT HTLV-1 MA GagLZ to PI(4,5)P2-
containing liposomes. The average liposome binding efficiencies of WT HTLV-1 MA GagLZ is 
43.0%.  Data from at least three experiments are shown as means ± standard deviation. P values 
were determined by Student’s t-test. **, P<0.005; *, P<0.05; ns, not significant.  
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Fig. 2.12. HTLV-1 MA GagLZ mutant that contains an expanded basic patch in the MA 
domain fails to localize to the plasma membrane or intracellular compartments. (A) HeLa 
cells expressing YFP-tagged HTLV-1 MA GagLZ constructs with either WT or D42K/E55K 
mutant MA sequences were fixed and stained with ConA conjugated with Alexa Fluor 594. Note 
that punctate signals of WT HTLV-1 MA GagLZ localized to both PM and intracellular 
compartments, whereas D42K/E55K HTLV-1 MA GagLZ displayed no PM signal. (B) Pearson’s 
correlation coefficients (PCC) for colocalization between Gag-YFP and ConA were calculated 
and shown as means ± SEM. At least twenty cells per condition were analyzed. ***, P<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 71 
REFERENCES 
1. Adamson CS, Freed EO. 2007. Human immunodeficiency virus type 1 
assembly, release, and maturation. Adv Pharmacol 55:347-387. 
2. Garnier L, Bowzard JB, Wills JW. 1998. Recent advances and remaining 
problems in HIV assembly. AIDS 12 Suppl A:S5-16. 
3. Swanstrom R, Wills JW. 1997. Synthesis, Assembly, and Processing of Viral 
Proteins, p. 263-334. In Coffin JM, Hughes SH, Varmus HE (ed.), Retroviruses. 
Cold Spring Harbor Laboratory Press, New York. 
4. Balasubramaniam M, Freed EO. 2011. New insights into HIV assembly and 
trafficking. Physiology (Bethesda) 26:236-251. 
5. Bieniasz PD. 2009. The cell biology of HIV-1 virion genesis. Cell Host Microbe 
5:550-558. 
6. Sundquist WI, Krausslich HG. 2012. HIV-1 assembly, budding, and 
maturation. Cold Spring Harb Perspect Med 2:a006924. 
7. Bryant M, Ratner L. 1990. Myristoylation-dependent replication and assembly 
of human immunodeficiency virus 1. Proc Natl Acad Sci U S A 87:523-527. 
8. Gottlinger HG, Sodroski JG, Haseltine WA. 1989. Role of capsid precursor 
processing and myristoylation in morphogenesis and infectivity of human 
immunodeficiency virus type 1. Proc Natl Acad Sci U S A 86:5781-5785. 
9. Zhou W, Parent LJ, Wills JW, Resh MD. 1994. Identification of a membrane-
binding domain within the amino-terminal region of human immunodeficiency 
virus type 1 Gag protein which interacts with acidic phospholipids. J Virol 
68:2556-2569. 
10.  Hermida-Matsumoto L, Resh MD. 1999. Human immunodeficiency virus type 
1 protease triggers a myristoyl switch that modulates membrane binding of 
Pr55(gag) and p17MA. J Virol 73:1902-1908. 
11.  Ono A, Freed EO. 1999. Binding of human immunodeficiency virus type 1 Gag 
to membrane: role of the matrix amino terminus. J Virol 73:4136-4144 
12.  Paillart JC, Gottlinger HG. 1999. Opposing effects of human 
immunodeficiency virus type 1 matrix mutations support a myristyl switch model 
of gag membrane targeting. J Virol 73:2604-2612. 
13.  Saad JS, Loeliger E, Luncsford P, Liriano M, Tai J, Kim A, Miller J, Joshi 
A, Freed EO, Summers MF. 2007. Point mutations in the HIV-1 matrix protein 
turn off the myristyl switch. J Mol Biol 366:574-585. 
 72 
14.  Saad JS, Miller J, Tai J, Kim A, Ghanam RH, Summers MF. 2006. Structural 
basis for targeting HIV-1 Gag proteins to the plasma membrane for virus 
assembly. Proc Natl Acad Sci U S A 103:11364-11369. 
15.  Spearman P, Horton R, Ratner L, Kuli-Zade I. 1997. Membrane binding of 
human immunodeficiency virus type 1 matrix protein in vivo supports a 
conformational myristyl switch mechanism. J Virol 71:6582-6592. 
16.  Tang C, Loeliger E, Luncsford P, Kinde I, Beckett D, Summers MF. 2004. 
Entropic switch regulates myristate exposure in the HIV-1 matrix protein. Proc 
Natl Acad Sci U S A 101:517-522. 
17.  Zhou W, Resh MD. 1996. Differential membrane binding of the human 
immunodeficiency virus type 1 matrix protein. J Virol 70:8540-8548. 
18.  Alfadhli A, Barklis RL, Barklis E. 2009. HIV-1 matrix organizes as a hexamer 
of trimers on membranes containing phosphatidylinositol-(4,5)-bisphosphate. 
Virology 387:466-472. 
19.  Anraku K, Fukuda R, Takamune N, Misumi S, Okamoto Y, Otsuka M, 
Fujita M. 2010. Highly sensitive analysis of the interaction between HIV-1 Gag 
and phosphoinositide derivatives based on surface plasmon resonance. 
Biochemistry 49:5109-5116. 
20.  Chan R, Uchil PD, Jin J, Shui G, Ott DE, Mothes W, Wenk MR. 2008. 
Retroviruses human immunodeficiency virus and murine leukemia virus are 
enriched in phosphoinositides. J Virol 82:11228-11238. 
21.  Chukkapalli V, Hogue IB, Boyko V, Hu WS, Ono A. 2008. Interaction between 
the human immunodeficiency virus type 1 Gag matrix domain and 
phosphatidylinositol-(4,5)-bisphosphate is essential for efficient gag membrane 
binding. J Virol 82:2405-2417. 
22.  Chukkapalli V, Oh SJ, Ono A. 2010. Opposing mechanisms involving RNA and 
lipids regulate HIV-1 Gag membrane binding through the highly basic region of 
the matrix domain. Proc Natl Acad Sci U S A 107:1600-1605. 
23.  Shkriabai N, Datta SA, Zhao Z, Hess S, Rein A, Kvaratskhelia M. 2006. 
Interactions of HIV-1 Gag with assembly cofactors. Biochemistry 45:4077-4083. 
24.  Ono A, Orenstein JM, Freed EO. 2000. Role of the Gag matrix domain in 
targeting human immunodeficiency virus type 1 assembly. J Virol 74:2855-2866. 
25.  Freed EO, Orenstein JM, Buckler-White AJ, Martin MA. 1994. Single amino 
acid changes in the human immunodeficiency virus type 1 matrix protein block 
virus particle production. J Virol 68:5311-5320. 
 73 
26.  Hermida-Matsumoto L, Resh MD. 2000. Localization of human 
immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal 
imaging. J Virol 74:8670-8679. 
27.  Ono A, Ablan SD, Lockett SJ, Nagashima K, Freed EO. 2004. 
Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the 
plasma membrane. Proc Natl Acad Sci U S A 101:14889-14894. 
28.  Yuan X, Yu X, Lee TH, Essex M. 1993. Mutations in the N-terminal region of 
human immunodeficiency virus type 1 matrix protein block intracellular transport 
of the Gag precursor. J Virol 67:6387-6394. 
29.  Chan J, Dick RA, Vogt VM. 2011. Rous sarcoma virus gag has no specific 
requirement for phosphatidylinositol-(4,5)-bisphosphate for plasma membrane 
association in vivo or for liposome interaction in vitro. J Virol 85:10851-10860. 
30.  Inlora J, Chukkapalli V, Derse D, Ono A. 2011. Gag localization and virus-like 
particle release mediated by the matrix domain of human T-lymphotropic virus 
type 1 Gag are less dependent on phosphatidylinositol-(4,5)-bisphosphate than 
those mediated by the matrix domain of HIV-1 Gag. J Virol 85:3802-3810. 
31.  Burniston MT, Cimarelli A, Colgan J, Curtis SP, Luban J. 1999. Human 
immunodeficiency virus type 1 Gag polyprotein multimerization requires the 
nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and 
the basic region of matrix protein. J Virol 73:8527-8540. 
32.  Chang CY, Chang YF, Wang SM, Tseng YT, Huang KJ, Wang CT. 2008. 
HIV-1 matrix protein repositioning in nucleocapsid region fails to confer virus-
like particle assembly. Virology 378:97-104. 
33.  Chukkapalli V, Inlora J, Todd GC, Ono A. 2013. Evidence in support of RNA-
mediated inhibition of phosphatidylserine-dependent HIV-1 Gag membrane 
binding in cells. J Virol 87:7155-7159. 
34.  Cimarelli A, Luban J. 1999. Translation elongation factor 1-alpha interacts 
specifically with the human immunodeficiency virus type 1 Gag polyprotein. J 
Virol 73:5388-5401. 
35.  Hearps AC, Wagstaff KM, Piller SC, Jans DA. 2008. The N-terminal basic 
domain of the HIV-1 matrix protein does not contain a conventional nuclear 
localization sequence but is required for DNA binding and protein self-
association. Biochemistry 47:2199-2210. 
36.  Lochrie MA, Waugh S, Pratt DG, Jr., Clever J, Parslow TG, Polisky B. 1997. 
In vitro selection of RNAs that bind to the human immunodeficiency virus type-1 
gag polyprotein. Nucleic Acids Res 25:2902-2910. 
 74 
37.  Ott DE, Coren LV, Gagliardi TD. 2005. Redundant roles for nucleocapsid and 
matrix RNA-binding sequences in human immunodeficiency virus type 1 
assembly. J Virol 79:13839-13847. 
38.  Purohit P, Dupont S, Stevenson M, Green MR. 2001. Sequence-specific 
interaction between HIV-1 matrix protein and viral genomic RNA revealed by in 
vitro genetic selection. RNA 7:576-584. 
39.  Sun M, Grigsby IF, Gorelick RJ, Mansky LM, Musier-Forsyth K. 2014. 
Retrovirus-specific differences in matrix and nucleocapsid protein-nucleic acid 
interactions: implications for genomic RNA packaging. J Virol 88:1271-1280. 
40.  Webb JA, Jones CP, Parent LJ, Rouzina I, Musier-Forsyth K. 2013. Distinct 
binding interactions of HIV-1 Gag to Psi and non-Psi RNAs: implications for 
viral genomic RNA packaging. RNA 19:1078-1088. 
41.  Ramalingam D, Duclair S, Datta SA, Ellington A, Rein A, Prasad VR. 2011. 
RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein 
bind to the matrix and nucleocapsid domains and inhibit virus production. Journal 
of virology 85:305-314. 
42.  Alfadhli A, McNett H, Tsagli S, Bachinger HP, Peyton DH, Barklis E. 2011. 
HIV-1 matrix protein binding to RNA. J Mol Biol 410:653-666. 
43.  Alfadhli A, Still A, Barklis E. 2009. Analysis of human immunodeficiency virus 
type 1 matrix binding to membranes and nucleic acids. J Virol 83:12196-12203. 
44.  Dick RA, Kamynina E, Vogt VM. 2013. Effect of multimerization on membrane 
association of Rous sarcoma virus and HIV-1 matrix domain proteins. J Virol 
87:13598-13608. 
45.  Christensen AM, Massiah MA, Turner BG, Sundquist WI, Summers MF. 
1996. Three-dimensional structure of the HTLV-II matrix protein and 
comparative analysis of matrix proteins from the different classes of pathogenic 
human retroviruses. J Mol Biol 264:1117-1131. 
46.  Conte MR, Matthews S. 1998. Retroviral matrix proteins: a structural 
perspective. Virology 246:191-198. 
47.  Dalton AK, Ako-Adjei D, Murray PS, Murray D, Vogt VM. 2007. 
Electrostatic Interactions Drive Membrane Association of the Human 
Immunodeficiency Virus Type 1 Gag MA Domain. J Virol 81:6434-6445. 
48. Heidecker G, Lloyd PA, Soheilian F, Nagashima K, Derse D. 2007. The role of 
WWP1-Gag interaction and Gag ubiquitination in assembly and release of human 
T-cell leukemia virus type 1. J Virol 81:9769-9777. 
 75 
49.  Murray PS, Li Z, Wang J, Tang CL, Honig B, Murray D. 2005. Retroviral 
matrix domains share electrostatic homology: models for membrane binding 
function throughout the viral life cycle. Structure (Camb) 13:1521-1531. 
50.  Gudleski N, Flanagan JM, Ryan EP, Bewley MC, Parent LJ. 2010. 
Directionality of nucleocytoplasmic transport of the retroviral gag protein 
depends on sequential binding of karyopherins and viral RNA. Proc Natl Acad 
Sci U S A 107:9358-9363. 
51.  Parent LJ, Cairns TM, Albert JA, Wilson CB, Wills JW, Craven RC. 2000. 
RNA dimerization defect in a Rous sarcoma virus matrix mutant. J Virol 74:164-
172. 
52.  Rye-McCurdy TD, Nadaraia-Hoke S, Gudleski-O'Regan N, Flanagan JM, 
Parent LJ, Musier-Forsyth K. 2014. Mechanistic Differences Between Nucleic 
Acid Chaperone Activity of the Gag Proteins of Rous Sarcoma Virus and Human 
Immunodeficiency Virus Type 1 are Attributed to the MA Domain. J Virol. 
53.  Wang H, Norris KM, Mansky LM. 2003. Involvement of the matrix and 
nucleocapsid domains of the bovine leukemia virus Gag polyprotein precursor in 
viral RNA packaging. J Virol 77:9431-9438. 
54.  Chen K, Bachtiar I, Piszczek G, Bouamr F, Carter C, Tjandra N. 2008. 
Solution NMR characterizations of oligomerization and dynamics of equine 
infectious anemia virus matrix protein and its interaction with PIP2. Biochemistry 
47:1928-1937. 
55.  Hamard-Peron E, Juillard F, Saad JS, Roy C, Roingeard P, Summers MF, 
Darlix JL, Picart C, Muriaux D. 2010. Targeting of murine leukemia virus gag 
to the plasma membrane is mediated by PI(4,5)P2/PS and a polybasic region in 
the matrix. J Virol 84:503-515. 
56.  Nadaraia-Hoke S, Bann DV, Lochmann TL, Gudleski-O'Regan N, Parent 
LJ. 2013. Alterations in the MA and NC domains modulate phosphoinositide-
dependent plasma membrane localization of the Rous sarcoma virus Gag protein. 
J Virol 87:3609-3615. 
57.  Saad JS, Ablan SD, Ghanam RH, Kim A, Andrews K, Nagashima K, 
Soheilian F, Freed EO, Summers MF. 2008. Structure of the myristylated 
human immunodeficiency virus type 2 matrix protein and the role of 
phosphatidylinositol-(4,5)-bisphosphate in membrane targeting. J Mol Biol 
382:434-447. 
58.  Stansell E, Apkarian R, Haubova S, Diehl WE, Tytler EM, Hunter E. 2007. 
Basic residues in the Mason-Pfizer monkey virus gag matrix domain regulate 
intracellular trafficking and capsid-membrane interactions. J Virol 81:8977-8988. 
 76 
59.  Fernandes F, Chen K, Ehrlich LS, Jin J, Chen MH, Medina GN, Symons M, 
Montelaro R, Donaldson J, Tjandra N, Carter CA. 2010. Phosphoinositides 
Direct Equine Infectious Anemia Virus Gag Trafficking and Release. Traffic. 
60.  Coffin JM HS, Varmus HE, editors. 1997, posting date. Overview of Retroviral 
Assembly. [Online.] 
61.  Accola MA, Strack B, Gottlinger HG. 2000. Efficient particle production by 
minimal Gag constructs which retain the carboxy-terminal domain of human 
immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J Virol 
74:5395-5402. 
62.  LeBlanc JJ, Beemon KL. 2004. Unspliced Rous sarcoma virus genomic RNAs 
are translated and subjected to nonsense-mediated mRNA decay before 
packaging. J Virol 78:5139-5146. 
63.  Massiah MA, Starich MR, Paschall C, Summers MF, Christensen AM, 
Sundquist WI. 1994. Three-dimensional structure of the human 
immunodeficiency virus type 1 matrix protein. J Mol Biol 244:198-223. 
64.  McDonnell JM, Fushman D, Cahill SM, Zhou W, Wolven A, Wilson CB, 
Nelle TD, Resh MD, Wills J, Cowburn D. 1998. Solution structure and 
dynamics of the bioactive retroviral M domain from Rous sarcoma virus. J Mol 
Biol 279:921-928. 
65.  Riffel N, Harlos K, Iourin O, Rao Z, Kingsman A, Stuart D, Fry E. 2002. 
Atomic resolution structure of Moloney murine leukemia virus matrix protein and 
its relationship to other retroviral matrix proteins. Structure 10:1627-1636. 
66.  Arnold K, Bordoli L, Kopp J, Schwede T. 2006. The SWISS-MODEL 
workspace: a web-based environment for protein structure homology modelling. 
Bioinformatics 22:195-201. 
67.  Bordoli L, Kiefer F, Arnold K, Benkert P, Battey J, Schwede T. 2009. Protein 
structure homology modeling using SWISS-MODEL workspace. Nat Protoc 4:1-
13. 
68.  Golebiewska U, Gambhir A, Hangyas-Mihalyne G, Zaitseva I, Radler J, 
McLaughlin S. 2006. Membrane-bound basic peptides sequester multivalent 
(PIP2), but not monovalent (PS), acidic lipids. Biophysical journal 91:588-599. 
69.  Crist RM, Datta SA, Stephen AG, Soheilian F, Mirro J, Fisher RJ, 
Nagashima K, Rein A. 2009. Assembly properties of human immunodeficiency 
virus type 1 Gag-leucine zipper chimeras: implications for retrovirus assembly. J 
Virol 83:2216-2225. 
 77 
70.  Zhang Y, Qian H, Love Z, Barklis E. 1998. Analysis of the assembly function 
of the human immunodeficiency virus type 1 gag protein nucleocapsid domain. J 
Virol 72:1782-1789. 
71.  Fogarty KH, Berk S, Grigsby IF, Chen Y, Mansky LM, Mueller JD. 2014. 
Interrelationship between cytoplasmic retroviral Gag concentration and Gag-
membrane association. Journal of molecular biology 426:1611-1624. 
72.  Llewellyn GN, Grover JR, Olety B, Ono A. 2013. HIV-1 Gag associates with 
specific uropod-directed microdomains in a manner dependent on its MA highly 
basic region. J Virol 87:6441-6454. 
73.  Finzi A, Orthwein A, Mercier J, Cohen EA. 2007. Productive human 
immunodeficiency virus type 1 assembly takes place at the plasma membrane. J 
Virol 81:7476-7490. 
74.  Jouvenet N, Neil SJ, Bess C, Johnson MC, Virgen CA, Simon SM, Bieniasz 
PD. 2006. Plasma membrane is the site of productive HIV-1 particle assembly. 
PLoS Biol 4:e435. 
75.  Leventis PA, Grinstein S. 2010. The distribution and function of 
phosphatidylserine in cellular membranes. Annu Rev Biophys 39:407-427. 
76.  Yeung T, Gilbert GE, Shi J, Silvius J, Kapus A, Grinstein S. 2008. Membrane 
phosphatidylserine regulates surface charge and protein localization. Science 
319:210-213. 
77.  Dick RA, Vogt VM. 2014. Membrane interaction of retroviral Gag proteins. 
Front Microbiol 5:187. 
78.  Ako-Adjei D, Johnson MC, Vogt VM. 2005. The retroviral capsid domain 
dictates virion size, morphology, and coassembly of gag into virus-like particles. J 
Virol 79:13463-13472. 
79.  Colicelli J, Goff SP. 1988. Sequence and spacing requirements of a retrovirus 
integration site. J Mol Biol 199:47-59. 
80.  Lee YN, Bieniasz PD. 2007. Reconstitution of an infectious human endogenous 
retrovirus. PLoS Pathog 3:e10. 
81.  Monde K, Contreras-Galindo R, Kaplan MH, Markovitz DM, Ono A. 2012. 
Human endogenous retrovirus K Gag coassembles with HIV-1 Gag and reduces 
the release efficiency and infectivity of HIV-1. J Virol 86:11194-11208. 
82.  Kisseleva MV, Wilson MP, Majerus PW. 2000. The isolation and 
characterization of a cDNA encoding phospholipid-specific inositol 
polyphosphate 5-phosphatase. J Biol Chem 275:20110-20116. 
 78 
83.  Nguyen KL, llano M, Akari H, Miyagi E, Poeschla EM, Strebel K, Bour S. 
2004. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA 
and allows for highly efficient Rev-independent expression. Virology 319:163-
175. 
84.  Hogue IB, Hoppe A, Ono A. 2009. Quantitative fluorescence resonance energy 
transfer microscopy analysis of the human immunodeficiency virus type 1 Gag-
Gag interaction: relative contributions of the CA and NC domains and membrane 
binding. J Virol 83:7322-7336. 
85.  Grover JR, Llewellyn GN, Soheilian F, Nagashima K, Veatch SL, Ono A. 
2013. Roles played by capsid-dependent induction of membrane curvature and 
Gag-ESCRT interactions in tetherin recruitment to HIV-1 assembly sites. J Virol 
87:4650-4664. 
86.  Li L, Li C, Sarkar S, Zhang J, Witham S, Zhang Z, Wang L, Smith N, 
Petukh M, Alexov E. 2012. DelPhi: a comprehensive suite for DelPhi software 
and associated resources. BMC Biophys 5:9. 
87.  Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng 
EC, Ferrin TE. 2004. UCSF Chimera--a visualization system for exploratory 
research and analysis. J Comput Chem 25:1605-1612. 
 
 
 79 
 80 
CHAPTER III 
Evidence in support of RNA-mediated inhibition of phosphatidylserine-dependent 
HIV-1 Gag membrane binding in cells 
 
ABSTRACT 
The matrix domain promotes plasma-membrane-specific binding of HIV-1 Gag 
through interaction with an acidic lipid phosphatidylinositol-(4,5)-bisphosphate. In in 
vitro systems, matrix-bound RNA suppresses Gag interaction with phosphatidylserine, an 
acidic lipid prevalent in various cytoplasmic membranes, thereby enhancing the lipid 
specificity of matrix. Here we provide in vitro and cell-based evidence supporting that 
this RNA-mediated suppression occurs in cells and hence is a physiologically relevant 
mechanism that prevents Gag from binding promiscuously to phosphatidylserine-
containing membranes. 
 
INTRODUCTION 
Membrane binding of HIV-1 Gag is one of the essential steps in virus assembly, 
which takes place primarily at the plasma membrane (PM) (1). The matrix (MA) domain 
of Gag is essential for directing virus assembly specifically to the PM. MA has an N-
terminal myristoyl moiety that facilitates hydrophobic interaction of Gag with 
membranes (2, 3). The second signal required for efficient association of Gag with 
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membranes is the highly basic region (HBR) in MA, which spans residues 17 to 31 of 
MA. The HBR mediates the electrostatic interaction with cellular acidic lipids (4-10), in 
particular, a PM-specific phospholipid, phosphatidylinositol-(4,5)-bisphosphate 
[PI(4,5)P2] (9, 11-13). Notably, in vitro studies have shown that MA or its HBR binds 
RNA as well (13-17). Furthermore, we and others have shown that RNA bound to HBR 
also regulates membrane binding of Gag in vitro. RNA bound to MA abolishes Gag 
binding to negatively charged membrane composed of a neutral lipid phosphatidylcholine 
(PC) and an acidic lipid phosphatidylserine (PS) at the 2:1 ratio; however, addition of 
PI(4,5)P2 allows Gag to alleviate the block imposed by RNA (9, 16, 18). These results 
collectively support an attractive model in which RNA binding to MA HBR prevents Gag 
from binding non-PI(4,5)P2 acidic lipids, of which PS is the most abundant in the 
cytoplasmic leaflet of cellular membranes. This RNA-mediated inhibition can thus 
enhance the specificity of Gag binding to membranes that contain PI(4,5)P2, which in 
cells is the PM. However, because the available data supporting this model were all 
obtained by in vitro studies, it remains unknown whether RNA-dependent regulation of 
membrane binding actually takes place in cells.  In this study, we show that the cellular 
level of RNA is sufficient for blocking Gag binding to PS. In addition, we observed that 
Gag present in the cytosol is bound to RNA partially via MA HBR and that MA-HBR-
dependent PS binding of cytosolic Gag is indeed suppressed by RNA. 
 
RESULTS 
Inhibition of Gag binding to PC- and PS-containing liposomes by RNA takes place 
at RNA concentrations lower than that in cells 
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Myristoylated full-length Gag synthesized in reticulocyte lysates does not bind 
negatively charged liposomes containing PS at the physiological concentration of this 
acidic lipid (~30%)(12, 19, 20). Even at higher concentrations (~50%), palmitoyl-oleoyl-
PS (POPS), the most abundant form of PS in viral and plasma membranes (21), does not 
support efficient liposome binding although di-oleoyl-PS does (20). In previous studies 
(9, 22), we observed that RNase A treatment drastically increases binding of Gag to 
liposomes with a 2:1 ratio of POPC and POPS (here termed PC+PS liposome). To 
determine the minimal RNA concentration that is sufficient to inhibit membrane binding 
of Gag, we added back different amounts of RNA to RNase-treated Gag. Gag synthesized 
using rabbit reticulocyte lysates as described previously (9, 12), was treated with 0.028 
Units (400 ng) of RNase A (Qiagen) and incubated in a 30-µl reaction at 37C for 20 
min. RNase A was then inactivated by 10 µl of RNasin (40 U/µl; Promega). The reaction 
containing RNase-treated Gag was then incubated with different concentrations of yeast 
tRNA (Ambion) for 30 min at 30C. After another 15-min incubation of Gag with PC+PS 
liposomes (final volume 50 µl), the mixture was subjected to equilibrium flotation 
centrifugation using sucrose gradient as described previously (12). We found that tRNA 
in the range of 0.01-0.1 µg/µl was sufficient in inhibiting Gag binding to PC+PS 
liposomes (Fig. 3.1A). Considering that a typical HeLa cell volume is at most 5x10-6 l 
(ranging 0.5-5x10-6 µl) (23) and that a cell has around 10-30 pg of RNA (based on the 
typical RNA yield from a known number of cells) (24, 25), there is at least 2-6 g/l of 
RNA in a HeLa cell (data not shown). Consistent with this, total RNA concentration 
measured for a mammalian cell line is ~4 µg/µl (26). Under normal physiological 
conditions, eighty percent of cellular RNA is rRNA, 15-20 % are tRNA or other small 
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RNAs and the rest being mRNA (27, 28). Thus, the concentration of tRNA that inhibited 
Gag binding to PC+PS liposomes is lower than the concentrations of both total RNA and 
tRNA in HeLa and other cell lines (26), suggesting that RNA-mediated inhibition of Gag 
binding to PS-containing membranes can occur in cells. Notably, Gag binding to PC+PS 
liposomes containing 7.25 mol% PI(4,5)P2 was less sensitive to tRNA (Fig. 3.1B), a 
finding consistent with the model in which PI(4,5)P2 is capable of interacting with Gag 
even in the presence of MA-bound RNA.  
RNA binding in cells is mediated partly by MA 
While both total RNA and tRNA concentrations in cells would be sufficient for 
the inhibition of Gag binding to PS-containing, but not PI(4,5)P2-containing, membranes, 
it is likely that the majority of cellular RNA species are not accessible to the MA HBR in 
cells due to their localization or interactions with cellular proteins.  To determine whether 
MA HBR is able to interact with RNA in cells, we quantified the amount of RNA bound 
to Gag immunoprecipitated from cells. In these experiments, we examined non-
myristoylated Gag derivatives encoded in molecular clones that also lack active protease. 
We used non-myristoylated Gag constructs to eliminate the variation in 
immunoprecipitation efficiencies caused by differences in Gag epitope exposure between 
non-membrane-bound Gag and membrane-bound Gag that forms higher-order multimers 
(29, 30). We assessed the effect of the 6A2T substitutions in the MA HBR, in which all 
the basic amino acid residues were replaced with neutral ones (9). As a control, we also 
examined the RNA binding when NC, the main RNA binding domain of Gag, is replaced 
with a dimerization motif, leucine zipper (LZ), of an yeast transcription factor GCN4 
(31). This Gag derivative (GagLZ) lacks NC-mediated RNA binding, yet is capable of 
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forming virus-like particles in the context of intact MA (31-33). HeLa cells were 
transfected using Lipofectamine 2000 according to the manufacturer’s instruction with 
pNL4-3/1GA/PR- (34) and derivatives containing LZ, 6A2T, 6A2T/LZ changes 
[constructed using previously reported molecular clones (34-36) by standard molecular 
cloning techniques]. Six hours post-transfection, cells were labeled with [35S]-
methionine/cysteine. Twenty-four hours post-transfection, cells were lysed using the 
polysome lysis buffer (23), and Gag was immunoprecipitated using HIV-1 
immunoglobulin as described previously (9). A fraction of the immunoprecipitated 
materials was treated with proteinase K, and co-immunoprecipitated RNA was isolated 
using Qiazol and Qiagen miRNAeasy kit as recommended by the manufacturer. In 
parallel, the remaining immunoprecipitated materials were analyzed on SDS-PAGE, and 
the amount of Gag was quantified using phosphorimager analysis. The RNA was then 
quantified using Quant-iT Ribogreen reagent and normalized to the amount of 
immunoprecipitated Gag. As expected, there was significantly less RNA co-
immunoprecipitated with GagLZ than with full-length Gag (Fig. 3.2). This result is 
consistent with previous reports showing diminished RNA contents in extracellularly 
released NC-deficient particles (32, 37, 38). Importantly, the amount of RNA bound to 
Gag was also reduced when MA HBR was mutated in the full-length Gag context. While 
introduction of the same MA mutations in the GagLZ context (1GA/6A2T GagLZ) did 
not cause a statistically significant reduction in RNA binding compared with GagLZ, the 
amount of RNA bound to 1GA/6A2T GagLZ was most severely reduced relative to full-
length Gag among the Gag derivatives. Altogether, these results suggest that not only NC 
but also MA HBR participates in RNA binding of full-length cytosolic Gag. Consistent 
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with this observation, in vitro studies have shown that MA has stronger affinities for 
some RNA aptamers compared to NC, suggesting a potential specific interaction between 
MA and RNA(13-15, 18, 39).  However, these data do not rule out the possibility that the 
RNA bound to NC is the same RNA that binds MA in cells. If this is the case, due to its 
inherent high affinity for RNA, NC may facilitate MA-RNA interaction by bringing the 
RNA in close proximity to the MA HBR.  
Gag in the cytosol binds negatively charged liposomes upon removal of RNA  
RNA present in in vitro translation reactions prevents PS-dependent liposome 
membrane binding of non-myristoylated Gag synthesized in these reactions (9). To 
address whether the RNA bound to Gag in cells inhibits PS-dependent membrane 
binding, HeLa cells (2 x 106 cells) were transfected with HIV-1 molecular clones 
encoding non-myristoylated Gag as in Fig. 3.2. Twenty hours post-transfection, the cells 
were treated with 100 µl of 0.04% digitonin (in 20 mM HEPES, 150 mM NaCl with 
Complete™ protease inhibitor) for 10 min on ice in a microcentrifuge tube. The 
permeabilized cells were then centrifuged at 13200 rpm for 10 min in a microfuge to 
separate the cytosol from perforated cells. The supernatant was then treated or not treated 
with RNase A (0.7 U or 10 µg) at 37 C for 20 min and further incubated with PC+PS 
liposomes at 37 C for 15 min. The liposome-bound proteins were then separated on 
equilibrium flotation centrifugation as previously described (9, 12). Gag present in each 
fraction was detected using Typhoon Trio imager (GE) after immunoblotting using HIV-
Ig as the primary antibody and anti-human Alexa Fluor 488 as the secondary antibody. 
As observed previously for in vitro synthesized Gag (9), RNase treatment significantly 
enhanced binding of cytosolic Gag to PC+PS liposomes (Fig. 3.3).  These results indicate 
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that RNAs in cells can block binding of cytosolic Gag to negatively charged membranes 
that do not contain PI(4,5)P2. This RNA-mediated inhibition was also observed when NC 
was replaced with LZ (Fig. 3.3A and B) or deleted (data not shown), suggesting that 
neither RNA binding to NC nor NC-driven Gag multimerization is essential for RNA-
mediated inhibition of MA-dependent Gag membrane binding. When MA HBR was 
mutated in the GagLZ context (Fig. 3.3A and B), there was negligible membrane binding 
regardless of RNase treatment. This observation indicates that the MA HBR mediates the 
PC+PS liposome binding of RNase-treated cytosolic Gag examined in these experiments.  
Experiments described above were performed using cells expressing non-myristoylated 
Gag derivative to maximize the yield of cytosolic Gag. To determine whether RNA 
regulates wild-type (WT) Gag in the cytosol in a similar manner, the cytosol of HeLa 
cells transfected with a molecular clone encoding WT Gag were harvested 8 hours post-
transfection. At this time point, fluorescently tagged WT Gag shows a cytosolic 
localization pattern in a larger fraction of cells than at 24 hours post-transfection (data not 
shown). We found that PC+PS liposome binding of WT Gag derived from the cytosol of 
transfected HeLa cells was enhanced upon RNase treatment (Fig. 3.3C and D) as 
observed for non-myristoylated Gag. These results support the conclusion that RNA 
prevents cytosolic Gag from binding to prevalent acidic lipids and further suggest that a 
substantial population of non-membrane-bound Gag that has been observed in cells is 
maintained due to the block mediated by RNA.  
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DISCUSSIONS AND CONCLUSIONS 
The data presented in this study show that RNA-mediated inhibition of Gag 
binding to PS-containing membranes can occur in cells and thus is a physiologically 
relevant mechanism for the regulation of Gag-membrane binding and HIV-1 assembly. 
While the observed MA-HBR-dependent RNA binding (Fig. 3.2) supports a direct 
mechanism whereby RNA outcompetes PS or other non-PI(4,5)P2 acidic lipids for 
electrostatic interactions with HBR, we do not rule out an indirect mechanism in which a 
cellular RNA-dependent factor is involved in regulation of MA-acidic lipid interactions . 
Interestingly, however, a recent report showed that nucleotides facilitate selective binding 
of synaptotagmin C2 domains to PI(4,5)P2-containing membranes by blocking 
electrostatic interactions with PS in untargeted membranes (40).  Therefore, the 
competition between nucleotides and acidic lipids may be a widely used mechanism to 
promote specific targeting of proteins to PI(4,5)P2-containing membranes. 
In addition to the regulation of Gag-membrane binding, previous in vitro studies 
suggested that the competition between RNA and acidic lipids explains the structural 
change of full-length HIV-1 Gag between bended and extended shapes (41) and 
regulation of the NC-dependent RNA chaperone activity (42). These findings collectively 
highlight the switch function of MA HBR during the late phase of HIV-1 life cycle. 
Nevertheless, molecular details of the balance between MA-PI(4,5)P2 and MA-RNA 
interactions remain to be determined. In particular, the potential roles for simultaneous 
binding of MA and NC domains to the same RNA molecule in coordinating Gag 
membrane binding with Gag multimerization or other steps in the assembly process 
warrant further investigation. RNA aptamers have been emerging as a new class of 
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potential therapeutics (43). With the current evidence supporting that the MA-RNA 
interaction regulates membrane binding of Gag in cells, RNA aptamers that specifically 
interact with MA with a higher affinity than PI(4,5)P2 might be useful to block HIV-1 
assembly in HIV-1-infected individuals.  
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Fig. 3.1. tRNA below intracellular levels inhibits Gag binding to liposomes containing PS 
but not PI(4,5)P2. (A). [35S]-labeled Gag synthesized using rabbit reticulocyte lysates was treated 
with 400 ng of RNase A at 37C for 20 minutes. RNase A was blocked using RNasin, and the 
mixtures were further incubated with indicated concentrations of tRNA at 30C for 30 minutes. 
PC+PS liposomes were then added and incubated further for 15 minutes before performing 
equilibrium flotation centrifugation. Five 1-ml fractions were collected, and 25 l of each fraction 
was loaded and analyzed on SDS-PAGE (inset). The liposome binding efficiency was calculated 
as the amount of membrane-bound Gag (M in inset) as a fraction of total Gag. Average of 3 
different experiments is shown. Error bars represent standard deviation. P values were determined 
by using Student’s t test. **, P < 0.01; ***, P < 0.001. (B). [35S]-labeled Gag incubated 
sequentially with RNase A, RNasin, and 0.1 µg/µl tRNA as in A was examined for binding to 
PC+PS liposomes that contain 7.25 mol% PI(4,5)P2 (PC:PS:PI(4,5)P2 = 62:31:7.25) in 
comparison with binding to PC+PS liposomes. The liposome binding efficiency was calculated as 
in panel A, and the relative liposome binding efficiency was calculated in comparison with the 
binding efficiency of RNase-treated Gag not incubated with tRNA for each experiment. Average 
of 2 different experiments is shown. The average liposome binding efficiencies of RNase-treated 
Gag not incubated with tRNA were 33% for PC+PS liposomes and 59% for PI(4,5)P2-containing 
liposomes in these experiments.  
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Fig. 3.2. MA HBR interacts with RNA in cells. HeLa cells were transfected with pNL4-
3/1GA/PR-, pNL4-3/1GA/6A2T/PR-, pNL4-3/1GA/LZ/PR- or pNL4-3/1GA/6A2T/LZ/PR- and 
metabolically labeled with [35S] Met/Cys overnight. Cells were lysed and immunoprecipitated 
with anti-HIV Ig antibody. A fraction of immunoprecipitated materials were examined for the 
amounts of bound RNA. The amount of co-immunoprecipitated RNA was quantified by 
fluorometry using Ribogreen reagent. The amount of RNA was normalized to the Gag levels, and 
the RNA bound to pNL4-3/1GA/PR- was set to 100%. Average of 3 different experiments is 
shown. Error bars represent standard deviation. *, P < 0.05; **, P < 0.01. The amounts of RNAs 
bound to 1GA/6A2T Gag and 1GA GagLZ are not significantly higher than that of 1GA/6A2T 
GagLZ.  
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Fig. 3.3. RNA inhibits membrane binding of Gag present in the cytosol. (A) and (B), HeLa 
cells (2 x 106) were transfected with pNL4-3/1GA/PR-, pNL4-3/1GA/LZ/PR- or pNL4-
3/1GA/6A2T/LZ/PR-. Twenty hours post-transfection, cells were treated with digitonin, and 
supernatants containing cytosolic Gag (100 µl) were separated from perforated cells by 
centrifugation. The supernatants were divided in two aliquots and treated with RNase A or left 
untreated. Five microliter of PC+PS liposomes (14.6 µg lipid/µl) were then added, and the 
reaction was further incubated for 15 minutes before performing sucrose gradient centrifugation. 
Five fractions were collected and analyzed by western blotting using anti-HIV Ig as the primary 
antibody and anti-human Alexa Fluor488 as the secondary antibody. M: membrane-bound Gag. 
(C) and (D), HeLa cells (6 x 106) were transfected with pNL4-3/PR-, which encodes WT Gag, or 
pNL4-3/1GA/PR-. Eight hours post-transfection, cells were treated with digitonin, and 
supernatants containing cytosolic Gag (200 µl) were separated from perforated cells by 
centrifugation. The supernatants were divided in two aliquots and treated with RNase A or left 
untreated. Ten microliter of PC+PS liposomes (14.6 µg lipid/µl) were then added, and the 
reaction was analyzed as in A and B. The amount of membrane-bound Gag versus the total 
amount of Gag was calculated and is shown as liposome-binding efficiency (B and D). Data from 
at least three independent experiments are shown as means ± SD. ns, not significant; *, P < 0.05; 
***, P<0.001. 
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Chapter IV 
 Molecular mechanism of HIV-1 assembly in primary macrophages 
ABSTRACT 
HIV-1 Gag is necessary and sufficient for the assembly process. The site of 
assembly of HIV-1 is cell-type dependent. In HeLa and T cells, HIV-1 assembles at the 
plasma membrane (PM). The PM binding and localization of HIV-1 Gag is mediated by 
the matrix (MA) domain, specifically the highly basic region (HBR), via interaction with 
a PM-specific acidic phospholipid, phosphatidylinositiol-4,5-bisphosphate [PI(4,5)P2]. 
HIV-1 MA also interacts with RNA, which prevents Gag from binding to membranes 
containing phosphatidylserine, a prevalent cellular acidic phospholipid. These results 
suggest that the MA-bound RNA promotes PM-specific localization of HIV-1 Gag by 
blocking non-specific interactions with cellular membranes that do not contain PI(4,5)P2. 
Interestingly, in polarized T cells, nucleocapsid(NC)-dependent multimerization was 
found to be important in Gag targeting to the uropod, the rear-end PM protrusion of the 
cell. The site of assembly of HIV-1 in primary macrophages is the virus-containing 
compartments (VCC). Whether targeting of HIV-1 Gag to the VCC is MA-dependent or 
NC-dependent is not known. Thus, to study the molecular mechanism of HIV-1 Gag 
targeting to the VCC, we first examined the impact of PI(4,5)P2 depletion by the 
overexpression of polyphosphoinositide 5-phosphatase IV (5ptaseIV) in  primary 
macrophages. We found that the VCC localization and virus release of HIV-1 are 
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severely impaired. Furthermore, we determined that myristoyl moiety, but not the intact 
HBR is important in VCC localization. Our analysis of HIV-1 Gag with MA-replacement 
mutations suggest that HIV-1 MA only contributes to membrane binding but not in Gag 
targeting to the VCC. We further determined that HIV-1 NC is important for VCC-
specific localization of HIV-1 Gag. HIV-1 Gag is still able to localize to the VCC 
efficiently when the NC domain is replaced with a leucine zipper dimerization motif 
(GagLZ), which is capable of promoting Gag-Gag multimerization. Altogether, our data 
suggest that targeting of HIV-1 Gag to the VCC requires NC-dependent multimerization, 
a mechanism that is reminiscent of HIV-1 Gag targeting to the uropod in polarized T cell. 
 
INTRODUCTION 
Macrophages represent one of the primary cell targets of HIV-1 and play 
important roles in HIV-1 pathogenesis (1-3). They are terminally differentiated 
phagocytic cells of myeloid lineage and are found at various tissues in the body. Similar 
to T cells, macrophages express HIV-1 receptor, CD4, albeit at lower level, and co-
receptors CCR5 and CXCR4. CCR5 is expressed in higher levels than CXCR4 in 
macrophages. HIV-1 enters the host through the mucosal and gastrointestinal surfaces 
(4). With macrophages residing at these sites, it is thought that they represent one of the 
earliest immune cells that encounters HIV-1 at mucosal surfaces.  
Macrophages are long-lived and are seen to accumulate HIV-1 particles for long 
period of time (5-7). They are more resistant to cytopathic effects of virus replication 
than CD4 T cells, and are not efficiently depleted during acute infection (3, 8). Thus, they 
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are thought to represent one of the latent reservoirs for viruses that evade or are resistant 
to HAART (1, 4, 9, 10). Furthermore, because macrophages are found circulating the 
body and are capable of passing the blood-brain barrier, they are important as a means of 
HIV-1 dissemination and establishment of infection at the brain, causing HIV 
encephalitis (HIVE) (9, 11). 
The site of assembly of HIV-1 is defined by the presence of immature particles as 
well as budding virus structures from the limiting cellular membrane as visualized by 
electron microscope (EM) [see (12, 13) for EM images]. In addition, the presence of Env 
protein and Gag can also be used to identify the site of assembly. In T cells and other cell 
lines, such as 293T cells, COS cells and HeLa cells, HIV-1 assembly occurs at the plasma 
membrane (14-16). Ultrastructural study of macrophages reveal that the HIV-1 particles 
accumulates intracellularly and contain not only mature particles but immature ones as 
well (5, 17-19). These compartments where HIV-1 accumulates in primary macrophages 
are called the virus containing compartments (VCC).  
Composition of VCC 
The identity of VCC is currently unknown. Previously, VCC was categorized as 
an endosomal compartment or multivesicular bodies (MVB) as Gag was found to 
colocalize with CD63, an endosomal/MVB marker (20). In another study, HIV-1 
particles were seen to bud from major histocompatibility complex class II (MHCII) 
compartments, where CD63 are also present (17). By assembling and budding into the 
MHCII compartments, HIV-1 was also thought to have used exocytosis pathway to 
release the particles into extracellular milieu (17). In support of this hypothesis, immuno–
EM studies showed that numerous internal vesicles containing HIV-1 was found to be in 
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close proximity with the plasma membrane, resembling the exosomal secretion pathway 
in B cells (17, 18, 21, 22). Other than serving as the site of assembly, VCC also seems to 
be involved in cell-to-cell transmission of HIV-1. In particular, HIV-1 Gag is observed to 
traffic from intracellular compartments to macrophage-T cell contact sites (23).  
Despite accumulating evidence suggesting that HIV-1 bud into endosomal/MVB 
compartments, recent studies seem to content these findings. Firstly, Jouve et al. found 
that VCC was not as efficiently stained by BSA-Gold, an endocytic tracer, as the 
endocytic/MVB compartments (19). Furthermore, using a membrane-permeable acidic 
organelle probe, DAMP (D1552), Jouve et al. also estimated the pH of VCC to be 6.8 
(19). This finding is inconsistent with the pH found in the endocytic compartments, 
which has acidic environment. More importantly, VCC seems to be accessible from the 
cellular surface. This surface connection was visualized by EM after staining the infected 
macrophages with membrane-impermeable dye, ruthenium red (RR) (21, 24, 25). In these 
cells, HIV-1 particles are found in the RR-positive intracellular compartments that has 
narrow channels (<20nm) connecting to the cell surface (24, 25). Thus, the current 
consensus is that VCC are deep invaginations of the plasma membrane (21). 
However, not all VCC are cell-surface accessible as some but not all VCC can be 
stained with cell-impermeable dye or small molecules (26, 27). Furthermore, sequential 
feeding of HIV-1 infected macrophages with two different fluorescently-labeled 10kDa 
dextran revealed that not all VCC remain accessible to both compounds. This indicates 
that VCC exposure to the extracellular milieu is transient (26). Overall, current data 
suggest that VCC in macrophages are heterogeneous and dynamic in nature. 
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Recent studies have focused on characterizing the membrane composition of the 
VCC. VCC is shown to contain tetraspanin markers such as CD9, CD53, CD81 and 
CD82 (18, 25, 28, 29). In addition, CD18, a leukocyte-specific 2 integrin, CD44, cell 
adhesion protein/hyaluronic acid receptor and CD36, an LDL-receptor, are also present 
(29-31). Moreover, PH-GFP, a PI(4,5)P2-specific marker, is shown to overlap with CD81 
and Gag puncta at intracellular sites in macrophages, suggesting that PI(4,5)P2 is also 
present at the VCC (28). PI(4,5)P2 is a negatively charged phospholipid that is found 
predominantly at the plasma membrane (32, 33) and was previously shown to be 
important for HIV-1 release and Gag localization to the plasma membrane (13, 34). In 
addition to these membrane protein markers, interestingly, CD63 segregates from the two 
VCC markers, CD81 and CD9, in uninfected cells (25). The VCC only become CD63-
positive upon HIV-1 infection. It is unknown at the moment whether this is because HIV-
1 actively organizes the membrane at the VCC, or because the cycling of CD63-positive 
compartments to the cell surface is trapped due to the expanding VCC in the cell (25, 35). 
Nonetheless, it seems that CD63 is not required for HIV-1 localization to the VCC nor is 
it required for productive virus release (25, 35). 
3D morphological analyses of RR-stained membranes have shown that VCCs are 
made up of a complex meshwork of convoluted, membranous structures (24). 
Furthermore, comparison between RR-stained uninfected versus infected macrophages 
reveal that VCC exist prior to virus infection. Consistent with this, intracellular staining 
of CD81, CD9 and CD53 are observed in uninfected macrophages. However, upon HIV-
1 infection, the volume of VCC expands, possibly through the accumulation of virus 
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particles in the compartments (24). Thus, current studies suggest that VCC formation is 
not a result of de novo membrane synthesis upon HIV-1 infection. 
VCC staining by tetraspanin markers also overlap with actin staining and are 
shown to contain focal adhesions proteins such as vinculin, paxillin and talin (29). VCC 
are also reported to be in close association with KIF3A microtubules (36). Actin 
depolymerization by latrunculin A or cytochalasin treatments disperse Gag localization 
from the VCC (14, 28) and increase virus release from infected macrophages (28). 
Altogether, these results suggest that the integrity of VCC seems to be dependent upon 
actin assembly.  
Tetherin and VCC 
Tetherin is an interferon-inducible cellular restriction factor that restricts virus 
particle release from the cell surface (37). HIV-1-encoded Vpu protein is able to 
overcome this restriction by downregulating tetherin surface expression and targeting 
tetherin for degradation (37, 38). In T cells, tetherin accumulates at virus budding sites 
and restricts the release of HIV-1 particles that lack the vpu gene (37). These Vpu-deleted 
HIV-1 strain are internalized and accumulate in intracellular vacuoles (39, 40). Similar to 
T cells and other cell lines, HIV-1 infection in macrophages upregulates tetherin 
expression (27, 41). However, whether tetherin is involved in VCC formation remains 
controversial. Tetherin is present at the VCC in uninfected and HIV-1 infected 
macrophages (27, 41). In one report, tetherin knockdown was found to shrink the size of 
Gag-positive VCC in infected macrophages, suggesting that tetherin also plays a role in 
VCC formation (27). The authors also proposed that HIV-1 infection in MDM results in 
high levels of tetherin induction and that Vpu is insufficient to counteract the tetherin 
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effectively in MDM. This consequently leads to tetherin-mediated trapping of HIV-1 
particles at the VCCs. In contrast, Giese et al. reported that HIV-1 Gag is detected at 
VCC regardless of the presence of Vpu, although mature Gag by p17 staining at VCC 
was increased in macrophages infected with Vpu-deficient viruses (41). This suggests 
that tetherin restricts and accumulates Vpu-deficient HIV-1 particles at VCC. They 
further analyzed the intracellular CD81 and CD9 staining in untreated or tetherin-
knockdown macrophages and saw no difference in their localization regardless of tetherin 
level. Altogether, Giese et al. concluded that tetherin is not important for VCC 
morphology (41). 
SAMHD1 and Vpx 
One of the reasons why it remains challenging to study HIV-1 infection in 
primary macrophages is because macrophages resist HIV-1 infection much better than 
CD4 T cells (1). In addition to the presence of tetherin, HIV-1 faces additional replication 
restrictions in macrophages. A macrophage-specific interferon-inducible restriction factor 
seems to reduce HIV-1 Env expression and virus release (42). Although the restriction 
factor is yet to be determined, it was found that HIV-1 Vpr is able to counteract this 
restriction pathway. Moreover, cells of myeloid lineage, including dendritic cells, 
monocytes and macrophages, express a restriction factor known as SAM domain and HD 
domain-containing protein 1 (SAMHD1) at high levels (43). Interestingly, HIV-1 does 
not encode any protein to counteract this inhibition (see Chapter I). SAMHD1 restricts 
HIV-1 replication by depleting the intracellular pool of deoxynucleoside triphosphates 
(dNTPs), an essential component for synthesizing viral cDNA during reverse 
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transcription (43). As a result of lower dNTPs concentration, incomplete or inefficient 
reverse transcription occur, leading to abortive infection. 
In contrast to HIV-1, viruses of SIVsm/HIV-2 lineage encode the vpx gene (44, 
45). Vpx is an accessory protein that counteracts SAMHD1 restriction by targeting it to 
proteasome degradation, thereby allowing infection to proceed. Vpx is packaged into the 
virion by interacting with the p6 domain of Gag (44, 46). Upon virus entry, Vpx is 
released into the cytosol of the target cell where it interacts with E3 ubiquitin ligase 
complex to target SAMHD1 for degradation. 
HIV-1 infection is highly sensitive to the presence of SAMHD1. However, when 
Vpx is exogenously introduced, such as in the form of pseudotyped virus-like particles 
(VLP) to the target cell prior or during infection, HIV-1 infection can occur efficiently 
(44, 46). More importantly, introduction of Vpx into the cell does not alter macrophage 
maturation (upon LPS stimulation) or affect their survival (47). This method of using 
Vpx-VLP for increasing HIV-1 infection rate in macrophages was previously used to 
examine the role CD36 at the VCC and its effect on HIV-1 release (31).   
Unanswered questions 
Even though much effort has been carried out to characterize the structure and 
composition of VCC, very few have examined the molecular determinants that targets 
Gag to the VCC. HIV-1 assembly is driven by its structural protein, Gag. Gag is 
synthesized as a polyprotein (Pr55Gag) containing multiple structural domains, where each 
domain plays critical role during the assembly process (48-50). The Matrix (MA) domain 
makes up the N terminus of the Gag protein and is responsible for Gag targeting to and 
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membrane binding at the site of assembly. CA and NC are involved in Gag-Gag 
interaction, resulting in the formation of Gag multimers. The p6 domain contains the late 
domain motif, which is responsible for the recruitment of ESCRT proteins, to aid in the 
release of virus particles from the cell surface. 
In cells where the site of HIV-1 assembly takes place at the plasma membrane, it 
was hypothesized that the MA domain of HIV-1 Gag mediates membrane binding and 
Gag targeting. HIV-1 MA contains two key signals: the N-terminus myristoyl moiety, 
which helps in establishing hydrophobic interactions with the membrane, and the highly 
basic region (HBR) (51-54). The HBR binds membrane via specific electrostatic 
interactions with PI(4,5)P2, a plasma membrane-specific phospholipid. Mutations in HBR 
have resulted in membrane binding defect in vitro or mislocalization of HIV-1 Gag in 
HeLa and T cells (13, 34, 55-59). Moreover, depletion of cellular PI(4,5)P2 by 
overexpressing polyphosphoinositide-5-phosphatase IV (5ptaseIV) has resulted in a 
defect of Gag binding to the plasma membrane and a reduction in virus release from the 
cell (13, 34). Altogether, these results suggest that myristoyl moiety, HBR and PI(4,5)P2 
interaction are required for Gag localization to the plasma membrane and efficient virus 
assembly.  
In addition to PI(4,5)P2, HIV-1 MA, in particular the HBR, also binds RNA (60-
66). Removal of MA-bound RNA by RNase treatment reduces HIV-1 Gag membrane 
binding specificity to PI(4,5)P2 in vitro (55). Based on these results and other studies, we 
hypothesize that MA-bound RNA prevents HIV-1 Gag from binding cellular membranes 
that do not contain PI(4,5)P2. This way, MA-RNA interaction ensures specific binding of 
HIV-1 Gag to the plasma membrane, where PI(4,5)P2 is found (see Chapter I). Recent 
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studies have found that not only in vitro synthesized HIV-1 Gag, but the membrane 
binding of cell-derived HIV-1 Gag are also responsive to RNase treatment, suggesting 
that RNA-mediated membrane binding inhibition can exist in cellular context as well 
(67). Interestingly, a recent RNA-seq study reported that HIV-1 MA-bound RNA are in 
the form tRNA, specifically GluCTC, GluTTC, GlyGCC, GlyCCC, LysCTT, LysTTT, 
ValAAC, and ValCAC tRNAs (68). Whether these tRNA has specific regulatory role in 
HIV-1 Gag membrane binding is not yet known. 
In polarized T cells, HIV-1 Gag is targeted to a specific site of the plasma 
membrane known as the uropod (69). The uropod is a plasma membrane protrusion at the 
rear end of a polarized T cell. This region is enriched in membrane proteins that are also 
found in the VCC, such as CD9, CD44, CD81 and CD82. Uropod also contain important 
adhesion molecules such as P-Selectin Glycoprotein Ligand 1 (PSGL-1) and Intracellular 
adhesion molecules (ICAMs) such as ICAM-1 and ICAM-3 (69-71). Uropod serves as a 
contact site between cells and participates in virological synapse (VS) formation, where 
cell-to-cell transmission of HIV-1 occur (71). Interestingly, Gag targeting to the uropod is 
not MA-dependent; rather, NC-mediated multimerization is required (71). Such NC-
dependent multimerization is thought to cluster Gag at the plasma membrane and 
mediates interactions with uropod-specific microdomains (UDMs), which eventually co-
migrate with Gag to the uropod. 
The information above describes that HIV-1 Gag uses different mechanisms for 
targeting to specialized sites in the cell. While HIV-1 MA interactions with PI(4,5)P2 and 
RNA seem to regulate Gag binding to the plasma membrane in HeLa and T cells, NC-
dependent Gag multimerization plays a major role in Gag targeting to the uropod in 
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polarized T cells. It is not known which of these factors are important in HIV-1 Gag 
targeting to the VCC in macrophages. Since PI(4,5)P2 is present at the VCC, we 
hypothesize that HIV-1 Gag localization to VCC is PI(4,5)P2-dependent. Alternatively, 
Gag-Gag multimerization can play a role in VCC-targeting as well.  
To test our hypotheses, we first examined the role of PI(4,5)P2 in VCC targeting 
of HIV-1 Gag and in HIV-1 assembly. We analyzed the localization of HIV-1 Gag in 
infected macrophages that are overexpressing 5ptaseIV and quantified HIV-1 release 
efficiency from these cells. We found that PI(4,5)P2 depletion results in a reduction in 
HIV-1 Gag targeting to the VCC and that virus release efficiency is reduced in 5ptaseIV-
expressing macrophages. Next, we compared a panel of HIV-1 Gag with MA-mutations 
or multimerization-defective mutations on their abilities to localize to the VCC. Our 
results indicate that Gag-Gag multimerization is important for specific VCC localization. 
Altogether, HIV-1 Gag localization to the VCC is NC-dependent, and that PI(4,5)P2 
serves as an important membrane anchor, but plays a less important role in targeting Gag 
to the VCC than in other cells such as HeLa cells and T cells. 
 
MATERIALS AND METHODS 
Cells and plasmids. Monocyte derived macrophages (MDM) were obtained from 
peripheral blood mononuclear cells and isolated from buffy coats from healthy donors 
(New York Blood Center, NY) as previously described (20). Cells were cultured in RPMI 
1640 medium supplemented with 10% fetal bovine serum (FBS) for 7 days before they 
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are used for experiments. 293T cells was cultured and maintained in DMEM (Lonza) 
supplemented with 10%FBS (HyClone) as described previously (71). 
The HIV-1 molecular clones encoding Gag-Venus (pNL4-3/GagVenus) was 
described previously (34). pNL4-3/KFS/398/IRES-Myc-5ptaseIV and pNL4-
3/KFS/398/IRES-Myc-5ptaseIVΔ1 encode Myc-5ptaseIV and an inactive deletion 
mutant, Myc-5ptaseIVΔ1, respectively, following an internal ribosome entry site (IRES) 
sequence in place of the nef gene as previously described (72). These plasmids were 
derived from a parental plasmid, pNL4-3/KFS/398, which has the nef gene sequence 
replaced with a sequence containing multiple restriction sites derived from a plasmid, 
p398-6 (a kind gift from K. T. Jeang) and contain a frameshift mutation (KFS), which 
disrupts Env expression (73). pNL4-3/GagVenus/KFS/398/IRES-Myc-5ptaseIV and 
pNL4-3/GagVenus/398/IRES-Myc-5ptaseIVΔ1 were constructed using standard 
molecular cloning techniques using pNL4-3/GagVenus. pNL4-3/1GA GagVenus, pNL4-
3/29KT/31KT GagVenus, pNL4-3/Fyn10-MA GagVenus, pNL4-3/Kmyr-MA 
GagVenus, pNL4-3/PH-MA GagVenus, pNL4-3/HTMA GagVenus, pNL4-3/delNC 
GagVenus, pNL4-3/EE75,76AA GagVenus, pNL4-3/GagLZ-Venus, pNL4-3/Gag-LZ4-
Venus were also constructed using standard molecular cloning techniques using pNL4-
3/GagVenus as described previously (70, 74-76). 
Virus stock and infection. Vesicular stomatitis virus G glycoprotein (VSV-G) 
pseudotyped HIV-1 stocks were prepared as previously described with modification (71). 
Briefly, 3.4 × 106 293T cells were transfected with 9μg of pNL4-3-derived molecular 
clones, 9μg of pCMVNLGagPol-RRE and 3μg of pHCMV-G. Two days post-
transfection, virus-containing supernatants were filtered through a 0.45-μm filter and 
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virus particles were pelleted using ultracentrifugation (35,000 rpm, 4C, 45 
minutes). Virus pellets were resuspended in 900ul of RPMI-10. VSV-G pseudotyped SIV 
virus-like particles containing Vpx were prepared by transfecting 9μg of SIV3+ [a kind 
gift from Dr. Andrea Cimarelli (46)], and 3μg of pHCMV-G into 3.4 × 106 293T cells. 
Virus particles were then pelleted in the same way as described above. 
MDM were first transduced with Vpx-containing VLPs (SIV-Vpx) for 2 hours 
and then incubated with pseudotyped HIV-1 particles with high titer virus stocks for 6 
more hours. Virus-containing supernatants were then removed and cells were washed and 
cultured for additional 48 hours (Fig. 4.1A).   
Virus release assay. Virus release assay was performed as previously described with 
modifications ((13). Briefly, MDM were treated with SIV-Vpx followed by infection 
using pseudotyped HIV-1 molecular clones. At 48 h post-infection, culture medium was 
changed to RPMI-1640 lacking both methionine (Met) and cysteine (Cys) and 
supplemented with 2% FBS [RPMI-2 (−Met/−Cys)] and incubated for 30 min. 
Subsequently, these cells were metabolically labeled with [35S]Met/Cys (Perkin-Elmer) in 
fresh RPMI-2 (−Met/−Cys) for 4 h. Cell and virion lysates were prepared and subjected 
to immunoprecipitation with HIV-Ig antiserum (NIH AIDS Research and Preference 
Reagent Program). The virus release efficiency was calculated as the amount of virion-
associated Gag as a fraction of the total amount of Gag synthesized during the labeling 
period. 
Immunostaining and Confocal fluorescence microscopy. For visualization of the 
plasma membrane, MDM infected with VSVG-pseudotyped HIV-1 particles were 
incubated with Alexa Fluor 594-conjugated concanavalin A (ConA; Invitrogen) for 5 min 
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at room temperature before fixation. Cells were then washed and fixed with 4% 
paraformaldehyde (Electron Microscopy Sciences) in phosphate-buffered saline (PBS) 
for 30 min at room temperature, permeabilized in PBS containing 0.1% Triton-X for 2 
min, and washed thoroughly with PBS. The cells were immunostained with anti-CD81 
antibody (#555675, BD Biosciences Pharmingen. San Diego, CA) for 1 h at room 
temperature, washed twice with PBS, and stained with goat anti-mouse IgG conjugated to 
Alexa Fluor 647 (Invitrogen). The immunostained cells were subsequently washed with 
PBS and mounted. Cells were visualized using Leica confocal fluorescence microscope. 
Pearson’s correlation coefficients of ConA and GagVenus as well as CD81 and 
GagVenus were calculated using the Coloc2 plugin in the ImageJ software program. Ten 
cells per donor were analyzed for each condition. MDM from at least 2 donors were used 
in the experiments. 
 
RESULTS 
SIV-Vpx transduction increases HIV-1 infectivity in macrophages but does not 
change CD81 staining pattern 
HIV-1 is known to replicate poorly in myeloid cells such as monocytes, 
macrophages and dendritic cells (1, 4, 6). This is mainly due to the presence of a 
restriction factor known as SAM domain and HD domain-containing protein 1 
(SAMHD1), which depletes cellular dNTPs, thereby reducing HIV-1 reverse 
transcription efficiency (43). On the other hand, SIVsm/HIV-2 are able to replicate 
efficiently in myeloid cells. Recent studies reveal that this phenomenon is attributed to 
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the presence of Vpx protein, which targets SAMHD1 for degradation, resulting in 
successful reverse transcription and infection (44).  HIV-1 does not contain vpx gene; 
however, transduction of Vpx-containing virus like particle (SIV-Vpx) prior or during 
infection is able to relieve restriction and enhance HIV-1 infection (46, 47).  
We first compared the effect of SIV-Vpx transduction on GagVenus expression 
level in monocyte-derived macrophages (MDM). The general scheme of SIV-Vpx 
transduction followed by HIV-1 infection of MDM is shown in Fig. 4.1A. As expected, 
we found that more cells express GagVenus in MDM that were transduced with SIV-Vpx 
(Fig. 4.1B). We next compared the localization of CD81, a VCC marker, in uninfected 
and HIV-1-infected cells with or without SIV-Vpx transduction. HIV-1 infection in 
MDM without SIV-Vpx transduction was allowed to progress up to 6 days post-infection. 
We found that CD81 localize to both the plasma membrane and intracellular 
compartments regardless of SIV-Vpx transduction (Fig. 4.1C). Moreover, GagVenus co-
localize with CD81 in all conditions, suggesting that SIV-Vpx does not alter GagVenus 
localization in MDM.  
PI(4,5)P2 depletion reduces HIV-1 release efficiency from MDM 
We previously reported that 5ptaseIV overexpression, which depletes cellular 
PI(4,5)P2, in HeLa cells and T cells significantly reduced HIV-1 release efficiency (20, 
34, 72, 74). To assess the role of PI(4,5)P2 in HIV-1 release in MDM, we infected SIV-
Vpx-transduced MDM with HIV-1 molecular clone encoding full-length 5ptaseIV or the 
catalytically inactive 5ptaseIV-1. At 48 hours post-infection, cells were metabolically 
labeled with [35S]Met/Cys for 4 hours and 35S-labeled HIV-1 Gag in cell and virus lysate 
were immunoprecipated using HIV-Ig. We found that HIV-1 release efficiency is reduced 
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by more than 3-fold in 5ptaseIV-expressing cells than in 5ptaseIV-1-expressing cells 
(Fig. 4.2A, 4.2B). This indicates that PI(4,5)P2 is important for efficient release of HIV-1 
from MDM. 
PI(4,5)P2 is required for HIV-1 Gag localization to the VCC in MDM 
In addition to virus release, we previously also demonstrated that PI(4,5)P2 is 
required for HIV-1 Gag localization to the site of assembly, the plasma membrane, in 
HeLa and T cells (20, 34, 72, 74). To assess whether PI(4,5)P2 depletion can influence 
HIV-1 Gag localization to the VCC in MDM, we transduced MDM with SIV-Vpx 
followed by infection using pseudotyped HIV-1 particles containing GagVenus and either 
full-length 5ptaseIV or 5ptaseIV-1. In 5ptaseIV-1-expressing cells, we found that 
GagVenus colocalized with CD81 (Fig. 4.3A). In contrast, in full-length 5ptaseIV-
expressing cells, HIV-1 GagVenus failed to localized to the VCC. Instead, GagVenus 
displayed hazy cytosolic signal or is mislocalized to CD81-negative compartments (Fig. 
4.3A).  
To quantitatively measure the effect of PI(4,5)P2 depletion on GagVenus 
localization to the VCC on a single-cell basis, we measured the Pearson’s correlation 
coefficient (PCC) between GagVenus and CD81 signals from confocal images (Fig. 
4.3B). In this analysis, we found that GagVenus and CD81 showed higher PCC (≈0.50) 
in 5ptaseIV-1-expressing cells than in 5ptaseIV-expressing cells (PCC ≈ 0.19). 
Altogether, these data support that PI(4,5)P2 is required for HIV-1 Gag localization to the 
VCC in MDM. 
Gag targeting to the VCC requires myristate moiety but not intact HBR 
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Previous studies in HeLa cells demonstrate that the interaction between HIV-1 
MA and PI(4,5)P2 is important for HIV-1 Gag localization to the plasma membrane (13, 
34). In particular, the two signals present in HIV-1 MA, the myristoyl moiety and the 
highly basic region (HBR), are essential for proper targeting and binding of Gag to the 
plasma membrane. To test whether membrane binding is necessary for HIV-1 Gag 
localization to the VCC, we transduced MDM with SIV-Vpx and infected them with 
HIV-1 molecular clone containing GagVenus that has myristoylation-defective mutation 
(1GA GagVenus) (Fig. 4.4A, 4.4B). We found that 1GA GagVenus displayed hazy 
cytosolic signal in MDM, indicative of membrane binding defect, and does not colocalize 
with CD81 (Fig. 4.4B, Fig. 4.4C). Consistent with this, PCC of 1GA GagVenus and 
CD81 (≈0.2) is lower than PCC of WT GagVenus and CD81 (Fig. 4.4C). This indicates 
that myristoyl moiety of HIV-1 Gag is required for membrane binding in MDM and that 
membrane binding is required for VCC localization. 
We next tested the role of HBR in Gag targeting to the VCC. Previous studies 
have shown that mutations in the HBR results in HIV-1 Gag relocalization to perinuclear 
region in HeLa cells and a reduced binding efficiency to PI(4,5)P2-containing membrane 
in vitro (34, 77). To see if HBR is important in Gag targeting to the VCC, we infected 
MDM with pseudotyped HIV-1 particles encoding GagVenus that contains basic-to-
neutral mutations in the HBR (Fig. 4.4A) (34, 77). Surprisingly, we saw that 29KT/31 
KT GagVenus colocalized with CD81 with similar PCC as WT GagVenus and CD81 
(Fig. 4.4B, 4.4C). Basic-to-acidic mutation of the same amino acid residues 
(29KE/31KE) in HIV-1 Gag was previously reported to also show colocalization with 
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CD81 (23). Thus, this suggests that an intact HBR is not required for Gag targeting to the 
VCC. 
MA-RNA interaction in not required for Gag localization to the VCC 
In addition to PI(4,5)P2, HIV-1 MA also interacts with RNA (55, 60-67). Our 
recent study showed that removal of the MA-bound RNA by RNase treatment enables 
HIV-1 Gag to bind negatively charged liposomes containing phosphatidylserine (PS) 
even in the absence of PI(4,5)P2 in vitro (55). In contrast to HIV-1 Gag, we found that 
membrane binding of HTLV-1 Gag or the chimeric HIV-1 Gag protein, containing 
HTLV-1 MA in place of HIV-1 MA (HTMA Gag or HTLV-1 MA GagLZ) do not 
require PI(4,5)P2. In addition, membrane binding of HTLV-1 Gag and HTLV-1 MA 
GagLZ are not responsive to RNase treatment (74, 78). We found that HTLV-1 Gag and 
the chimeric Gag proteins also localize to both the plasma membrane and intracellular 
compartment in HeLa cells, consistent with the lack of PI(4,5)P2-dependence and RNA-
mediated membrane binding inhibition (74, 78). 
To test whether Gag localization to VCC requires MA-RNA interaction, we 
constructed an HIV-1 molecular clone encoding Gag chimera in which the HIV-1 MA is 
replaced with HTLV-1 MA [HTMA Gag (74)] (Fig. 4.4A). When MDM are infected 
with this construct, we found that HTMA Gag colocalized with CD81 with similar 
efficiency as WT GagVenus (Fig. 4.4B, 4.4C). This suggests that RNA-mediated 
membrane binding inhibition is not required for HIV-1 Gag localization to the VCC. 
HIV-1 MA is not required for VCC localization in MDM 
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To further study the role of membrane binding in Gag localization to the VCC, we 
replaced the HIV-1 MA with various membrane binding motifs, namely: (i) PH domain, 
which binds to PI(4,5)P2 (32, 33); (ii)K-myr, which contains a myristoylation signal and 
the K-Ras4B polybasic sequence and binds to membrane through myristoylation and 
basic residues (79, 80); (iii) Fyn(10), which contains N-terminal 10 residues of Fyn 
kinase encoding myristoylation and dual-palmitoylation signals and binds membrane via 
hydrophobic interactions (34) (Fig. 4.5A). These MA-replacement mutants were 
introduced into HIV-1 molecular clones encoding GagVenus, and the pseudotyped virus 
particles were generated and used to infect MDM. Interestingly, we found that, similar to 
WT GagVenus, PH-MA-GagVenus, Kmyr-MA-GagVenus and Fyn(10)-MA-
GagVenus are able to colocalize with CD81 (Fig. 4.5B, 4.5C), indicating that HIV-1 MA 
is not required for VCC localization in MDM. Altogether, our data suggest that HIV-1 
MA’s role in membrane binding is necessary for Gag localization to the VCC, but its role 
in Gag targeting is dispensable from VCC localization. We also found that PI(4,5)P2 
mainly serves as an important membrane anchor that facilitate HIV-1 Gag membrane 
binding.  
Higher-order multimerization is required for HIV-1 Gag localization to the VCC in 
MDM 
The lack of requirement of HIV-1 MA for VCC localization suggests that 
downstream region of HIV-1 Gag may be important for targeting to the VCC. Our 
previous work looking at HIV-1 Gag targeting to uropod in polarized T cells 
demonstrated that NC-dependent multimerization is necessary for this specific 
localization (70, 71). To test whether multimerization is similarly important for specific 
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targeting to the VCC in MDM, we tested a panel of HIV-1 Gag containing various 
multimerization mutations (Fig. 4.6A).  
We first tested EE75,76AA Gag, an HIV-1 Gag mutant with mutation in the CA 
domain. This mutant was previously shown to form electron-dense patches at the plasma 
membrane, suggesting their abilities to multimerize, but are not able to cause membrane 
curvature or form virus particles (70, 76, 81). We found that GagVenus containing 
EE75,76AA mutation was able to colocalize with CD81 as efficiently as WT Gag (Fig. 
4.6B, 4.7A). These results are analogous with our previous findings in that uropod 
localization of HIV-1 Gag does not require membrane curvation or full particle formation 
(70).  
We next examined if NC is required for VCC targeting. We first compared the 
ability of HIV-1 delNC Gag, an NC-deleted HIV-1 Gag mutant, to localize to the VCC. 
delNC Gag was previously shown to bind membrane but display lower level Gag-Gag 
interaction than WT Gag in HeLa and T cells (71, 82). We found that deletion in NC 
results in Gag failing to localize specifically to CD81 (Fig. 4.6B, 4.7A). Interestingly, 
delNC Gag are found at the plasma membrane and binding to tubular-like intracellular 
compartments (Fig. 4.6B). The PCC of delNC GagVenus and ConA, a plasma membrane 
marker, show that they colocalize with relatively high efficiency (Fig. 4.7B). In contrast 
to this, WT Gag showed lower colocalization with ConA as most Gag puncta are found in 
the intracellular compartments in MDM (Fig. 4.6B, 4.7B). These results suggest that NC 
is required for specific targeting of HIV-1 Gag to the VCC, which is reminiscent of the 
NC-dependent Gag targeting to uropod in T cells. 
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We next examined how NC contributes to VCC targeting. Specifically, we 
wanted to know if NC contributes to the targeting by promoting Gag-Gag 
multimerization, as was previously observed in polarized T cells. To test this, we 
replaced HIV-1 NC with a leucine zipper dimerization motif (GagLZ) (Fig. 4.6A). 
GagLZ was previously shown to multimerize efficiently and are able to form virus-like 
particles that are indistinguishable from WT-HIV-1 Gag (83). We found that GagLZ 
restored colocalization with CD81 to similar extent as WT Gag and that less Gag is found 
on the plasma membrane (Fig. 4.6B, 4.7A, 4.7B). This indicates that the key role of NC 
in targeting to the VCC is to serve as a multimerization domain for promoting higher 
order interactions between Gag proteins. 
Finally, we examined the minimal level of multimerization that is needed for Gag 
targeting to the VCC. Our previous studies demonstrated that an LZ domain mutant that 
forms a tetramer (LZ4) is able to restore Gag localization to the uropod in T cells (70, 84) 
(Fig. 4.6A). Thus, it is possible that similar level of multimerization is sufficient to target 
Gag to VCC in MDM. Interestingly, we observed that Gag-LZ4 showed an intermediate 
phenotype between delNC Gag and GagLZ (Fig. 4.6B). Although Gag-LZ4 was able to 
colocalize with CD81 at higher PCC than delNC Gag, a large portion of Gag-LZ4 
remained at the plasma membrane and colocalize with ConA (Fig. 4.6B, 4.7). This 
suggests that tetrameric Gag is insufficient to drive Gag targeting to the VCC in MDM, 
unlike in polarized T cells, where Gag-LZ4 was able to restore specific targeting to the 
uropod.  
Altogether, our data demonstrate that Gag targeting to VCC in MDM share 
similar mechanism as Gag targeting to the uropod in T cells. We found that MA only 
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serves as a membrane binder and is not required for targeting. We also found that NC-
dependent multimerization plays a key role this process. Interestingly, a higher order of 
multimerization may be needed for VCC targeting MDM than for uropod targeting in T 
cells, despite that a whole virus particle formation is not required for these processes. 
 
DISCUSSION 
Human primary macrophages represent one of the natural target cells of HIV-1. 
Despite its importance, very little is known about HIV-1 replication in these cells. In 
particular, how HIV-1 Gag is targeted to the site of assembly, known as the VCC, in 
macrophages is not well understood. In this study, we found that the targeting mechanism 
of HIV-1 Gag to the VCC is driven by the NC domain, resembling the mechanism of Gag 
targeting to the uropod in polarized T cells. We observed that deletion of NC results in a 
failure of Gag to specifically localize to with CD81, a VCC marker, and are found to 
localize at the plasma membrane instead (Fig. 4.6 and 4.7). In contrast, WT Gag or Gag 
mutants that are capable of higher-order of multimerization (such as EE75,76AA Gag 
and GagLZ) are found mostly in the intracellular compartments and colocalizing with 
CD81. Based on these results, we propose a working model in which NC-mediated 
multimerization facilitates Gag movement from the plasma membrane to the VCC (Fig. 
4.8). In this model, we propose that VCC are connected to the plasma membrane, and 
that HIV-1 Gag (i) is initially targeted to the plasma membrane, (ii) binds to the 
membrane, (iii) begins to multimerize and (iv) is subsequently transported to the VCC. 
Gag multimerization may result in reorganization of microdomains and/or promote the 
association with VCC-specific microdomains. While the presence and identity of VCC-
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specific microdomain is beyond the scope of this study, we speculate that it is likely to 
comprise of membrane proteins that are enriched in the VCC, such as CD9, CD18, CD36, 
CD53 , CD81 and CD82 (18, 25, 29, 31). Interestingly, delNC Gag does not only localize 
to the PM but it localizes to a seemingly tubular membranenous webs as well. Therefore, 
it is tempting to speculate that VCC are not only connected to the cell surface but are 
interconnected intracellularly. Consistent with this idea, PH-GFP, a PI(4,5)P2 marker, 
does not fully colocalize with CD81 in the intracellular compartments in MDM (28). 
Instead, PH-GFP was found to label the plasma membrane as well as CD81-negative 
intracellular compartments. This suggests that other seemingly intracellular 
compartments may contain PI(4,5)P2, possibly enabling Gag to bind to these 
membranous compartments. While we propose that HIV-1 Gag multimerization drives 
VCC localization, what determine VCC as the site of assembly and how HIV-1 Gag 
distinguishes VCC from any other intracellular compartments is not known. 
The role of tetherin in retaining virus particles at VCC remains controversial. In 
one study, Chu et al. reported that knockdown of tetherin by RNAi redistributes and 
reduces the size of Gag-positive VCC, hence implicating tetherin in the formation of 
VCC (27). On the other hand, Giese et al. argued that tetherin does not influence the 
integrity of VCC [or Intracellular plasma membrane-connected compartments (IPMC)], 
and that the presence or absence of Vpu -- the virus-encoded tetherin antagonist -- does 
not influence Gag localization pattern in macrophages (41). Consistent with this finding, 
we find that Gag localization to the VCC is unlikely to be a consequence of tetherin 
effect. EE75,76AA Gag was previously shown to be unable to recruit tetherin to the site 
of assembly in HeLa cells (76). However, in this study, we found that both WT Gag and 
119 
 
EE75,76AA Gag are able to localize to VCC in MDM, suggesting that Gag targeting to 
VCC is independent of tetherin recruitment (Fig. 4.6). Nevertheless, one major caveat of 
this experiment is that cell-type differences may influence the phenotypes of this 
EE75,76AA Gag mutant (i.e., the ability to recruit tetherin), and more in-depth studies on 
Gag-tetherin interaction in macrophages needs to be carried out.  
Our study showed that HIV-1 MA can be replaced with any membrane binding 
motifs, such as PH domain, Kmyr or Fyn(10), suggesting that the HIV-1 MA contributes 
to VCC localization by serving as a membrane binder. We also found that PI(4,5)P2 
remains important for efficient virus release and Gag localization to the VCC (Fig. 4.2 
and 4.3). Thus, these data suggest that MA-PI(4,5)P2 interaction is required for Gag 
binding to the membrane, thereby allowing Gag to multimerize and be targeted to the site 
of assembly. 
Our previous study looking at the role of HTLV-1 MA in Gag targeting and 
membrane binding showed that, unlike HIV-1 MA, HTLV-1 MA membrane binding 
does not require PI(4,5)P2 and is not inhibited by RNA (74, 78). Consistent the lack of 
PI(4,5)P2 requirement and RNA-mediated inhibition, we observed that Gag containing 
HTLV-1 MA (HTMA Gag) localizes to not only the plasma membrane but intracellular 
compartments as well in HeLa cells. In contrast the observations in HeLa cells, in MDM, 
we found that HTMA Gag is able to localize specifically to the VCC (Fig. 4.2). This 
further emphasizes that HIV-1 MA domain does not play significant role in Gag targeting 
to the VCC. However, we do not eliminate the possibility that HTMA Gag, due to its lack 
of PI(4,5)P2-dependence and RNA-mediated membrane binding inhibition, may initially 
be targeted to both the plasma membrane and intracellular CD81-negative compartments, 
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such as endosomal compartments, and subsequently fuse with the expanding VCC during 
infection.  
In conclusion, our study provides crucial insights into the molecular mechanism 
of Gag targeting during HIV-1 assembly in macrophages. We showed that HIV-1 Gag 
targeting to the site of assembly in macrophages is a two-step process: successful 
membrane binding via PI(4,5)P2-MA interaction, followed by NC-dependent higher-
order multimerization. This multimerization-driven targeting mechanism is reminiscent 
of Gag targeting to the uropod in polarized T cells. However, unlike in T cells, where 
tetramers are sufficient to restore uropod-specific Gag localization, multimers of higher 
than a tetramer may be required for VCC localization.  
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Fig. 4.1. SIV-Vpx VLP transduction does not affect HIV-1 Gag and CD81 localization in 
MDM. (A) MDM were transduced with SIV-Vpx for 2 hours followed by infection with 
pseudotyped HIV-1 particles. Cell are then washed and infection is allowed to progress up to 48 
hours post-infection. (B) SIV-Vpx transduction improved HIV-1 infection in MDM. (C) SIV-Vpx 
does not alter HIV-1 Gag and CD81 localizations in MDM. 
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Fig. 4.2. HIV-1 release from MDM is sensitive to 5ptaseIV overexpression. (A) MDM 
infected with pseudotyped HIV-1 particles along with 5ptaseIV FL or its ∆1 mutant, were 
metabolically labeled for 4 hours. Cell- and virus-associated Gag were recovered by 
immunoprecipitation and analyzed by SDS-PAGE. (B) Relative virus release efficiency of HIV-1 
were calculated. Data from 7 donors are shown as means ± standard deviations. The average virus 
release efficiencies by HIV-1 infected MDM along with 5ptaseIVΔ1 were 18.4%. P values were 
determined using Student’s t-test using raw data. ***, P<0.001. 
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Fig. 4.3. HIV-1 Gag failed to localize to VCC upon 5ptaseIV overexpression. (A) MDM were 
infected with pseudotyped HIV-1 GagVenus particles along with 5ptaseIV FL or its ∆1 and were 
stained with ConA labeled with Alexa Fluor 594, fixed and immunostained with mouse 
monoclonal anti-CD81 antibody and anti-mouse IgG conjugated with Alexa Fluor 647, and 
analyzed using a confocal fluorescence microscope. Note that HIV-1 GagVenus in 5ptaseIV-
expressing cells were unable to localize to CD81-positive sites. (B) Pearson’s correlations 
coefficients (PCC) for colocalization of GagVenus with CD81 were calculated and are shown as 
means ± SEM. Ten cells were analyzed per condition. ***, P<0.001.  
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Fig. 4.4. Myristoyl moiety but not intact HIV-1 MA is required for VCC localization. (A) 
Schematic illustrations of WT, 1GA, 29KT/31KT and HTMA GagVenus are shown. (B) MDM 
were infected with pseudotyped HIV-1 GagVenus containing MA mutations and were stained 
with ConA labeled with Alexa Fluor 594, fixed and immunostained with mouse monoclonal anti-
CD81 antibody and anti-mouse IgG conjugated with Alexa Fluor 647, and analyzed using a 
confocal fluorescence microscope. (C) Pearson’s correlations coefficients (PCC) for 
colocalization of GagVenus with CD81 were calculated and are shown as means ± SEM. Ten 
cells were analyzed per condition. **, P<0.005; n.s., not significant. 
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Fig. 4.5. Only membrane binding role of HIV-1 MA is required for VCC localization. (A) 
Schematic illustrations of WT, PH-MA, Kmyr-MA and Fyn(10)-MA GagVenus are shown. 
(B) MDM were infected with pseudotyped HIV-1 GagVenus containing MA mutations and were 
stained with ConA labeled with Alexa Fluor 594, fixed and immunostained with mouse 
monoclonal anti-CD81 antibody and anti-mouse IgG conjugated with Alexa Fluor 647, and 
analyzed using a confocal fluorescence microscope. (C) Pearson’s correlations coefficients (PCC) 
for colocalization of GagVenus with CD81 were calculated and are shown as means ± SEM. Ten 
cells were analyzed per condition. *, P<0.05; n.s., not significant. 
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Fig. 4.6. HIV-1 Gag localization to VCC requires higher order multimerization. (A) 
Schematic illustrations of WT, EE75,76AA, delNC, LZ and LZ4 GagVenus are shown. LZ4 
GagVenus also contains WM184,185AA CA mutation to abolish Gag-Gag dimerization. (B) 
MDM were infected with pseudotyped HIV-1 GagVenus containing NC mutations and were 
stained with ConA labeled with Alexa Fluor 594, fixed and immunostained with mouse 
monoclonal anti-CD81 antibody and anti-mouse IgG conjugated with Alexa Fluor 647, and 
analyzed using a confocal fluorescence microscope. Ten cells were analyzed per condition. 
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Fig. 4.7. PCC of HIV-1 GagVenus mutants with CD81 or ConA. (A) Pearson’s correlations 
coefficients (PCC) for colocalization of GagVenus containing NC mutations with CD81 were 
calculated and are shown as means ± SEM. Ten cells were analyzed per condition. ***, P<0.001; 
n.s., not significant. (B) Pearson’s correlations coefficients (PCC) for colocalization of GagVenus 
containing NC mutations with ConA were calculated and are shown as means ± SEM. Ten cells 
were analyzed per condition. **, P < 0.005; ***, P<0.001; n.s., not significant. 
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Fig. 4.8. A working model for HIV-1 Gag targeting to the VCC. HIV-1 Gag are synthesized in 
the cytosol and are first targeted to the plasma membrane. At the plasma membrane, HIV-1 Gag 
bind to PI(4,5)P2 begin to multimerize in NC-dependent manner. As higher-order multimers 
begin to form, HIV-1 Gag are transported intracellularly to the VCC where assembly takes place. 
In addition to being connected with the plasma membrane, VCC may also be connected 
intracellularly. 
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CHAPTER V 
 DISCUSSIONS AND FUTURE DIRECTIONS 
The focus of my thesis is to examine how retroviral Gag drives the assembly 
process for successful virus production. In Chapter II, I performed a broad analysis of the 
different retroviral MA in targeting Gag to the site of assembly. Further focusing on HIV-
1 assembly, in Chapter III, I examined whether membrane binding inhibition by RNA on 
HIV-1 Gag can occur in cells and provided evidence that RNA can inhibit HIV-1 Gag 
membrane binding in a concentration-dependent manner. Finally in Chapter IV, I 
investigated the molecular mechanism of HIV-1 Gag targeting to the site of assembly in 
primary macrophages, the VCC. In this chapter, I will summarize the findings from 
previous chapters, discuss the implications and future directions of these findings and 
comment on the future of medicine against HIV-1 infection. 
 
SUMMARY OF DATA 
(i) Membrane binding mediated by retroviral MA can be divided into two broad 
categories: those that are PI(4,5)P2-dependent and RNase-responsive, and those that 
are neither 
Previously, we proposed a working model for the regulation of HIV-1 Gag 
membrane binding in which MA-bound RNA prevents HIV-1 Gag from binding to non-
PI(4,5)P2-containing cellular membrane [see Fig.1.4] (1). This RNA-mediated membrane 
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binding inhibition can be relieved upon binding to PI(4,5)P2, which is predominantly 
found at the plasma membrane. Therefore, MA-RNA interaction ensures HIV-1 Gag 
specific binding to the plasma membrane. However, whether PI(4,5)P2 or RNA can 
regulate membrane binding of other retroviral Gag is not known. In Chapter II, in order 
to broadly study the specific roles of retroviral MA in Gag membrane binding, we 
constructed HIV-1 GagLZ chimeric proteins, where the HIV-1 MA is replaced with 
different retroviral MA, each coming from different retroviral genus (2). We observed a 
correlation between PI(4,5)P2 dependency and RNase responsiveness in the membrane 
binding of different retroviral MA GagLZ. That is, if the membrane binding of the 
chimeric GagLZ is PI(4,5)P2-dependent, it is also RNase-responsive. On the other hand, 
if the chimeric GagLZ does not require PI(4,5)P2 for membrane binding, it is also not 
RNase-responsive. This correlation seems to extend to the subcellular localization of 
chimeric GagLZ in cells and their sensitivity to 5ptaseIV overexpression. We found that 
chimeric GagLZ that require PI(4,5)P2 for membrane binding in vitro, localize mainly to 
the plasma membrane in HeLa cells. Upon 5ptaseIV overexpression, these GagLZ fail to 
localize to the plasma membrane and their VLP release efficiency is significantly 
reduced. In contrast, chimeric GagLZ that do not require PI(4,5)P2 for membrane binding 
in vitro are usually found to localize at the plasma membrane and intracellular 
compartments (with the exception of HERV-K MA GagLZ). The localization and VLP 
release of these chimeric GagLZ are less sensitive to 5ptaseIV overexpression than the 
chimeric GagLZ that are PI(4,5)P2-dependent. Moreover, a comparison of previously 
solved retroviral MA domains showed that all MA contain basic patches. Specifically, 
GagLZ that are observed to be PI(4,5)P2-dependent and RNase-responsive (HIV-1 MA 
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and RSV MA) show bigger surface exposed basic patches than those whose membrane 
binding do not require PI(4,5)P2 and are not inhibited by RNA [HTLV-2 MA (HTLV-2 is 
a close relative of HTLV-1), MLV MA]. Further mutational analyses of HTLV-1 MA 
showed that size of basic patches correlates with susceptibility to RNA-mediated 
membrane binding inhibition. Altogether, these results suggest that RNA serves as a 
general membrane binding block for retroviral MA with large basic patches and that 
some retroviruses overcome this block either by binding to PI(4,5)P2 or by having smaller 
basic patches to subvert the inhibition.  
(ii) RNA-mediated membrane binding inhibition can occur in cells 
Many studies have demonstrated the RNA binding ability of HIV-1 MA; 
however, it was only recently that RNA was found to have regulatory role in membrane 
binding of HIV-1 Gag during assembly. Even though cellular-based assays are in support 
of the results from the in vitro liposome binding assays (1-3), whether RNA-mediated 
membrane binding inhibition actually occurs in cells has not been demonstrated. In 
Chapter III, we modified our in vitro liposome binding assay, by using HIV-1 Gag 
derived from the cytosolic fraction of transfected HeLa cells, to show that cell-derived 
HIV-1 Gag also require PI(4,5)P2 for efficient liposome binding (4). Furthermore, the 
membrane binding of these cell-derived HIV-1 Gag are responsive to RNase treatment. 
Consistent with in vitro studies, the HBR of cell-derived HIV-1 Gag is important for 
membrane binding and RNA-binding. We also determined that RNA can inhibit HIV-1 
Gag membrane binding to negatively-charged liposomes (PC:PS liposomes) in a 
concentration-dependent manner. Since the inhibition can take place at much lower RNA 
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concentration than the estimated total RNA concentration in HeLa cells, it is likely that 
RNA-mediated membrane binding inhibition can occur in cells as well.  
(iii) NC-dependent multimerization promotes HIV-1 targeting to the VCC in 
macrophages  
Our previous results showed that PI(4,5)P2 is important for HIV-1 Gag targeting 
and membrane binding to the plasma membrane during virus assembly in HeLa and T 
cells. Additionally, HIV-1 MA, in particular the HBR, is important for correct Gag 
targeting in cells and interaction with PI(4,5)P2. Interestingly, we found that HIV-1 Gag 
targeting to the uropod, the rear-end protrusion of the plasma membrane, was dependent 
on NC-mediated multimerization in polarized T cells (5). In Chapter IV, we sought to 
understand the targeting mechanism of HIV-1 Gag to the site of assembly in primary 
macrophages, one of the natural target cells of HIV-1. HIV-1 assembles at the virus-
containing compartments (VCC) in primary macrophages. We found that HIV-1 Gag 
targeting to the VCC also depends on NC-mediated multimerization. Furthermore, 
PI(4,5)P2 depletion of HIV-1 infected macrophages leads to membrane binding defect or 
mislocalization of HIV-1 Gag and reduction in virus release. Our analysis of HIV-1 Gag 
mutants containing different membrane binding motifs in place of MA suggested that 
HIV-1 MA only contributes to membrane binding and plays a less significant role in Gag 
targeting to the VCC. Moreover, HIV-1 Gag with deletion in the NC domain failed to 
localize specifically to the VCC. This defect is rescued when dimerization motif (LZ), 
which enables Gag to form higher-order multimer, is added back in place of NC. Based 
on our results, we propose a two-step process of HIV-1 Gag targeting to the VCC: HIV-1 
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Gag binding to PI(4,5)P2, followed by NC-driven Gag-Gag multimerization, leading to 
Gag transport to the VCC. 
 
IMPLICATIONS AND FUTURE DIRECTIONS 
The role of other phosphoinositides and negatively charged phospholipids in 
retroviral Gag assembly 
The work discussed thus far mainly involves the study of PI(4,5)P2 and an 
abundant negatively charged cellular phospholipid, phosphatidylserine (PS), in retroviral 
Gag membrane binding. However, the cell membrane clearly comprises of more than just 
these lipids (6, 7). Thus, it may be important to understand the roles of other 
phospholipids in regulating the membrane binding of these retroviral Gag. Our previous 
in vitro studies showed that liposomes containing either PI(4,5)P2 or PI(3,4,5)P3 are able 
to support efficient binding of HIV-1 Gag (8). It remains to be determined whether RSV 
MA GagLZ, which also showed PI(4,5)P2 dependency in membrane binding, is able to 
bind PI(3,4,5)P3 efficiently as well. Additionally, our working model propose that 
PI(4,5)P2 is able to alleviate RNA-mediated membrane binding block. It will also be 
interesting to further examine the efficiency of other phosphoinositides in helping HIV-1 
Gag overcome this membrane binding block by RNA.   
In our study, 5ptaseIV overexpression was used to deplete cellular PI(4,5)P2. This 
enzyme converts PI(4,5)P2 to PI4P (7, 9). In addition, 5ptaseIV is able to hydrolyze 
PI(3,4,5)P3, which is also present at the plasma membrane albeit at much lower 
abundance than PI(4,5)P2, yielding PI(3,4)P2. Whether PI4P or PI(3,4)P2 can support 
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efficient HIV-1 Gag binding has not been tested yet. Interestingly, 5ptaseIV 
overexpression in HeLa and macrophages not only results in membrane binding defect of 
HIV-1 Gag, but also causes mislocalization of HIV-1 Gag to perinuclear region or CD63-
positive compartments (in HeLa cells) and non-CD81-containing compartments (in 
macrophages). While the identity of these compartments are not fully known, it is 
tempting to speculate that these mistargeted HIV-1 Gag can possibly be interacting with 
other phospholipids in cells, such as PI4P (in Golgi) or PI(3,4)P2 (in endosomal 
compartments), which may be increased in abundance upon 5ptaseIV perturbations. 
Our studies also demonstrate that GagLZ containing the MA domain of HTLV-1, 
MLV or HERV-K are able to bind PS-containing liposomes efficiently (2). When RNase-
treated, HIV-1 Gag, HIV-1 GagLZ and RSV MA GagLZ derivative are also able to bind 
PS-containing liposomes in the absence of PI(4,5)P2 (1-3). While it was inferred that 
these Gag proteins bind negatively charged liposomes via non-specific electrostatic 
interactions, further studies need to be performed to rule out the possibility that PS can 
play a specific role in retroviral Gag membrane binding. As a preliminary study, we 
compared the membrane binding efficiencies of chimeric GagLZ to other negatively 
charged phospholipids, namely, phosphatidylglycerol (PG) and phosphatidic acid (PA) 
(Figure 5.1). We found that HTLV-1 MA GagLZ, MLV MA GagLZ and HERV-K MA 
GagLZ are able to bind liposomes that contain either PS, PG or PA (PC:PS, PC:PG and 
PC:PA, respectively) with similar efficiencies. Importantly, HIV-1 GagLZ and RSV MA 
GagLZ are unable to bind to these liposomes prior to RNase treatment, further 
demonstrating that PI(4,5)P2 is required for their efficient membrane binding. However, 
upon RNase treatment, both HIV-1 GagLZ and RSV MA GagLZ are able to bind PC:PS, 
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PC:PG and PC:PA liposomes with similar efficiencies. Overall, our data support that in 
vitro, GagLZ containing MA domains of HTLV-1, MLV or HERV-K are able to bind to 
membrane via electrostatic interactions. Additionally, removal of RNA from HIV-1 MA 
and RSV MA also allows these chimeric GagLZ to bind to negatively charged liposomes 
via electrostatic interactions.  
PS is the most abundant negatively charged phospholipid (5-10%) in the cell, 
whereas PG and PA are found in lower abundance (roughly 1%) (10, 11). Given the large 
quantity of PS in the cell, retroviral MA may still prefer to bind to PS over other 
negatively charged phospholipids. Thus, further studies examining the effect of PS 
pertubrations in cells, either by PS-decarboxylase overexpression or knockdown of 
phosphatidylserine synthases (11), on Gag localization and virus release efficiency will 
provide a better understanding of the role of PS in retrovirus assembly. 
Identifying cellular proteins that have similar membrane binding properties as 
HIV-1 Gag 
As mentioned in Chapter I, HIV-1 MA share some structural similarities with 
PI(4,5)P2-binding cellular proteins, such as the PH domain of PLC1. Both HIV-1 Gag 
and the PH-domain contain basic cluster that interacts specifically with the phospholipid 
heagroup of PI(4,5)P2 (7, 12). HIV-1 MA also interacts with RNA and that RNA is able 
to regulate HIV-1 Gag membrane binding. However, whether RNA can regulate 
membrane binding of cellular proteins, such as PLC1, is not known. To begin 
identifying cellular proteins that are both PI(4,5)P2-dependent and RNase responsive, we 
collected cellular proteins that are found in the cytosolic fraction of HeLa cells as 
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previously mentioned in Chapter III. The proteins are treated with or without RNase, 
and are allowed to bind to either PS-containing liposomes (PC:PS) or PI(4,5)P2-
containing liposomes [PC:PS + PI(4,5)P2]. The mixtures were subjected to membrane 
floatation centrifugation and the cellular proteins that are found in the membrane-bound 
fractions are visualized by SDS-PAGE followed by silver staining (Fig. 5.2). 
Surprisingly, we found that many cellular proteins show increased binding to PC:PS 
liposomes upon RNase treatment. We also found that some cellular proteins show more 
efficient membrane binding to PI(4,5)P2-containing liposomes than PC:PS liposomes 
(Fig. 5.2). Further analysis of these proteins by mass-spectrometry will help identify 
cellular proteins whose membrane binding are both PI(4,5)P2-dependent and RNase 
responsive.  
Despite the ease of using cytosolic fractions to identify cellular proteins that have 
similar membrane binding properties as HIV-1 Gag, one caveat for using such method is 
that PI(4,5)P2-specific proteins may be found in low abundance in the cytosol as these 
proteins are already binding to the plasma membrane. Thus, methods to increase the 
amount of PI(4,5)P2-binding proteins in the cytosol, such as by 5ptaseIV overexpression, 
may be necessary. 5ptaseIV overexpression will reduce the plasma membrane binding of 
PI(4,5)P2-specific proteins, hence increasing their concentrations in the cytosolic fraction. 
Identifying MA-bound RNAs that have regulatory role in HIV-1 Gag membrane 
binding 
In Chapter III, we found that yeast tRNA is able to inhibit HIV-1 Gag binding to 
PS-containing liposomes (PC:PS) in a concentration dependent manner in vitro. The 
membrane binding inhibition can occur at a much lower RNA concentration than the 
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estimated RNA concentration in the HeLa cell. In the same study, we found that the 
membrane binding of cell-derived HIV-1 Gag are also RNase responsive, suggesting that 
RNA-mediated membrane binding block can occur in the cell. Thus, it is likely that 
cellular RNA can regulate HIV-1 Gag membrane binding. Consistent with this finding, a 
recent study reported that MA-bound RNA in cells almost exclusively comprises of 
tRNAs, in particular, Glu, Gly, Lys, Val tRNAs (13). However, it is also likely that other 
RNA, such as viral RNA, can regulate Gag membrane binding. Purohit et al. previously 
identified an RNA consensus sequence that specifically interact with HIV-1 MA (14). 
This RNA sequence shares high sequence homology as a region in the Pol open reading 
frame. This suggests that HIV-1 MA can also interact with genomic RNA (gRNA) at 
least in vitro. HIV-1 NC recognizes gRNA via the psi packaging signal (see Chapter I). 
Thus, it is likely that HIV-1 NC “pre-selects” gRNA and brings it to close proximity with 
HIV-1 MA. Whether MA selects specific RNA for binding or whether these RNA are 
pre-selected by HIV-1 NC is currently unknown. Furthermore, it is also not known 
whether these specific MA-bound tRNA or gRNA are able to regulate HIV-1 Gag 
membrane binding. Thus, as an initial study, we compared ability of different RNA 
species in inhibiting HIV-1 Gag membrane binding to PS-containing liposomes. Using 
the same RNA concentration (100ng/ul), we found that the psi region of the gRNA can 
inhibit liposome binding as efficiently as yeast tRNA (Fig. 5.3). Interestingly, Lys tRNA, 
which is used as a primer for reverse transcription and is packaged specifically into the 
virus particle (15) (see Chapter I), has no inhibitory effect on HIV-1 Gag membrane 
binding. This result suggests a possibility that not all Gag-interacting RNA have a 
regulatory effect on HIV-1 Gag membrane binding. In addition, given that both HIV-1 
145 
 
MA and NC are able to bind RNA, it is not known if both domains have to be engaged to 
the same strand of RNA for the RNA to have a regulatory effect. If this is the case, longer 
RNA may have higher inhibitory effect in membrane binding than shorter RNA.  Further 
experiments looking at the roles of HBR and NC, as well as the physical properties of 
RNA, will shed light on how specific RNA confer inhibitory effect on HIV-1 Gag 
membrane binding. 
Virus assembly at cell surface versus “intracellular” compartments 
HIV-1 has proven time and again that it is a highly successful virus. Selecting 
plasma membrane as a site of assembly certainly benefit HIV-1 with ease of egress and 
efficient virus transfer to adjacent cells. Similarly, directing HIV-1 Gag to the uropod in 
polarized T cells is beneficial as uropod contain numerous adhesion molecules and 
possibly allowing easier establishment of virological synapse. Thus, it seems unlikely 
that HIV-1 Gag localization to the seemingly intracellular compartments (the VCC) in 
primary macrophages is a mere coincidence. Macrophages have extremely low dNTP 
(16) that discourages efficient virus replication. Moreover, given that macrophages are 
long-lived cells, they may serve as a virus reservoir. Macrophages are also found to be 
involved in cell-to-cell virus transmission. Indeed, numerous studies have demonstrated 
that formation of virological synapse (VS) are observed in co-culture of infected 
macrophages and T cells (17-19). A recent finding show that VCC-localizing HIV-1 Gag 
is trafficked to macrophage-T cell contact site, and that an HIV-1 MA mutant 
(29KE/31KE) failed to be recruited to the contact sites (18). This suggests that HIV-1 
Gag transport to cell-to-cell contact sites is MA-dependent. However, exactly how Gag is 
transported to the VS is not yet understood. Further analysis of HIV-1 Gag MA mutants 
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and its efficiency in transporting to cell contact site may reveal the molecular mechanism 
of this process. 
In Chapter IV, we found that deletion of HIV-1 NC results in a failure of Gag to 
be targeted to the VCC specifically. Furthermore, HIV-1 Gag mutants with low 
multimerization ability (delNC Gag, Gag-LZ4) are found to localize to the plasma 
membrane, suggesting that HIV-1 Gag is first targeted to the plasma membrane and is 
subsequently transported to the VCC (see Fig. 4.8). In polarized T cells, NC-dependent 
multimerization is also found to drive Gag localization to the uropod. HIV-1 Gag is 
found to associate with the uropod-directed microdomains (UDM). The UDM comprises 
of P-selectin glycoprotein ligand 1(PSGL-1), CD43 and CD44 (5, 20). Likewise, HIV-1 
Gag in macrophages may also interacts with specific microdomains prior or during its 
transport to the VCC. Whether this form of Gag-microdomain association is required for 
VCC localization is not known. 
Similar to the uropod, VCC is also enriched in tetraspanins (such as CD81, CD9 
and CD53) (21). In addition, Chan et al. previously reported that HIV-1 particles derived 
from macrophages or T cell line showed similar lipid composition (22). In particular, 
PI(4,5)P2, cholesterol and GM3 are enriched in virus particles when compared to the 
plasma membrane lipid composition, consistent with the observation that Gag associates 
with and causes reorganization of microdomains on the cellular membrane. 
Unfortunately, the comparison of lipid composition of virus particle versus the VCC was 
not carried out and may in fact prove to be a challenging task. Thus, it remains to be 
determined whether the membrane organization of the VCC is similar or different from 
the plasma membrane or the virus particle. Future studies looking at the association of 
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membrane markers with HIV-1 Gag at the plasma membrane versus the VCC may reveal 
the presence (or absence) of VCC-directed microdomains and whether HIV-1 Gag 
organizes the microdomains at the VCC during infection. Further experiments of siRNA 
knockdown of some VCC-localized tetraspanin markers may also give clue to the 
importance of tetraspanin in HIV-1 Gag transport to the VCC. 
VCC localization may require higher order multimerization than uropod 
localization 
 In Chapter IV, we also observed that Gag-LZ4 was unable to fully restore VCC-
specific localization. This observation is different in polarized T cells, where Gag-LZ4 
was targeted specifically to the uropod (23). LZ4 was previously reported to be able to 
form tetramer (24). Thus, these results suggest that Gag-tetramer is sufficient for uropod 
localization but is insufficient for VCC localization. Certainly, one major caveat is that 
whether Gag-LZ4 truly form tetramers in these cells is not known. Nevertheless, it is 
tempting to speculate that there could be intrinsic differences in protein transport 
mechanisms between polarized T cell and MDM. Previous studies reported that Gag 
multimerization defects can reduce steady-state membrane binding (25-27). For these 
reasons, Fyn(10) sequence was added to HIV-1 NC mutants (including Gag-LZ4) in the 
study of Gag localization to the uropod to compensate for the reduced membrane binding 
(5). In contrast to these observations, multimerization defects did not seem to influence 
membrane binding of HIV-1 Gag in MDM as Gag was still observed to be localizing to 
either CD81-containing compartments and/or the plasma membrane efficiently (Fig 
4.6B). These observations may suggest that HIV-1 Gag is able to bind membrane more 
efficiently in MDM than in other cells such as HeLa and T cells. However, transporting 
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all membrane-bound HIV-1 Gag to the VCC may result in overcrowding at the VCC. 
Thus, selecting and transporting only HIV-1 Gag with higher order multimer (more than 
tetramer) to the VCC may serve as additional checkpoints to help prevent overcrowding 
at the VCC and ensure proper virus assembly. 
VCC localization – an HIV-1 specific phenomenon? 
Many pathogens other than HIV-1 are found to infect macrophages. Bacteria such 
as Salmonella enterica has been found to replicate in modified phagosomes [known as 
Salmonella containing vacuole (SCV)] in macrophages (28). Mycobacterium tuberculosis 
is also found to replicate efficiently in macrophages by preventing fusion of phagosomes 
with lysosomes (29). Leishmania major utilize granulocytes as “Trojan horse” to enter 
and establish infection in macrophages silently (30). Phagosomes containing pathogens 
such as Escherichia coli, Staphylococcus aureus, Candida albicans and Aspergillus 
fumigatus actively recruits CD82 (31). Moreover, influenza virus is able to infect alveolar 
macrophages (32) and are found to incorporate CD9 and CD81 into its viral envelope 
(33). Given that tetraspanin-enriched compartments are found even in the absence of 
HIV-1 infection in macrophages and that many viruses are reported to associate with 
tetraspanins (34-36), it seems unlikely that VCC localization could be a HIV-1-specific 
phenomenon. The difference in experimental procedures and the difficulty in infecting 
macrophages may be some of the reasons why no other pathogens have yet been found to 
localize at VCC in macrophages.  
Perhaps the lack of motivation in studying virus replication (or specifically, 
assembly) in macrophages is due to the difficulty in infecting these cells and the high 
variability from donor to donor. Furthermore, the distribution of macrophages in the body 
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is widespread and isolation of tissue macrophages is usually inefficient. Thus far, the 
most relevant in vitro HIV-1 infection relies upon monocyte derived macrophages 
(MDM). Over the years, MDM have served as the standard model for studying HIV-1 
infection in macrophages and established protocols in isolation and differentiation of 
MDM have been reported. The use MDM to study virus-macrophage interaction and 
along with the advent of SIV-Vpx transduction system, which down-regulates the 
SAMHD1 restriction factor, will hopefully provide an easier and more standardized way 
to study retroviral replication in macrophages. 
Understanding how HIV-1 Gag operates as one entity during assembly is important 
Retroviral assembly is a multi-step process leading to the formation of nascent 
virions. Despite being stepwise, each structural domain of Gag actually influences one 
another during assembly. For example, HIV-1 MA is mainly responsible for membrane 
binding. However, the exposure of myristoyl moiety is dependent on Gag-Gag interaction 
(that is, CA and NC domains) and binding to PI(4,5)P2 (37-45). Similarly, membrane 
binding efficiency of HIV-1 Gag has been shown to be influenced by Gag-Gag 
interaction (25-27). This suggests that downstream sequence of HIV-1 MA can influence 
membrane binding. Pertaining MA-RNA interaction, it is not known whether MA binds 
RNA that is pre-selected by the NC or that MA and NC can bind two different RNA 
strands at one time. Importantly, how NC-RNA interaction influence MA-RNA 
interaction is not known. Thus, a deeper analysis into how Gag functions as one entity 
will help in identifying key steps during assembly for the development of more efficient 
inhibitors to abolish HIV’s ability to produce new virions in infected cells. 
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FUTURE OF ANTIRETROVIRAL MEDICINE 
Targeting the membrane binding step of HIV-1 assembly  
Our results show that different RNA species can inhibit HIV-1 Gag binding to 
negatively charged (PS-containing) liposomes to various degrees (Fig. 5.3). Based on our 
working model, we find that PI(4,5)P2 can successfully outcompete RNA for HIV-1 MA. 
By harnessing RNA’s ability to regulate HIV-1 Gag membrane binding, a therapeutic 
RNA aptamers can be developed to inhibit HIV-1 replication. One potential direction 
towards developing this RNA aptamer is by selecting RNA sequence that have higher 
binding affinity to the HIV-1 MA than PI(4,5)P2. HIV-1 MA association with C4 
PI(4,5)P2 was estimated to be 150 ± 30 uM (42). Thus, effective RNA aptamers should be 
able to bind HIV-1 with Kd values that are lower than of MA-PI(4,5)P2. To date, 
numerous studies have been performed to identify short-length RNA that can inhibit 
HIV-1 replication. These studies usually use the in vitro selection method known as 
Systematic evolution of ligands by exponential enrichment (SELEX) to isolate RNA or 
DNA that bind specifically to  HIV-1 proteins or gRNA (14, 46-49). Previously reported 
RNA ligands that was bound to HIV-1 MA specifically showed Kd values ranging from 
~1 to 10nM (49). It remains to be determined if these RNA are able to regulate HIV-1 
Gag membrane binding. Further consideration regarding RNA folding structure and 
whether it is aminoacylated (for tRNA) may be important in designing effective RNA 
aptamers. As an initial study, our RNA add-back liposome binding assay as mentioned in 
Chapter III can be used to screen for important RNA species that can inhibit HIV-1 Gag 
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membrane binding. Thus, our study lays groundwork for potential development of 
therapeutic RNA aptamers that will inhibit HIV-1 infection. 
In Chapter II, we discovered that RNA can serve as a general inhibitor for 
retroviral membrane binding. We also found that retroviral MA containing bigger basic 
patch on its surface is more susceptible to RNA-mediated membrane binding inhibition 
and that retroviral MA with smaller basic surface patch is less inhibited by RNA. With 
HIV-1 ability to mutate, revertants are likely to arise upon the introduction of 
antiretroviral treatments to the cells. These revertants may become resistant to the given 
antiviral treatments. Thus, when designing inhibitors against HIV-1 infection, it is 
important to anticipate what type of HIV-1 mutants may appear when such selective 
pressure is introduced to the virus. Based on my results from Chapter II, I speculate that 
the likely HIV-1 revertants upon the treatment of RNA aptamers will be those containing 
mutations within the HIV-1 HBR that reduces the overall basic patch size of HIV-1 MA, 
such that RNA block on membrane binding is subverted. 
In addition to developing RNA aptamers that can block HIV-1 membrane 
binding, one can also identify small molecule inhibitors that block essential component 
that is involved in HIV-1 Gag membrane binding. Recently, Compound 7 was identified 
to be effective in blocking HIV-1 MA interaction with PI(4,5)P2 (50, 51). While 
effective, this drug is still at its infancy and more study is needed to identify the 
mechanism of this inhibition. Our previous study looking at HIV-1 replication in 
PI(4,5)P2-minimal T cells have identified a mutation in HIV-1 MA (74LR) that adapts to 
this selection pressure by increasing its infectivity in T cells (52). Whether compound 7 
will result in similar HIV-1 revertant has not yet been tested. 
152 
 
Targeting the Gag multimerization step of HIV-1 assembly 
Our study looking at HIV-1 assembly in polarized T cell and macrophages have 
suggested the importance of NC-mediated multimerization in targeting Gag specifically 
to the site of assembly. In HeLa and T cells, high order HIV-1 Gag multimerization 
usually occurs after the arrival of HIV-1 Gag to the site of assembly, that is, the plasma 
membrane. However, it seems that Gag-Gag multimerization happens earlier during the 
assembly in polarized T cells and macrophages, as this step is required prior to the arrival 
to the site of assembly. Since multimerization is likely occur earlier, the use of inhibitors 
that disrupt Gag-Gag multimerization may be more effective in polarized T cells and 
macrophages than in other cells. As mentioned in Chapter I, NC promote Gag 
multimerization by binding to RNA and using it as a scaffold for higher order Gag 
interactions. NC binds RNA via its zinc finger motif, which is highly conserved among 
all retroviruses. To date, there are many compounds that target HIV-1 NC by ways of 
disrupting the zinc finger motifs or ejecting the zinc cations (50). For example, zinc 
ejector compound such as cystamine and Pyridinioalkanoyl thioesters (PATEs) were 
shown to have low cytotoxicity and are effective in reducing HIV-1 replication in MDMs 
or monocytic U1, a cell line that is chronically infected with HIV-1 (53-55). The mode of 
action of these zinc ejectors in inhibiting virus replication is not known, although it was 
proposed that it could potentially disrupt NC-RNA binding and reverse transcription. 
Whether PATEs and similar compounds inhibits HIV-1 replication by mistargeting Gag 
to non-VCC or non-uropod sites in macrophages or polarized T cells, respectively, is not 
known. 
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CONCLUSION 
Membrane binding and targeting of retroviral Gag proteins to subcellular sites are 
important steps during retroviral assembly. The basic patch found on the retroviral MA 
are important regions that facilitates MA-lipid interaction, MA-RNA interaction and Gag 
targeting to the site of assembly. Additionally, our cell-derived liposome binding assay 
has provided evidence that RNA-mediated inhibition of HIV-1 Gag membrane binding 
can occur in cells. Such study will lay groundwork for the discovery of relevant 
cellular/viral RNA that have regulatory effects on HIV-1 Gag membrane binding in cells. 
Extending our cell-derived liposome binding assay, cellular proteins that share similar 
membrane binding properties as HIV-1 Gag (that its, PI(4,5)P2-dependent and RNase 
responsive) can be identified. Such analysis will further our understanding in the role of 
RNA in regulating the membrane binding of cellular proteins. Finally, our study on HIV-
1 assembly in macrophages has revealed an important mechanism of HIV-1 Gag 
targeting to the VCC. Further examination of Gag movement from VCC to cell contact 
sites will shed light on important factors necessary for virus dissemination via cell-to-cell 
transmission and provide new strategies for inhibiting virus spread. 
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Fig. 5.1. Binding efficiency of chimeric GagLZ to various negatively charged liposomes. 
HIV-1 GagLZ, RSV MA GagLZ, HTLV-1 MA GagLZ, MLV MA GagLZ and HERV-K MA 
GagLZ proteins were synthesized using rabbit reticulocyte lysates and were incubated with 
PC:PS [2:1], PC:PG [2:1] or PC:PA [2:1] liposomes. The samples were subsequently subjected to 
membrane flotation centrifugation. Five 1-ml fractions were collected from each sample. The 
liposome binding efficiency was calculated as the percentage of membrane-bound versus the total 
Gag synthesized in the reaction. Data from at least three different experiments are shown as 
means ± standard deviations. P values were determined using Student’s t-test. **, P<0.005; *, 
P<0.05, n.s., not significant.  
 
155 
 
 
Fig. 5.2. Many cellular proteins bind PI(4,5)P2-containing liposomes and are RNase-
responsive. (A) Schematic diagram of cell-derived liposome binding assay. This method was 
adapted from (56) with modifications. Briefly, HeLa cells that are transfected with HIV-1 
molecular clone are harvested and subjected to low amount of digitonin treatment. Cells are then 
centrifuged at high speed and cytosolic fractions are collected and treated or not treated with 
RNase A, followed by incubation with liposomes. Samples are subsequently subjected to 
membrane floatation centrifugation. Five 1-ml fractions were collected from each sample. The 
top 2 fractions are subjected to SDS-PAGE followed by silver staining to visualize the 
membrane-bound cellular proteins. (B) A representative image of silver-stained gel. Note that 
more proteins are detected upon binding to PI(4,5)P2-containing liposomes and in RNase-treated 
condition. 
Fraction #: 
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Fig. 5.3. Different RNA species can inhibit HIV-1 Gag PC:PS liposome binding to varying 
degrees. [35S]-labeled HIV-1 Gag synthesized using rabbit reticulocyte lysates was untreated or 
treated with RNase A. RNase A was blocked using RNasin and the mixtures were further 
incubated with indicated RNA species at 100ng/ul final concentration. PC:PS liposomes were 
then added and incubated further before performing equilibrium flotation centrifugation. Five 1-
ml fractions were collected and samples each fraction was loaded and analyzed on SDS-PAGE. 
The liposome binding efficiency was calculated as the amount of membrane-bound Gag as a 
fraction of total Gag.  
[The data from this figure was collected by Dr. Gabrielle Todd.] 
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